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Chinese hamster ovary (CHO) cells represent the predominant platform in 
biopharmaceutical industry for the production of recombinant biotherapeutic proteins, 
especially glycoproteins. This dissertation focuses on comprehensive glyco-analytics and 
glyco-engineering of recombinant proteins secreted from CHO cells.        
For advanced glyco-analytics, an intact glycopeptide analysis method was performed to 
simultaneously analyze the site-specific N- and O-glycan profiles of the recombinant EPO-Fc protein 
secreted from the CHO-GS stable cell line and compared the effects of two commercial culture media, 
EX-CELL (EX) and immediate Advantage (IA) media, on the site-specific glycosylation profile of the 
target protein.   
For glyco-engineering in CHO cells, a novel chemical analog (1,3,4-O-Bu3ManNAc) 
was investigated on the sialic acid content of cellular proteins and a model recombinant 
glycoprotein, erythropoietin (EPO). Addition of 200-300 μM 1,3,4-O-Bu3ManNAc resulted in 
>40% increase in final sialic acid content of recombinant EPO, while feeding of ManNAc at 
almost 100 times higher concentration of 20 mM concentration produced a less profound 
change in EPO sialylation. Further, supplementation with 1,3,4-O-Bu3ManNAc for two stable 
CHO cell lines, expressing human EPO or IgG, enhanced protein expression for both products 
with negligible impact on cell growth, viability, glucose utilization, and lactate accumulation. 
In contrast, sodium butyrate treatment resulted in a ~20 % decrease in maximal viable cell 
density and ~30 % decrease in cell viability. In addition, the beneficial impact of 1,3,4‐O‐
Bu3ManNAc on EPO glycan quality, while evident in wild‐type CHO cells, is particularly 
pronounced in glycoengineered CHO cells with stable overexpression of β‐1,4‐ and β‐1,6‐N‐
acetylglucosaminyltransferases (GnTIV and GnTV) and α‐2,6‐sialyltransferase (ST6) enzymes 
responsible for N‐glycan antennarity and sialylation.  
Moreover, the two critical human genes-β-1,4-galactotransferase 1 (B4GALT1) and β-1,3-N-
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acetylglucosaminyltransferase (B3GNT2)-for the initiation and elongation of poly-LacNAc on N-glycans 
in CHO cells were also investigated. The overexpression of B3GNT2 in EPO-expressing CHO cells 
did not increase the LacNAc content on recombinant EPO protein, but also resulted in nearly 
100% elimination of sialylation on recombinant EPO and overall glyco-conjugates in CHO cells.  
 
 





This dissertation consists of 6 chapters and is focused on the glycoengineering in CHO cells to 
produce recombinant proteins with optimized glycan structures and advanced mass 
spectrometry-based glycosylation analysis methodology.  
Chapter 1 provides an introduction of the glycosylaiton pathways in mammalian cells, and 
compared the CHO glycosylation with human glycosylation. CHO cells is currently the 
predominant production platform in biopharmaceutical manufacturing.  The glycan patterns on 
recombinant proteins secreted from CHO cells is compatible to humans. This work has been 
published in Biotechnology & Bioengineering [1],  Emerging Topics in Life Sciences [2], 
Glyco-Engineering [3] and Heterologous Protein Production in CHO Cells [4]. Permission for 
use was granted by John Wiley and Sons (license number 4577911163772) and by Springer 
Nature (license number 4577920069010 and 4577920279468). 
Chapter 2 describes an advanced glycosylation analysis using an intact glycopeptide analysis 
method to simultaneously analyze the site-specific N- and O-glycan profiles of the recombinant 
EPO-Fc protein secreted from a CHO-GS stable cell line.  
Chapter 3 introduces 1,3,4-O-Bu3ManNAc analog as a novel sugar analog can simultaneously 
increase both the productivity and sialylation of recombinant proteins in CHO cells. This 
work has been published in Biotechnology & Bioengineering and Biotechnology Journal [5] 
[6] [7]. Permission for use was granted by John Wiley and Sons (license number 
4577920746464, 4577920855810 and 4577920941689). 
Chapter 4 explores the ability of B3GNT2 and B4GALT1 for LacNAc initiation and 
elongation on recombinant EPO in CHO cells.  
Chapter 5 introduce a protocol of using CRISPR/Cas9 gene editing method for modulating 
antibody fucosylation in CHO cells. This work has been published in Recombinant Protein 
Expression in Mammalian Cells. Permission for use was granted by Springer Nature (license 
v  
number 4578571144913). 
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Chapter 1 Glyco-engineering strategies in mammalian cells 
1.1 Summary 
Chinese hamster ovary (CHO) cells represent the predominant platform in biopharmaceutical 
industry for the production of recombinant biotherapeutic proteins, especially glycoproteins. 
These glycoproteins include oligosaccharide or glycan attachments that represent one of the 
principal components dictating product quality. Especially important are the N-glycan 
attachments present on many recombinant glycoproteins of commercial interest. Furthermore, 
altering the glycan composition can be used to modulate the production quality of a 
recombinant biotherapeutic from CHO and other mammalian hosts. This chapter as a review 
first describes the glycosylation network in mammalian cells and compares the glycosylation 
patterns between CHO and human cells, which provided as an introduction to the dissertation. 
Next genetic strategies used in CHO cells to modulate the sialylation patterns through 
overexpression of sialyltransfereases and other glycosyltransferases are summarized. In 
addition, other approaches to alter sialylation including manipulation of sialic acid biosynthetic 
pathways and inhibition of sialidases are described. Finally, this chapter also covers other 
strategies such as the glycosylation site insertion and manipulation of glycan heterogeneity to 
produce desired glycoforms for diverse biotechnology.  
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1.2 Glycosylation in mammalian cells 
Glycosylation is a critical post-translational modification found on most of these biotherapeutics.  
What is unique about glycosylation compared to other post-translational processing events is the 
structural variety and functional diversity present, in which the glycosylation can vary widely even for a 
single protein and also from organism to organism.   Glycosylation characteristics can play a major role in 
modulating a protein’s stability, folding, targeting/trafficking, immunogenicity, biological activity, and 
especially circulatory half-life [8]. Oligosaccharides are attached cotranslationally through glycosidic 
linkages on specific asparagine (N-linked) or serine/threonine (O-linked) residues. While N-glycans are 
the most common  modification on biotherapeutics including monoclonal antibodies and will be the focus 
of the current review, several  therapeutic glycoproteins such as erythropoietin (EPO) and 
etanercept (Enbrel) also include O-glycan modifications[9]. N-glycans are linked to the Asn of the Asn-
X-Ser/Thr consensus sequence in which X denotes any amino acid except proline [10]. A consensus 
sequence for O-linked glycosylation has yet to be identified [8]. Given its non-template driven nature, 
heterogeneity of glycosylation arises both from variations in glycosylation site occupancy and in the 
diversity of final glycan structures attached to glycoproteins emerging from the cellular secretory 
compartments.  As a result of the stochastic nature of interactions between enzymes and oligosaccharide 
substrates and the variety of enzymes that can act on any one glycan substrate, a wide range of different 
glycans are generated for most proteins as these proteins traverse through the endoplasmic reticulum (ER) 
and various Golgi compartments [11] [12].   
In particular, the N-linked glycosylation pathway in mammalian cells involves a highly complex and 
interconnected reaction network catalyzed by glycosidases and glycosyltransferases contained within 
different compartments of ER and Golgi apparatus, depicted in the schematic of  Figure 1-1. The 
biosynthesis of mammalian N-glycans initiates at the cytoplasmic face of the ER membrane with the 
assembly of GlcNAc-P from UDP-GlcNAc to the dolichol phosphate (Dol-P) lipid carrier to generate 
dolichol pyrophosphate N-acetylglucosamine (Dol-P-P-GlcNAc) [13]. Then fourteen monosaccharides 
are sequentially added to Dol-P-P-GlcNAc to form an oligosaccharide precursor (Glc3Man9GlcNAc2) 
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[13]. Next, oligosaccharyltransferase (OST) selects Asn-X-Ser/Thr sequons in a nascent polypeptide and 
proceeds with an en bloc transfer of Glc3Man9GlcNAc2 to the side chain amide of asparagine and 
releasing Dol-P-P in the process [14]. The glucose residues on the precursor are sequentially trimmed by 
the ER α-glucosidase I and II to form monoglucosylated glycan, which is a key intermediate in the ER 
lectin chaperones calnexin/calreticulin-associated glycoprotein folding control cycle [15]. Once correctly 
folded, the precursor is trimmed by ER α-mannosidase I to yield Man8GlcNAc2-protein before exiting the 
ER. After translocation into the cis-Golgi, the Man8GlcNAc2 glycoform is further trimmed by Golgi α-
mannosidases I to give Man5GlcNAc2, a key intermediate along the pathway to form hybrid and complex 
N-glycans and sometimes found as a final glycan product.  
As shown in Figure 1-1, biosynthesis of hybrid and complex N-glycans begins in the medial-Golgi 
by the action of an N-acetylglucosaminyltransferase (GnT-1 or Mgat1), which adds a GlcNAc to 
Man5GlcNAc2 [13]. Then the majority of N-glycans are trimmed by Golgi α-mannosidase II removing 
two mannoses from GlcNAcMan5GlcNAc2 to yield GlcNAcMan3GlcNAc2.   Hybrid N-glycans result 
when a structure such as GlcNAcMan5GlcNAc2 undergoes no further extensions and two terminal Man 
residues remain exposed.  In addition, another GlcNac can be added to the innermost Man group by the 
enzyme β1,4-N-acetylglucosaminyltransferase III (GnT-III or Mgat3) in the medal Golgi, resulting in 
bisecting GlcNAc structures which can also alter the capacity for other downstream enzymes to act on the 
glycan structure.   
Then the enzyme β-1,2-N-acetylglucosaminyltransferase II (GnT-II or Mgat2) adds a 
second GlcNAc to the GlcNAcMan3GlcNAc2 structure to generate the glycan product 
GlcNAc2Man3GlcNAc2, which is the precursor for all multiantennary complex N-glycans. Tri-and tetra-
antennary branches can be achieved by adding GlcNAc at α(1,3)-mannose site by N-
acetylglucosaminyltransferase IV  (GnT-IV or Mgat 4) and at α(1,6)-mannose site by N-
acetylglucosaminyltransferase V (GnT-V or Mgat 5) . Additional modification of complex and hybrid N-
glycans can occur in the trans-Golgi and include the addition of core α(1,6)-fucose to the GlcNAc 
adjacent to Asn at the N-glycan sites by α-(1,6)-fucosyltransferase and the branch elongation by the 
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addition of a β-linked galactose residue to GlcNAc to produce Galβ1-4GlcNAc, or poly-acetyl-
lactosamine (poly-LacNAc) sequences. Finally, these terminal GlcNAc residues can serve as acceptors 
for a range of galactosyltransferases followed by sialyltransferases and fucosyltransferases, leading to 
even more complex structures [13].   
 
1.3 Glycosylation differences between human cells and CHO cells 
Chinese hamster ovary (CHO) cells are widely used in many commercial and clinical 
biopharmaceuticals due to their capacity to produce glycoforms which are, with exceptions, accepted by 
the human immune system [16, 17]. Alternative mammalian cell lines also used in the production of 
biopharmaceuticals include baby hamster kidney (BHK21), murine myeloma and hybridoma cell lines 
(NS0 and Sp2/0), and, to a lesser extent, human host cell lines such as human embryonic kidney 
(HEK293) and human retinal cells (PER.C6)[17-19].  
Especially, two non-human glycans—terminal Galα1,3-Gal residues (alpha-Gal) and N-
glycolylneuraminic acid (Neu5Gc) epitope—exist in non-human mammalian cells and could elicit 
adverse immunogenic reactions in humans [20] [17]. Mouse cells have an α1,3-galactosyltransferase 
enzyme that produces glycans containing the alpha-Gal linkage [21]. The second potential immunogenic 
epitope Neu5Gc is common in all non-primate mammalian cells [17] due to the presence of the enzyme, 
N-acetylneuraminic acid hydroxylase, which coverts CMP-Neu5Ac to CMP-Neu5Gc in all mammals 
other than old-world primates  [22]. Furthermore the presence of a circulating polyclonal anti-Neu5Gc 
antibody response have been detected in humans [17] [20]. In contrast to the alpha-Gal epitope, Neu5Gc  
can even be taken up from the media as a metabolite by all mammalian cells, including human cells, and 
then metabolically incorporated onto cell surface glycoconjugates, While all mammalian cells have the 
potential for immunogenic epitopes, mouse myeloma cells (NS0 and Sp2/0) tend to express higher levels 
of both of these epitopes compared to hamster (CHO and BHK), making recombinant products form 
murine cells a higher likelihood for being immunogenic in humans,  This potential immunogenicity can 
especially be a  concern when the therapeutic glycoproteins are administered repeatedly in large doses for 
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chronic diseases  [22] [23] [24]. 
Even without these two non-human immunogenic epitopes, the glycosylation patterns of proteins 
expressed in CHO and human cell lines can be different [25]. CHO cells typically do not express N-
acetylglucosaminyltransferase III (GnT-III) and thus lack bisecting GlcNAc residues in their glycoforms, 
which can impact antibody efficiency [26]. Human cells can produce the glycans with GnT III and 
antibodies produced in mouse myeloma cells contain a fraction of glycans with bisecting GlcNAc 
residues [27].  
1.4 Glyco-engineering strategies in mammalian cells 
The numerous applications of recombinant monoclonal antibody (rMAb) therapeutics ranging from 
diagnosis to treatment of major diseases including cancers, autoimmune disease and inflammatory 
disorders have continuously expanded, in step with technological improvements and innovations in the 
development and production of rMAbs [28].  To date, the majority of recombinant glycoproteins in 
production from the most widely used mammalian cell lines such as Chinese hamster ovary (CHO), 
Murine myeloma (NS0) and mouse myeloma (Sp2/0) are recombinant monoclonal antibodies, including 
chimeric, humanized or human immunoglobulin Gs (IgGs) [27]. Many biotherapeutics such as growth 
factors, cytokines, hormones, and enzymes are glycoproteins. The glycosylation of biotherapeutics has 
been identified as a critical quality attribute [29] because each biotherapeutic requires defining 
glycosylation to maintain consistent characteristics such as solubility, thermal stability, protease 
resistance [30], aggregation, serum half-life [31], immunogenicity and efficacy [32]. 
1.4.1 Non-immunoprotein sialylation 
Among the numerous sugar moieties found in glycans, the terminal sialic acid (Neu5Ac) is considered 
particularly important for the lifespan of glycosylated proteins. As an electro-negatively charged acidic 9-
carbon monosaccharide, sialic acid is α-glycosidically linked on the C3- or the C6-hydroxyl group of the 
terminal galactose in humans, through the action of a2,3-sialyltransferases (ST3) or the a2,6-
sialyltransferase-1 (ST6) [33] [34] [35]. Terminal sialic acid residues can alter protein properties 
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including biological activity and in vivo circulatory half-life [35]. Serving as a biological mask, the distal 
sialic acid can shield Gal residues that when exposed prompt a fast removal of the protein from blood 
circulation due to endocytosis-mediated uptake by asialoglycoprotein receptors on the hepatocytes [36] 
[37] [35]. Therefore, in mammalian cells, it is generally desirable to maximize the distal sialic acid 
content of a glycoprotein in order to ensure its quality and consistency as an effective therapeutic [38]. 
However, the sialic acids of glycoproteins expressed in mammalian cells are incomplete, which is 
affected by two opposing cellular processes. The first process consists of two steps-- the biosynthesis of 
sialic aid and its addition to glycans from a cytidine monophospho-sialic acid (CMP-SA) substrate 
catalyzed by sialyltransferase and the second process is the extracellular removal of sialic acid by 
sialidase cleavage [39] [35]. Both of these pathways are targets for genetic engineering. Hence here we 
mainly discuss the genetic manipulation in sialylation process, and divide it into three parts--- genetic 
engineering in sialylation pathways, overexpression of N-acetylglucosaminyltransferase (GnT) genes, 
inhibition of sialidase activity, which has also been summarized in Table 1-1. 
1. Genetic engineering in sialylation pathways 
Genetic engineering of sialyltransferase enzymes is probably the most straightforward method to 
alter sialylation content in terms of modifying the oligosaccharide biosynthesis reaction networks. 
Sialyltransferases are ultimately responsible for introducing a Neu5Ac residue to the penultimate 
galactose residue.  
Six β-galactoside a2,3-sialyltransferases (ST3GAL1-6) and two β-galactoside a2,6-sialyltransferases 
(ST6GAL 1-2) are responsible for forming these terminal sialic acids in mammalian cells. Human 
glycoproteins bear sialic acid residues in both α2,3- and α2,6-linkages, whereas only α2,3-terminal sialic 
acids are found in glycoproteins from CHO and BHK cells. Earlier report from our group revealed that 
three genes from the a2,3-sialyltransferase family (ST3GAL3, ST3GAL4 and ST3GAL6) are responsible 
for a2,3-sialylation in CHO cells using siRNA knockdown approaches, among which ST3GAL4 plays the 
critical role in determine glycoprotein a2,3-sialylation [40]. Besides, ST6GAL l is the sole member of the 
ST6GAL family that can synthesize the terminal NeuAc α2,6-Gal glycoconjugates [41] . 
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In the past,  the overexpression of heterologous α2,6-sialyltransferase with or without recombinant 
α2,3-sialyltransferase serves to introduce linkages similar to those found in human cells and has long been 
adapted to elevate the amounts of sialic acid on recombinant proteins [35]. Since the first introduction of 
ST6GAL1 in CHO cells in 1989 [42], rat or human ST6GAL1-expressing CHO and BHK cells were 
successively generated and tested for various therapeutic glycoproteins production [43] [44]. Expressing 
rat ST6GAL1 in recombinant human tissue plasminogen activator (tPA) CHO expressing cell line has 
significantly increased the a2,6 sialylation level [43]. A similar protocol was applied to modify 
recombinant human interferon-ɤ (IFN-ɤ) and the tissue-inhibitor of metalloproteinases-1 in CHO and 
human erythropoietin (EPO) in BHK-21A cells. Especially, analysis of the IFN-ɤ showed >40 % content 
of α2,6-linked sialic acid with improved pharmacokinetics in clearance studies when compared to wild-
type IFN-ɤ produced by CHO cells[14]. In all cases, the total content of sialic acid did not rise drastically 
and the ratio of a2,6- to a2,3-linked sialic acid never exceeded 50%. It was concluded that the 
recombinant ST6GAL1 enzyme poorly competes with the endogenous ST3 enzymes (ST3GAL3, 
ST3GAL4 and ST3GAL6) for the same donor and acceptors[23].  
Meanwhile, the step prior to sialylation for N-glycans typically involves the addition of galactose 
onto the branched N-glycan chains (Figure 1-1) and insufficient or inconsistent galactosylation would 
result in unsatisfactory sialylation level. Thus, co-overexpressing both the human β1,4-
galactosyltransferase (β1,4-GalT) and α2,3-sialyltransferase (a2,3-ST) would result in synthesis of 
glycoprotein products with a greater and consistent proportion of fully sialylated N-glycans [24, 35]. The 
resulting oligosaccharides showed greater homogeneity compared with control cell lines, in which ≥90 % 
of available branches were capped with sialic acid [24]. Compared to α2,3-ST expression alone, co-
expression of β1,4-GalT and α2,3-ST in  CHO producing EPO cell line achieved higher sialic acid 
content and more trisialyated glycans [45]. 
Except for sialyltransferases, the availability of nucleotide sugar substrates and the transport of them 
to the Golgi could also determine the extent of protein glycosylation [18]. The biosynthesis of sialic acid 
in mammalian cells takes place in the cytosol, finished in the nucleus and transported to the Golgi (Figure 
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1-2). Especially, in eukaryotes, uridine diphosphate (UDP)-GlcNAc is initially epimerized to N-acetyl 
mannosamine (ManNAc) by UDP-GlcNAc 2-epimerase (GNE), and ManNAc is phosphorylated to 
ManNAc-6-phosphate by ManNAc kinase (MNK). These two enzymes are integrated into a single 
bifunctional enzyme (encoded by GNE) [46] [47] [48]. As a rate-limiting enzyme, GNE is regulated by 
feedback inhibition of the level of cytoplasmic free CMP-Neu5Ac. A genetic disease called “sialuria” 
arises from the absence of feedback regulation of this enzyme, leading to excessive synthesis of free sialic 
acid, which is accumulated in cytoplasm and secreted into urine. 
   This sialic acid pathway enlightens researchers new approaches to increase the sialylation of 
therapeutic proteins.  As a direct precursor of sialic acid, N-acetylmannosamine (ManNAc) 
supplementation has long been studied for its effect on sialylation. Numerous reports demonstrated that 
ManNAc supplementation can significantly increase CMP-sialic acid in the intracellular pool up to 12-
fold ,but only improve protein sialylation to a very limited extent about 10%-20% sialylation increase 
[49] [50] [33].  A similar issue exists with the overexpression of CMP-SAS and sialuria-mutated 
GNE/MNK in the biosynthesis pathway, which cannot further increase sialylation [48] [51] [52] . All 
these approaches could easily increase the intracellular pool of CMP-sialic acid levels, but the next step-
transporting CMP-sialic acid to the Golgi is hampered by the inefficiency of CMP-sialic aid transporter 
(CMP-SAT) on the Golgi membrane, thereby causing the reduced availability of CMP-sialic acid 
substrate for sialylation. Nik Wong et al overexpressed CMP-SAT alone n CHO IFN-ɤ  cell line and 
resulted in 4%-16% increase in site sialylation of IFN-ɤ[3] .  Therefore, combinatorial engineering have 
been adapted in many groups by improving sialic acid content in the intracellular pool and the availability 
in the Golgi. Yeon Tae Jeong et al overexpressed a2,3-ST, CMP-SAS and CMP-SAT in CHO 
recombinant EPO cell line,  and a corresponding increase in the sialylation was observed compared to the 
co-expression of of a2,3-ST and CMP-SAS [52]. Son YD et al introduced sialuria-mutated rat 
GNE/MNK, Chinese hamster CMP-SAT  and human α2,3-sialyltransferase (α2,3-ST) simultaneously into 
recombinant human EPO-producing CHO cells and found the sialic acid content of rhEPO produced from 
engineered cells was 43% higher than that of control cells. Ratio of tetra-sialylated glycan of rhEPO 
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produced from engineered cells was increased ∼32%, and ratios of asialo- and mono-sialylated glycans 
were decreased ∼50%, compared with control [48]. 
1. Overexpression of N-acetylglucosaminyltransferase (GnT) genes  
Overexpresson of branching genes would increase sialylation acceptor sites. For human proteins, bi-, 
tri-, and tetra-antennary structures are produced with complex-type N-glycans consisting predominantly 
of the disaccharide Galβ1,4-GlcNAc capped by a terminal sialic acid. As illustrated in Figure 1-1, tri- and 
tetra-antennary complex N-glycans are controlled by UDP-N-acetylglucosamine:α-1,3-D-mannoside β-
1,4-N-acetylglucosaminyltransferase (GnT-IV or MGAT4) and UDP-N-acetylglucosamine:α-1,6-D-
mannoside β-1,6-N-acetylglucosaminyltransferase (GnT-V or MGAT5). These branched structures are 
associated with various biological functions, including cellular proliferation, cell surface signaling [26], 
cancer metastasis and regulation of T-cell activation [53] and also affect therapeutic proteins’ clearance 
rate by the glomeruli of the kidneys [54]. Nonetheless, in CHO cells, only a small percentage of 
glycoproteins contains the GlcNAcβ1-6 branch, the GnT-V product [55]. Thus, more extensive 
modifications for glycoform distribution are expected if genetic modulations are introduced in the 
branching pathway of N-oligosaccharide biosynthesis, thereby potentially increasing the number of 
sialylation acceptor sites. 
In order to tailor the multi-antennary glycoforms of recombinant proteins, overexpression of GnT IV 
and V were used in CHO cells producing human IFN-ɤ and EPO cell lines [55] [40] . In both cases, tri- 
and tetra-antennary sugar chains have dramatically increased, representing ≥ 50% of the total sugar chains 
and almost all N-glycans were in tri- or tetra-antennary glycoforms[40]. At the same time, an increase in 
poly-N-acetyllactosamine (Galβ1-4GlcNAcβ1-3) was also observed [55]. However, the increase in sialic 
acid content didn’t keep up with the increase of available sialylation acceptor sites because of incomplete 
sialylation. In further studies, mouse ST3 and/or rat ST6 were introduced in CHO IFN-ɤ cell line stably 
transfected with GnT V, reaching 61.2% in a2,3- and a2,6-linked sialic acid content. And the coordinated 
overexpression of GnT IV, GnT V and ST6GAL1 genes in CHO EPO cell line enhanced sialic acid 
content approximately 45% compared to control CHO EPO expressing cells.  
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More recently, an emerging approach to enhance sialylation is to restore GnT I function in CHO 
GnT I-deficient mutants.  The GnT I-deficient mutants are generated either through the lectin Ricinus 
communis agglutinin I (RCA-I) selection or by genetic modulations. Treating the CHO cells with the 
cytotoxic lectin Ricinus communis agglutinin I (RCA-I) was supposed to select mutants with defects in 
the N-glycosylation pathway upstream of galactose addition because it was reported to be specific for 
terminal β1,4-linked galactose [56]. Unexpectedly, genetic analysis of RCA-I-resistant CHO mutants 
showed they are all the same type of mutants with different genetic mutations in the GnT I gene [57], 
similar to Stanley’s Lec1 mutant. A plausible explanation is that RCA-I is not specific for terminal β1,4-
linked galactose but possibly binds many glycan structures except for Man5GlcNAc2 [58]. Without 
functional GnT I, the cells fail to transfer N-acetylglucosamine to Man5GlcNAc2 glycan (Figure 1-1). 
Surprisingly, the restoration of functional GnT I in these mutants led to an increase in the sialylation of 
recombinant proteins both in transient expression as well as in stably transfected clones [57]. While the 
molecular mechanism for this phenomenon remains unknown. Recombinant EPO produced in this RCA-1 
mutant line enhanced 30% sialylation compared with the control EPO producing CHO clone cultured 
under the same conditions. Moreover, HPAEC-PAD and MALDI-TOF MS analyses showed that EPO 
produced by the GnT I-restored CHO-GnT I-deficient cells contained higher content of tri- and tetra-
antennary glycans. 
2. Inhibition of sialidase activity  
Any attempt to maximize sialic acid content of therapeutic protein should also consider the sialidase 
activity because glycoprotein is subject to desialylation and degradation during prolonged cell culture 
[59] [35]. Sialidase (neuraminidases, N-acylneuraminosyl glycohydrolases, EC 3.2.1.18) are 
exoglycosidases catalyzing the hydrolytic removal of sialic acid from sialoglycoconjugates 
(glycoproteins, polysaccharides, gangliosides) [60].Then the asialoglycoprotein product would be rapidly 
cleared from the plasma by asialoglycoprotein receptors in the liver. There are four sialidases (Neu 1-4) 
identified in human, mouse, rat and CHO cells and their activity has been localized on different 
subcellular level: Neu1 is located in the lysosome, Neu2 is a cytosolic protein, Neu3 is located in the 
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plasma membrane and Neu4 is a second lysosomal sialidase. These sialidases can be crucial to various 
biological such as growth control and differentiation, tumorigenesis, T cell activation and immune cell 
interactions, neuronal differentiation and genetic defects [61] [60]. The functions of these sialidases vary 
in part due to different substrate specificities and subcellular locations [35] . Therefore, in mammalian 
cells, it is often desirable to lower the cellular sialidase activity to ensure protein product quality and 
consistency as an effective therapeutic.  
 In mammalian cell culture, the extracelluar sialidase originates from the cytosol of the CHO cells, 
and is released to the cell culture supernatant as a result of cell lysis [62]. The generic technique would be 
to genetically inhibit sialidases’ activity in CHO cells before they are released to the culture medium. 
When gene expression of CHO Neu2 was knocked down to 40% by homologous recombination or RNA 
interference (RNAi), the sialic acid content of the recombinant glycoprotein was improved but only when 
cells were in the death phase [59] [63]. In another study, CHO cells overexpressing recombinant human 
interferon gamma (IFN-ɤ) were treated using short interfering RNA (siRNA) and short-hairpin RNA 
(shRNA) to reduce expression of the Neu1 and Neu3 sialidase genes [38]. By knocking down expression 
of Neu3, a 98 % reduction in sialidase function in CHO cells was achieved. Correspondingly, the sialic 
acid content on recombinant IFN-ɤ was found to be increased 33 % and 26 %, respectively, with samples 
from the cell stationary phase and death phase as compared to corresponding controls [38]. Interestingly, 
Neu2 is a cytosolic protein, Neu3 is located in the plasma membrane, when using the same siRNA 
technique to knock down both genes individually, Neu3 knockdown almost silenced sialidase activity, 
while Neu2 knockdown only reduced sialidase activity to 40%. Unlike Neu2 knock down effects that 
acted exclusively on the death phase, protein sialylation was enhanced in the whole cell process after 
knocking down Neu3 expression, suggesting different mechanisms of protein sialylation regulation by 
Neu2 and Neu3 [35].  
In addition to silence the genes for sialidases, novel approaches have been focused on inhibiting the 
enzymatic activity of sialidase. Bcl-xL, an antiapoptotic protein that inhibits the release of proapoptotic 
molecules from mitochondria, is well-documented for its role on extending culture longevity by 
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suppressing apoptotic cell death and resulting in improved glycoprotein production [64] [65] [66]. While 
overexpression of Bcl-xL also can enhance the sialylation of glycoprotein produced in CHO cell lines by 
reducing cell lysis and delaying the extracellular accumulation of sialidase activity during prolonged cell 
culture [67]. Likewise, the investigation of anti-apoptotic components of silkworm hemolymoh revealed 
Bombyx mori 30Kc19 gene expression can also enhance recombinant protein production and sialylation in 
CHO [68] [69].  Stable expression of the 30Kc19 gene in a CHO cell line producing recombinant human 
EPO would increase the EPO production and sialylation by 102.6% and 87.1%, respectively [69]. 
Moreover, with the introduction of 30Kc19 gene the host suspension cells produced recombinant Human 
EPO with more complex glycan structures and a larger content of sialic acid and fucose. For increased 
productivity, 30Kc19 protein suppresses the loss of mitochondrial membrane potential and consequently 
improves the generation of intracellular ATP and inhibit CHO cell apoptosis[69]. For enhanced 
glycosylation, except for delaying cell lysis and release of sialisase into culture media, the 30Kc19 protein 
is somehow able to maintain the activity of glycotransferases involved in the glycosylation process.  
1.4.2 Antibody sialylation 
For many therapeutic glycoproteins, the terminal sialic acids on glycans can have a clear and critical role 
for a protein’s circulatory lifespan and efficacy.   Serving as a biological mask, the distal sialic acid can 
shield Gal residues that when exposed prompt the rapid removal of the protein from blood circulation due 
to endocytosis-mediated uptake by asialoglycoprotein receptors on hepatocytes [36] [37] [35]. Therefore, 
in mammalian cells, it is often highly desirable to maximize the terminal sialic acid content of non-
antibody glycoproteins in order to ensure their quality and half-life as an effective therapeutic. Even for 
antibodies, the sialic acid can act to alter the properties of the resulting protein[70].  The half-life of many 
antibodies is regulated through antibody Fc CH3 domain binding to the neonatal FcR (FcRn) and is 
believed to be independent of the Fc sugar moiety [71]. However, IgG Fc sialylation has emerged as an 
important topic of intense study in recent years.  Researchers have observed that increasing IgG Fc α2,6 
sialylation enhances the anti-inflammatory activity of intravenous immunoglobulin [72] and sialylation 
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enhancement deteriorates CDC activity[73]; while decreasing Fc sialylation can facilitate FcγR receptor 
binding onto natural killer (NK) cells followed by an increase in ADCC activity[74] [75], and lower 
affinity binding to insoluble or cell-surface antigens, but not affect the antibody binding to soluble 
antigens[76]. The mechanisms of antibody ADCC and CDC activity have been illustrated in Figure 1-3.  
1.  Increase antibody α2,6 sialylation for promoting anti-inflammatory activity. 
 Intravenous immunoglobulin (IVIg) predominantly consists of pooled polyclonal IgG from thousands of 
donors and has been used therapeutically to treat inflammatory diseases at high doses [77] [78]. The 
sialylation on the glycan of the Fc portion of IVIg has been reported to exhibit superior anti-inflammatory 
efficacies over desialylated IVIg and deglycosylated IVIg [72]. Both desialylated IVIg and 
deglycosylated IVIg abrogated the anti-inflammatory effect in vivo [72]. The demand for high doses (1-
2g/kg bodyweight) of unfractionated IVIg is due to a generally low concentration of sialylated IgG in 
human plasma. In a mice model of arthritis, equivalent levels of anti-inflammatory activity were exhibited 
when using 1g/kg IVIg and 0.1g/kg sialic acid-enriched IVIg, indicating a 10-fold enhancement with the 
addition of terminal sialic acids [72, 79]. Several independent in vivo models further confirmed this 
theory that the terminal sialylation of Fc glycans is essential to elicit a sufficient anti-inflammatory 
activity for IVIg [80] [81].  In addition, the presence of α2,6-linked sialic acid residues, rather than  α2,3-
sialic acids, plays a critical role in inducing IVIg-elicited anti-inflammatory activity [79] [82] [76].  
The major issue in using IVIg to treat auto-immune diseases is the inconsistent therapeutic efficacy and 
potency at high-dose administration and the lack of sialylated products for clinical use [83]. Lectin 
chromatography using sambucus nigra agglutinin (SNA) was considered for enriching sialylated IgG 
glycovariants in the IVIg preparation, due to this lectin’s binding specificity to α2,6 sialic acids. One 
analysis of fractions obtained by lectin chromatography revealed that SNA preferentially binds to glycans 
of Fab, which contains 46.2% sialylated N-glycans accounting for 15-25% of serum IgG  [84] [85] [86] 
[87] [88] and an easier accessibility than Fc glycans to bind to SNA lectin [89]. Moreover, experiments 
with a monoclonal antibody from a human cell line and IVIg Fc fragments indicated that at least two 
sialic acids in the Fc region of an antibody are required for lectin binding [89] [85]. Such glycoforms 
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contain either two monosialylated glycans (S1-S1 glycoform) or a disialyated glycan (S2-S0 glycoform), 
which represents 1% or less of the total human IgG [90] [89] [85]. 
These restrictions have stimulated researchers and engineers to generate therapeutic alternatives that 
could leverage the broad mechanisms of action of IVIg while improving therapeutic consistency and 
potency in a scalable and controllable antibody production process. Washburn et al proposed a controlled 
and scalable process to produce fully hyper-sialylated IVIg (S2-S2 glycoform) by treating native IVIg 
with in vitro β1,4-galactosyltransferase and α2,6-sialyltransferase [83]. The in vivo characterization of this 
drug candidate revealed consistent and enhanced anti-inflammatory activity up to 10-fold higher than 
native IVIg across different animal models [83]. A mass spectrometric quantification revealed that the 
IVIg preparation consist primarily of the IgG1 isotype[89]. Furthermore, a completely α2,6-sialylated 
recombinant IgG1 greatly enhanced potency at a much reduced dose of 0.03g/kg bodyweight compared to 
1-2g/kg bodyweight for native IVIg [79].  
In terms of increasing antibody sialylation in cells, the sialylation of the antibody is controlled 
primarily by the interaction of local IgG structure with the carbohydrate and the accessibility of the 
sialyltransferase to sialylate the N-glycan on the polypeptide[91]. Overexpression of α2,6 sialyltansferase 
(α2,6-ST) in a recombinant IgG-producing CHO cell line has been examined for increasing the sialylation 
content of recombinant IgG[92] [93].  For example, transfection of rat α2,6 sialyltransferase increased the 
sialylation content in a CHO IgG3 expressing cell line [92] .The recent report on genomic sequence of the 
CHO-K1 cell line revealed that ST6GAL1 gene is retained in CHO genome, but its expression is severely 
suppressed and regulated [94].  The introduction of an endogenous CHO ST6GAL1 gene into the CHO 
cell line can serve to enhance the α2,6 sialylation level of recombinant proteins in CHO[95]. Most 
attempts to overexpress ST6GAL1 in CHO revealed that this approach could only moderately enhance 
α2,6-sialylated glycans, and the mixture of α2,6 and α2,3 sialylation existed in the final glycoforms[96] 
[93]. Meanwhile, co-overexpression of β1,4-GalT and α2,6-ST was implemented to achieve a 
glycoprofile dominated by α2,6-sialylation for recombinant antibody production[74]. More recently, our 
group disrupted two α2,3 sialyltransferases (ST3GAL4 and  ST3GAL6) and combined this cell line 
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variant with α2,6 sialyltransferase overexpression in pursuit of  an exclusive α2,6 sialylated CHO cell line 
[97].  Antibody produced in our α2,3 sialyltransferase knockout-α2,6 sialyltransferase overexpressing 
cells contains solely α2,6 sialylation [97].   
 Amino acid substitution of specific residues in the CH2 domain of the IgG molecule provides an 
alternate route to modulate IgG sialylation level in independent of the sialyltransferase overexpression 
approach discussed above. Replacing Phe241, Phe243, Val264, Asp265 or Arg301 with alanine in each case on 
an IgG3 antibody can increase sialylation and galactosylation. In particular, 73% of oligosaccharide 
chains were monosialylated or disialylated in F243A mutant and around 40% of oligosaccharide chains 
were sialylated in F241A and V264A mutants relative to compared to wild-type IgG3 with negligible 
levels (4% sialylation) prior to the mutations 
[91] [98].  To an even lesser extent, D265A and R301A mutants increased IgG3 sialylation about 30% 
and 16% individually [91] [98]. Crystallographic analysis and nuclear magnetic resonance (NMR) 
analysis revealed that the F241A and F243A replacement caused localized destabilization of the protein-
glycan interface in the CH2 domain, indicating a greater degree of conformational flexibility and mobility 
compared to native Fc [98] [99] [100], enabling the carbohydrate to obtain increased access to 
glycosyltransferases [101].  
Taking together, the combination of  IgG protein mutations with sialyltransferase overexpression 
can further maximize the sialylation content on antibody Fc region.  In one study, the F243A replacement 
resulted in 53% α2,3 sialylation of either one or both branches of the N-glycans of a recombinant IgG3 
produced in CHO, and following transfection of rat ST6GAL1 into this line, 60% of IgG-Fc-linked 
glycans were S1 or S2 sialylated with a mixture of α2,3 and α2,6 sialic acids [92]. Our group investigated 
single and multiple amino acid substitutions of the Fc region with sialyltransferases knock-in and knock-
out strategy to alter the sialylation pattern on IgGs expressed from CHO cells.   Four single amino acid 
mutations (F241A, F243A, V262E and V264E) as well as combining all mutations in IgG expressing 
CHO cells resulted increased α 2,3 sialylation and combining all the 4 mutations resulted in the highest 
levels of α2,3 sialylation in unmodified CHO K1 cells.  Engineering CHO cells containing dual knockouts 
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of the ST3GAL4 and ST3GAL6 encoding α2,3 sialyltransferase together with overexpression of α2,6 
sialyltransferase (ST6Gal1) resulted in the exclusively α 2,6 sialylated antibodies.  One clonal isolate 
contained over 60% disialylated glycans (G2FS2) and approximately 80% glycans sialylated on one or 
both branches.  These studies demonstrated a new strategy in antibody glycan design incorporating 
genome and protein engineerings in order to control and tailor specific glycan profiles.  
2. Antibody Fc sialylation may affect ADCC and CDC activities 
Distinct from the anti-inflammatory activity, the sialylation of IgG Fc region can also affect other 
properties of antibody, such as ADCC and CDC activities. So far, the influence of antibody sialylation on 
ADCC activity has yet been settled and distinctive results exit. For example, expression of exogenous 
sialidase A gene in mammalian cells resulted in the expression of soluble enzyme that was capable of 
removing sialic acid from antibodies secreted into the medium. ADCC assay showed that the two IgG1 
antibodies expressed in sialidase A-transfected cells had greater than 10-fold improved potency compared 
to the control mock-transfected IgG1s [75]. Using zinc-finger nucleases to inactive CMP-sialic acid 
transporter gene resulted in a mutant CHO cell line lacking functional CMP-sialic acid transporter and the 
removal of sialic acid from IgG1 reported ADCC enhancement [102] . In contrary, several recent 
investigations revealed that Fc sialylation doesn’t impact the in vitro FcγRI and IIIa receptor binding and 
ADCC activity of IgG1, whether it is mono- or di-sialylated glycans[73, 103]. However, mono-sialyalted 
IgG1 showed a slight binding improvement to FcγRIIa than bi-sialylated IgG1[103, 104]. Regarding to 
CDC activity, the presence of terminal sialic acid deteriorate IgG1 C1q binding and reduced C3b 
deposition on the cell surface [73].  
Antibody sialylation clearly promote anti-imflammoary actitiy in a α2,6 sialylation manner, but the 
mechanisms of antibody sialylation on other effector functions, such as ADCC, has rarely been studied 
and further explorations are necessary to elucidate the role of  Fc sialylation on antibodies. 
1.4.3 Antibody defucosylation 
Numerous studies have shown that the core-fucose residue of the CH2-associated N-linked 
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oligosaccharides plays a critical role in regulating the magnitude of  antibody effector function ADCC 
[105] [106] [107] [108] [109]. Compared to the fucosylated antibodies from wild-type CHO cells, 
defucosylated antibodies exhibited 100-fold higher ADCC in vitro [110].  The core fucose is bound 
through a α-1,6 linkage to the innermost GlcNAc residue on an N-oligosaccharide (Figure 1-3C),  which 
could hinder Fc binding to Fc receptors of lymphocytes[108]. It has been demonstrated that the antibody 
ADCC enhancement due to fucose elimination is attributed to a subtle conformational change in a limited 
region of IgG1-Fc, resulting in higher Fc binding to gamma receptor IIIa (Fc FcɤRIIIa) on NK cells[109, 
111] [112].  Compared to amino acid mutations in the antibody Fc region, enhanced binding affinity for 
FcɤRIIIa of fucose-negative antibody alone is sufficient to induce maximal ADCC [113] . 
Moreover, antibodies with Fc regions containing nonfucosylated N-glycans exhibit dramatically 
enhanced ADCC without any detectable change in CDC or antigen binding capability [108] [114].  The 
lack of fucose is primarily responsible for controlling binding to FcɤRIIIa receptor and in the recruitment 
of mononuclear cells (primarily NK cells) as effector cells for ADCC[105, 110, 115]. However, studies 
on polymorphonuclear cells (PMNs) found that highly-fucosylated antibodies were preferentially more 
effective in triggering PMN, which mediated tumor cell lysis via FcɤRII[110]. Thus, the impact of Fc 
fucosylation on ADCC still needs further exploration and may be critically dependent on the specific 
effector cell type recruited. Given that the majority of monoclonal antibodies on the market are targeted to 
mediate cytotoxicity of NK effector cells, we will focus on the defucosylation of antibodies here.  
1. Inactivation of α1,6 fucosyltransferase---Disruption of FUT8 gene 
Inactivation of the α1,6 fucosyltransferase has been extensively studied and still represents the most 
efficient cellular modification preventing the addition of fucose to the core of the complex N-glycan .  In 
mammals, the FUT8 gene encodes α-1,6 fucosyltransferase in the medial Golgi cisternae that catalyze the 
transfer of fucose residues from GDP-fucose to the innermost GlcNAc of the tri-mannosyl core structure 
via the α1,6 linkage[116]. In order to generate non-fucosylated antibodies, disruption of the FUT8 gene 
has been investigated via various approaches as discussed below [117] [108] [118] [119].   
Traditionally, numerous methods such as antisense cDNA, shRNA or transgenic overexpression 
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were used to reduce or remove fucosylation [120]. The introduction of small interfering RNAs (siRNAs) 
against the FUT8 gene reduced FUT8 mRNA expression to 20% in CHO/DG44 cells and combined with 
Lens culinaris agglutinin (LCA) selection yielded 60% antibody defucosylation with over 100-fold higher 
ADCC [117]. Disrupting both FUT8 alleles in CHO/DG44 cell line by sequential homologous 
recombination produced completely defucosylated recombinant antibodies. Chimeric anti-CD20 IgG1 
produced from FUT8-/- CHO cells showed the same level of antigen-binding activity and CDC as the 
FUT8+/+-produced [108]. However, the time-consuming homologous recombination strategies either 
cannot produce completely nonfucosylated antibodies or the complete knockout of FUT8 is reversible and 
the difficulty of recapitulating the knockout in protein-production cell lines has prevented the widespread 
adoption of homologous recombination  FUT8-/- cells as hosts for antibody production [121] [120] [108]. 
To improve the efficiency of disrupting FUT8 gene, technologies such as zinc-finger nucleases (ZFNs) 
and transcription activator-like effector nucleases (TALENs) were developed and reported [121] [122]. 
Using zinc-finger nucleases (ZFNs) to disrupt the FUT8 gene in a region encoding the catalytic core of 
the enzyme produced FUT8-/- CHO cells in 3 weeks at a frequency of 5% in the absence of any selection, 
and these lines produced antibodies completely lacking core fucosylation but having an otherwise normal 
glycosylation pattern without adverse phenotypic effects [121]. Separately, Cristea et al. demonstrated 
knockout of FUT8 gene via simultaneous TALE nuclease-mediate integration of an antibody cassette 
[122]. Composed of sequence-specific DNA-binding domains connected to a nonspecific DNA nuclease, 
ZFNs and TALENs enable a broad range of genetic modulations by inducing DNA double-strand breaks 
that stimulate error-prone nonhomologous end joining (NHEJ) or homology-directed repair (HDR) at 
specific genomic locations [123] [124].  Thus, NHEJ can be harnessed to mediate functional disruptions 
of target genes, as indels occurring in a coding region could lead to frameshift mutations and protein 
function loss [125] [126].  
More recently, distinct from the protein-based ZFNs and TALENs, the CRISPR (clustered regularly 
interspaced short palindromic repeat)/Cas9 (CRISPR-associated protein 9) system,  derived from the 
microbial adaptive immune system [127], has emerged as a potentially facile and efficient alternative for 
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inducing targeted genetic alterations [124], , and applied to diverse species such as plants, animals, 
bacteria, and yeast [128], as well as in CHO cells [129] [126] . Instead of protein-DNA binding in ZFN 
and TALEN systems, the CRISPR system required only Cas9 nuclease and single guide RNA (gRNA) 
binding to targeted DNA sequence[130], giving it several advantages including ease of customization, 
higher targeting efficiency, and multiplexed genome editing capability [131]. Sun et al. reported 
functional FUT8 disruptive clones (FUT8-/-) in CHO cells using CRISPR/Cas9 were obtained within 3 
weeks at indel frequencies ranging from 9 to 25%, which was enhanced to 52% with LCA selection and 
the derived FUT8-/- clone had the ability to produce defucosylated therapeutic mAb with no detrimental 
effects on cell growth, viability or product quality [126]. Moreover, Grav et al. employed CRISPR/Cas 9-
targeted FUT8, BAK and BAX triple knockouts simultaneously and created a cell line producing 
afucoylated antibody with improved protein productivity [132].    
2. Overexpression of GnT-III 
A different and complementary approach to improve an antibody’s biological activity would be to 
overexpress β-1,4-N-acetylglucosaminyltransferase III (GnT-III) enzyme to produce antibodies enriched 
in bisecting oligosaccharides. GnT-III is a Golgi-localized enzyme that catalyzes the addition of an N-
acetylglucosamine (GlcNAc) residue on to a bisecting position of the N-linked oligosaccharide, as 
depicted in Figure 1-1 [133].  Overexpression of the GnT-III gene in a CHO cell line expressing an anti-
neuroblastoma IgG1 resulted in enhanced ADCC activity because bisecting GlcNAc inhibits fucosylation 
and further elongation of the N-glycan structures [134].  Thus, GnT-III overexpression leads to an 
increase in non-fucosylated and hybrid oligosaccharides content, which further enhance binding affinity 
for FcɤRs [135] [136]. Overexpression of the GnT-III in a CHO cell line producing anti CD-20 antibody 
resulted in a 20-fold lower antibody dosage in order to achieve the same ADCC effect induced by the 
antibody produced from the parental CHO cell line [137]. Furthermore, by fusing the catalytic domain of 
GnT-III to the localization domain (cytoplasmic, transmembrane, and stem region) of other Golgi-resident 
enzymes of the N-glycosylation pathway in HEK293-EBNA cells, a chimeric GnT-III was expressed that 
can compete even more efficiently against the endogenous core a1,6-fucosyltransferase, yielding 
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principally bisected non-fucosylated hybrid-rich glycans  [135]. Golgi alpha-mannosidase II (Man II) 
yields the GlcNAc2Man3GlcNAc1 precursor for all biantennary, complex N-glycans as illustrated in 
Figure 1-1. Co-expressing both GnT-III and Man II led to a higher proportion of bisected non-fucosylated 
complex-rich glycans [135]. While both glycovariants featured strongly increased ADCC activity 
compared to the wild-type antibody, the hybrid-rich antibody showed reduced CDC compared to 
complex-rich or wild-type counterparts [136] [138]. It is worth noting that the effect of bisecting GlcNAc 
of the IgG1 on enhancing ADCC is modest when compared to that of defucosylated IgG1, therefore, the 
lack of fucosylation  appears to play the critical role in the enhancement of ADCC[137] [134] [106].  
 3. Inhibiting the supply of nucleotide sugar substrate for fucosylation 
An alternative approach for producing fucose-negative antibodies is to knockout enzymes 
responsible for biosynthesis of GDP-fucose, the donor for fucosyltransferase in the Golgi apparatus. The 
advantage of this approach is that it targets all fucosyltransferases, not just FUT8 [120]. In mammalian 
cells, GDP-fucose is synthesized by two distinct pathways as illustrated in Figure 1-4. The de novo 
pathway is characterized by the conversion of GDP-mannose to GDP-4-keto-6-deoxymannose by GDP-
mannose 4,6-dehydratase (GMD). This keto intermediate is then converted to GDP-fucose by GDP-4-
keto-6-deoxymannose-3,5-epimerase-4-reductase (GMER, or FX protein). The salvage pathway directly 
utilizes fucose that is transported into the cytosol from an extracellular origin or fucose that is liberated 
from catabolism of fucosylated glycans in the lysosome and then transported into the cytosol [139]. The 
salvage pathway is enabled by fucokinase and GDP-fucose pyrophosphorylase (GFPP) [139]. 
Subsequently, GDP-fucose synthesized by these two pathways is transported into the lumen of the Golgi 
apparatus by GDP-fucose transporter (GFT) [140]. 
Reduction-of-function analyses using siRNA revealed three key genes involved in oligosaccharide 
fucosylation, including α1,6-fucosyltransferase (FUT8), GDP-mannose 4,6-dehydratase (GMD), and 
GDP-fucose transporter (GFT).  Single-gene knockdown of the individual targets was insufficient to 
completely defucosylate the products in antibody-producing cell lines [141]. For GFT, introduction of a 
CHO GFT siRNA expression plasmid into a human antithrombin III (AT-III)-producing cell line showed 
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approximately 75% reduction of Golgi GDP-fucose, resulting in 10-40% defucosylation in AT-III [140].  
Similarly, Kanda et al. reported expression levels of GFT mRNA could be reduced more than 90% in 
GFT siRNA-expressing antibody-producing CHO cells, but only a 20-40% reduction of the recombinant 
IgG Fc oligosaccharide fucosylation was observed [142]. In all, a positive relation between the Fc 
oligosaccharide fucosylation and the mRNA expression for both GMD and FUT8, but not for the GDP-
fucose transporter, was observed suggesting that GMD and FUT8 are independent bottlenecks for α1,6 
fucosylation [142] . 
 Alternatively, a mutant of the Pro- CHO 5 cell, Lec 13, has been isolated using lens culinaris 
agglutinin (LCA) selection, with a loss of GMD activity resulting in only 10% of fucose residing on the 
glycan chain compared to the parental cell line [143]. But Lec13 is unsuitable for the serum-free fed-
batch production of fucose-negative antibody because the remaining GMD activity in Lec13 accumulates 
intracellular GDP-fucose via the de novo pathway and gradually increases the ratio of fucosylated 
products with extended culture [144]. Alternatively, a GMD knockout in CHO/DG44 cells was devoid of 
intracellular GDP-fucose and to produce completely non-fucosylated antibodies, but the fucosylation 
could be recovered through the salvage pathway upon the addition of L-fucose into the culture medium 
[142]. Alternatively, a double knockdown of FUT8 and GMD using a short hairpin siRNA tandem 
expression vector could rapidly convert antibody-producing CHO cells to fully non-fucosylated antibody 
producers in serum-free fed-batch culture [141].  
Thus, a consideration of fucosylated and non-fucosylated antibody levels is important in order to 
control the product’s quality and efficacy, especially around ADCC, as required by regulatory authorities 
[145].  While a commonly used strategy in CHO host cells to generate defucosylated antibody is to knock 
out the FUT8 gene, which can result in completely afucosyalted antibodies, this approach may predicate 
parallel cell line development of both the afucosylated and unmodified host cell lines. Furthermore, large-
scale clone screening to obtain primarily unmodified and FUT8-KO clones with highly similar product 
quality attributes, excepting the presence of fucose residues in the unmodified clones, will be useful in 
ensuring that any advantage observed on ADCC can be attributed specifically to afucosylation [145]. To 
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circumvent these issues, other approaches have been explored and developed to evaluate the importance 
of fucosylation without knocking out or down the FUT8 gene. Given the nature of fucosylation 
mechanism in CHO (Figure 1-4), cells with an inhibition of the de novo pathway depend on the salvage 
pathway to synthesize GDP-fucose which requires L-fucose feeding to the cell culture media. Thus, once 
the de novo pathway is blocked,  L-fucose can added as a switch to changing antibody glycan profiles 
from the afucosylated to fucosylated glycan variants without affecting other product quality features 
The use of small interfering RNAs (siRNA) have knocked down the expression of  FUT8, GDP-
mannose 4,6-dehydratase (GMD) and GDP-fucose transporter (GFT) in the fucosylation pathway and 
reduced antibody fucosylation content[117, 141]. However, it may cause unpredictable off-target effects 
that are impractical to implement at the manufacturing level. Likewise, overexpression of the prokaryotic 
GDP-6-deoxy-D-lyxo-4-hexulose reductase (RMD) enzyme [146] could share similar drawbacks. RMD 
enzyme converts GDP-mannose to GDP-6-deoxy-d-lyxo-4-hexulose and reduces the GDP-6-keto-6-
deoxy-mannose synthesis in the de novo pathway [146]. Also, as mentioned above, the expression of 
GnTIII overexpression can generate glycan species that are not commonly present on antibodies and may 
not be desirable for product quality consistency [145]. Addition of chemical inhibitors such as 2-deoxy-2-
fluoro-L-fucose [147] add expense and have off-target activities that may risk increasing product 
heterogeneity.  
Furthermore, The utilization of a GMD KO host for expression of fully afucosylated antibodies has been 
suggested [142], but the specific productivity reported for the GMD knocked out cell line was not very 
high [142].  Alternatively, FX protein (or called GMER) knock out clones via CRISPR approach can 
express antibodies with comparable productivity as parental host with a desired ratio of primarily 
fucosylated to afucosylated glycans when L-fucose is titrated into the production media in order to 
achieve intended levels of FcγRIII-binding and ADCC for an antibody [145].   Thus, there are a variety of 
different cell engineering and media modification strategies that can be applied to alter the fucosylation 
status and potential ADCC efficacy of antibody biotherapeutics.  Choosing which one to use will depend 
on the effectiveness and practical implementation of the technique as well as a consideration of other 
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factors including biomanufacturing compatibility and availability based on intellectual patent 
considerations.  
1.4.4 High-mannose glycan generation 
Aside from complex and hybrid N-glycan types, high mannose glycans (Man5-9GlcNAc2) are 
characterized by terminal mannose sugars of five to nine residues attached to the GlcNAc2 core [148]. 
They are typically non-natural glycoforms, accounting for below 5% of the recombinant therapeutic 
antibody glycoprofile, but they can have a major impact on in vivo therapeutic activity--- enhancing 
ADCC , decreasing CDC and increasing clearance rate [149] [150] [151, 152]. In addition, high-mannose 
glycans have been widely applied to generate minimally glycosylated glycoproteins for X-ray 
crystallography [153]. 
Golgi N-acetylglycosaminyltransferase I (GnT-I, also called Mgat1) is a type II transmembrane 
enzyme that plays a key role in the biosynthesis of N-linked glycans [154].  As shown in Figure 1-1, it 
specifically transfers GlcNAc from UDP-GlcNAc onto the  α 1,3 branch  of the oligomannose core to 
initiate hybrid and subsequently complex N-linked carbohydrate synthesis in the medial Golgi [154]. 
Thus, methods for increasing high mannose levels focus on inhibiting glycosylation in or before the 
medial-Golgi, mainly by knocking down or knocking out the GnT-I gene.  
For high mannose glycans, one of the most widely used and numerously studied cell lines is the 
Lec1 CHO mutant cell line [155]. Owing to a defect in GnT-I, Lec1 cells synthesize only oligomannose-
type N-glcyans [156] [154, 157]. Over the years, two discrepancies have emerged concerning about the 
Lec 1 cells, one concerns the unpredictable high mannose oligosaccharide (Man5-Man9) distribution in 
Lec 1 cells[158] [112] [152], while another focuses on the presence or absence of core α1,6 fucosylaiton 
in theLec 1 cell line [159] [152] [160], which prohibits its extensive application in industry.  Recently, 
new high mannose cell line alternative to Lec 1 have been established using genetic techniques in order to 
study the role of GnT-I in glycosylation. Sealover et al. reported the use of zinc-finger nuclease (ZFN) 
genome editing technology to disrupt GnT-I gene in CHO, generating cell lines that produce recombinant 
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proteins predominantly bearing Man5 glycans [161]. They successfully generated 5 clones out of 90 
(5.6%) containing deletions in the GnT-I gene without lectin enrichment, and all five GnT-I-deficient cell 
lines demonstrated similar growth and productivity characteristics to the wild-type CHO-K1 host cell line 
[161]. Alternatively, Lee et al. demonstrated efficient targeted gene integration into site-specific loci in 
CHO through CRISPR/Cas9 genome editing together with a compatible donor plasmid harboring short-
homology arms, the gene of interest (GOI), and a fluorescent marker gene as an indicator of random 
integration[162]. By applying CRISPR/Cas9 and homology-directed DNA repair (HDR) mediated 
targeted integration, the GnT-I locus was completely disrupted in most target clonal cells (20 out of 25 
clones), which showed a relative GnT-I copy number of close to 0 compared with that of 1 in GnT-I in 
CHO-S wild type cells[162].  
1.4.5 Obtaining Homogeneous Glycan Patterns 
Another issue with N-glycans of recombinant antibody is the generation of heterogeneous glycoforms, 
which can present challenges in protein purification, product consistency and lot-to-lot reproducibility, 
resulting in variable therapeutic efficacy. For example, this diversity can adversely affect drug potency 
and pharmacokinetics [163] [164]. However, N-glycans are often crucial for protein folding, so these 
difficulties cannot be overcome by removing N-glycosylation sites [165]. Heterogeneity is attributed to 
the lack of 100% enzymatic efficacy of each step in mammalian N-glycan biosynthesis and the 
completion of different enzymes for same substrates [165].  
To solve this issue, Meuris et al. introduced a new strategy (GlycoDelete) of shortcutting N-glycosylation 
to simple and homogenous glycoproteins expressed in HEK293S cells, as shown in Figure 1-5[165]. 
Briefly, the authors inactivated N-acetylglucosaminyltransferase I (GnT-I) to produce high-mannose 
glycans. Then they overexpressed an endo-N-acetylglucsoaminidase (Endo T) targeted to the trans-Golgi, 
followed by Concanavalin A (ConA) lectin selection. With the following actions galactosyltransferases 
(GalT) and sialyltransferses (SialT) in the Golgi, GlycoDelete cells produce proteins with the Gal-
GlcNAc disaccharide or its α-2,3-sialylated trisaccharide derivative and some of the monsaccharide 
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intermediate [165] . To assess the potential of these GlycoDelete glycans and their influence on 
therapeutic proteins, human GM-CSF (hGM-CSF) and an anti-CD20 antibody were produced in 
HEK293s and HEK293sGlycoDelete cells [165]. For hGM-CSF the presence of altered glycan obtained 
using the GlycoDelete  cells had no detectable effect on the activity of the protein generated by these 
cells. On the other hand GlycoDelete anti-CD20 exhibited a significantly reduced FcɤR affinity and an 
increased circulation time in mice compared to HEK293s produced anti-CD20 [165] [166].             
Finally, in order to provide homogenous glycoforms, Zhang et al. conducted a comprehensive Zinc-finger 
nuclease knockout screen of 19 glycosyltransferase genes and identified the key genes that control 
decisive steps in N-glycosylation in CHO [167]. The authors stacked knockouts of GnT-IV-A/GnT-IV-
B/GnT-V to produce almost homogenous biantennary N-glycans [167]. Subsequently, the introduction of 
ST6Gal-I in CHO ST3Gal4/6 knockout cells produced a normal range of N-glycans with only a2,6-
sialylation, and when combined with  a GnT-IV-A/GnT-IV-B/GnT-V knockout, homogenous biantennary 
N-glycans capped by a2,6-sialylation were generated [167]. 
1.5 Summary and Conclusions 
This chapter has highlighted the role of glycosylation as a critical quality attribute in biotherapeutic 
production, and more importantly how these glycans can be manipulated in CHO expression system through 
cell engineering, as summarized in Table 1-1. Mammalian cell lines such as CHO can produce valuable 
recombinant proteins that can be accepted by human as therapeutics. However, subtle differences between 
glycosylation in human and other mammals exist and understanding these differences requires knowledge 
of the physiological characteristics of each cell type. Moreover, these differences can help to direct efforts 
towards glycan re-engineering in order to make a greater variety of glycan moieties in CHO cells. Efforts 
to exert control over protein glycosylation in CHO cells have been demonstrated through several success 
stories such as the maximization of terminal sialylation to extend therapeutic circulatory half-life. 
Furthermore, the implementation of a new set of valuable tools and technologies, such as the application of 
genomics, proteomics, glycomics and other ‘omics tools has enabled users to obtain an even better 
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understanding of the glycosylation pathways present in mammals and how they differ ever so subtly across 
species. The advent of advanced technologies such as CRISPR Cas9, TALE nucleases,RNA interference 
tools as well as the combination of  next-generation of sequencing with systems biotechnology enable 
specific changes in cell glycosylation processing. These tools and knowledge bases will enable cell 
engineers to make even more highly refined and targeted modifications to the processing capability of these 
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Figure 1-1. Schematic of N-glycosylation biosynthesis pathway in CHO cells 
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Figure 1-2. Schematic representation of sialic acid biosynthesis pathway in mammalian cells. 
  
Figure 1-3. The Fc glycans on IgG affects antibody effector functions. Figure 1-3A,Human IgG1 structure with glycans 
attached at Asn297 N-glycosylation site in the CH2 of the Fc region. C: constant domain; V: variable domain; H: heavy 
chain; L: light chain; S-S: disulfide bond; Fab: Fragment antigen binding domain; Fc: Fragment crystallizable domain. Fc 
regions which binds effector molecules and cells. Figure 1-3B, the schematic diagram of antibody-dependent cellular 
cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) mechanisms in immunology. Figure 1-3C, the 
representative glycan structures identified on antibody Fc region 
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Figure 1-4.  The pathways of oligosaccharide fucosylation in mammalian cell lines. GMD: GDP-




Figure 1-5. Schematic of GlycoDelete strategy, modified from  Meuris et al. [165]. 
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Chapter 2 Characterization of intact glycopeptides reveals the 
impact of culture media on site-specific glycosylation of EPO-Fc 
fusion protein generated by CHO-GS cells 
2.1 Summary 
With the increasing demand to provide more detailed quality attributes, more sophisticated 
glycan analysis tools are highly desirable for biopharmaceutical manufacturing. Here, we 
performed an intact glycopeptide analysis method to simultaneously analyze the site-specific N- 
and O-glycan profiles of the recombinant EPO-Fc protein secreted from a CHO-GS stable cell line 
and compared the effects of two commercial culture media, EX-CELL (EX) and immediate 
Advantage (IA) media, on the glycosylation profile of the target protein.  EPO-Fc, containing the 
Fc region of IgG1 fused to erythropoietin (EPO), was harvested at Day 5 and 8 of a batch cell 
culture process followed by purification and N- and O-glycopeptide profiling. A mixed anion 
exchange (MAX) chromatographic column was implemented to capture and enrich N-linked 
glycopeptides. Using intact glycopeptide characterization, the EPO-Fc was observed to maintain 
their individual EPO and Fc N-glycan characteristics in which the EPO region presented bi-, tri- 
and tetra-branched N-glycan structures, while the Fc N-glycan displayed mostly bi-antennary 
glycans. EPO-Fc protein generated in EX medium produced more complex tetra-antennary N-
glycans at each of the 3 EPO N-sites while IA medium resulted in a greater fraction of bi- and tri-
antennary N-glycans at these same sites. Interestingly, the sialylation content decreased from sites 
1 to 4 in both media while the fucosylation progressively increased with a maximum at the final 
IgG Fc site.  Moreover, we observed that low amounts of Neu5Gc were detected and the content 
increased at the later sampling time in both EX and IA media. For O-glycopeptides, both media 
produced predominantly three structures, N1F1F0SOG0, N1H1F0S1G0, and N1H1F0S2G0, with 
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lesser amounts of other structures. This intact glycopeptide method can decipher site-specific 
glycosylation profile and provide a more detailed characterization of N- and O-glycans present for 
enhanced understanding of the key product quality attributes such as media on recombinant 
proteins of biotechnology interest. 
2.2 Introduction 
The glycan profile of therapeutic proteins expressed in Chinese hamster ovary (CHO) cells 
is a critical quality attribute (CQA) in biopharmaceutical manufacturing because more than half of 
the biotherapeutic drugs on the market are glycoproteins and the majority are secreted from CHO 
cells [176]. As a result, CHO cells are currently the most prevalent platform for biotherapeutic 
production and monitoring and control of their glycan patterns is an important objective of the 
biotechnology industry since the glycosylation patterns on therapeutic proteins can sometimes 
affect their bioactivity, immunogenicity, drug efficiency, and clinical safety [18]. For example, the 
removal of core fucosylation can significantly improve the antibody-dependent cell-mediated 
cytotoxicity (ADCC) and increase antibody binding efficiency to the FcγRIIIa receptor [114] and 
its binding to natural killer (NK) cells [177]. Elimination of terminal galactose on IgG1 reduces 
its binding to C1q complex and impairs complement-dependent cytotoxicity (CDC) activity [151, 
178, 179]. Terminal sialylation on glycoproteins such as erythropoietin (EPO) is important for 
circulatory half-life in blood [48, 180]. The existence of N-glycolylneuraminic acid (Neu5Gc) in 
the final drug product represents a potential immunogenic chemical because human cells do not 
typically generate Neu5Gc due to a genetic mutation of the CMP-Neu5Ac hydroxylase (CMAH) 
gene [181, 182]. Therefore, the detailed characterization and control of the glycosylation profile 
of therapeutic proteins is pivotal to ensure the efficacy and safety of final drug products. 
According to recent regulatory documents (Fournier 2015), not only the glycan 
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composition, including mannosylation, galactosylation, fucosylation and sialylation, but also the 
glycan branch distribution and even the glycosylation site information can be useful and should be 
well characterized if possible. Indeed, the control and monitoring of the glycan profile of 
therapeutic drugs to ensure lot-to-lot consistency and accuracy is a continual challenge for 
manufacturers.  Given the non-template driven nature of post-translational glycosylation 
processes, various parameters intracellularly and extracellularly can affect the final glycoforms on 
glycoproteins in mammalian cells. The glycosylation process initiates in the lumen of the 
endoplasmic reticulum (ER) followed by elongation and completion in the Golgi apparatus [13, 
183]. As an enzyme-directed, site-specific process, the activity and availability of the relevant 
glycosyltransferases and the metabolite fluxes through nucleotide sugar synthesis and 
transportation pathways are critical to the final glycan profile of recombinant proteins [184]. 
Numerous process effects, such as the composition and nutrients in the culture media, harvest time, 
culture temperature, pH, CO2 and dissolved oxygen (DO) level can also affect the final glycoforms 
of therapeutic proteins [18].  Among all the variations, the culture media composition dictates the 
nutrients incorporated, which can directly affect the final glycan profile of recombinant proteins. 
For example, the feeding of uridine, manganese chloride, and galactose in the culture media can 
improve antibody galactosylation better than individual additions, and the extent of antibody 
galactosylation can be adjusted by changing their concentrations in the culture media [185, 186]. 
Supplementation with 20-40 mM N-acetylmannosamine (ManNAc), an intermediate precursor in 
the sialyation pathway, can also increase the protein sialylation about 10-20% [50]. Thus, the 
variety of glycosyltransferase types and contents, nutrient feedings, and possess parameters can 
lead to considerable diversity in the glycosylation of recombinant IgG and other therapeutic 
glycoprotein products. The glycans generated can further pose a daunting challenge for analytics 
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processing [187].  
Advanced analytical techniques based on mass spectrometry have revolutionized the 
identification and characterization of glycans [188, 189]. Current approaches for glycan analysis 
typically include the release of carbohydrates from glycoproteins (deglycosylation), either by 
enzymatic or chemical reactions [189]. For N-glycans, PNGase F, which reacts between the 
innermost GlcNAc and asparagine residues, is currently the most effective enzyme to cleave most 
N-glycans. For O-glycans, so far no single enzyme was found to be able to remove all the types of  
O-glycans, but O-Glycosidase can specifically remove Core 1 and Core 3 O-glycans [190]. 
Chemical reaction-beta elimination- is still the prevalent method for O-glycan release, which may 
pose low efficiency and high detection noise drawbacks [191].  Derivatization with a fluorescent 
tag, such as 2-aminobenzamide (2-AB) and 2-aminobenzoic acid (2-AA) through reductive 
amination or glycan permethylation are effective approaches to increase the detection sensitivity 
and gain glycan structural information [189, 192]. However, a major challenge for released glycan 
analysis is that it cannot provide site-specific glycan information, and often requires multiple 
sample preparation steps, which may be time-consuming.  
A complementary approach for glycan analysis is intact glycopeptide characterization. 
With glycans remaining attached to the protein sites, this strategy can elucidate the glycopeptide 
amino acid sequence, the glycosylation site information, and the glycan composition 
simultaneously [193] [194]. Due to the inherent complexities of intact glycopeptides, this 
analytical method faces several complications: 1. The glycopeptides can be suppressed by non-
glycopeptides in the mass spectrometry because of their low ionization efficiency [195]. Therefore, 
a glycopeptide enrichment step may help to enhance the mass spectrometry performance. 2. The 
commonly used collision-induced dissociation (CID) fragmentation method was reported to have 
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difficulty in generating a diverse collection of peptide backbone fragments, which can make 
peptide sequence identification problematic [195]. As an alternative approach, higher-energy C-
trap dissociation (HCD) fragmentation, often equipped with Orbitrap detection, represents a 
potentially powerful tool for generating high resolution MS/MS spectra. HCD can provide superior 
performance in representing low m/z glycan oxonium ions, which normally contain signal ions for 
glycopeptides [195]. By supporting multiple cleavage events, HCD fragmentation can provide a 
wealth of peptide identifications [195] [196] [197].  
Therefore, in this work, we applied an intact glycopeptide method to determine the site-
specific glycosylation profiles for both the N- and O-glycans of a recombinant fusion protein EPO-
Fc produced by CHO cells. Containing the well-studied Fc region of IgG1 fused to EPO, this 
fusion protein was stably expressed in a commercial CHO-GS cell line in order to test the intact 
glycopeptide analysis method. Furthermore, the impact of adding an anion-exchange 
chromatographic column to capture N-glycopeptides and the enhancement of the N-glycopeptide 
abundance was compared with performance without the step.  In order to examine the role that 
culture media plays on glycopeptides and glycan structures generated, we evaluated two different 
media:  EX-CELL (EX) medium and immediate Advantage (IA) medium from Millipore-Sigma 
and compared the effects of media difference on the EPO-Fc N- and O-glycan profiles using this 
intact glycopeptide method as illustrated in Figure 2-1 and the workflow in Supplemental Figure 
S2-1. In particular, we were able to distinguish the differences in the glycan structures at each site 
as well as the levels of sialylation and fucosylation present at each site, including the three EPO 
and one Fc N-glycan sites.  The glycopeptide analytical method was also used to identify the 
predominant O-glycans in the different media as well.   These findings demonstrate the potential 
of intact glycopeptide analysis to provide a robust and detailed profiling of both N- and O-glycans 
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at specific sites, which will allow biotechnologists to better understand and control the glycan 




2.3 Materials and Methods 
2.3.1 Cell culture 
The recombinant EPO-Fc expressing CHO-GS cell line was graciously provided by 
Millipore-Sigma as part of the AMBIC intact glycopeptide project. This cell line was cultured in 
both EX-CELL® CD CHO Fusion medium (Millipore-Sigma, Catalog No. 14365C), and 
immediate ADVANTAGE medium (Millipore-Sigma, Catalog No. 87093C) individually. These 
two media were abbreviated as EX and IA media respectively in this work. EX and IA media are 
commercial proprietary media graciously provided by Millipore-Sigma.  EX is a first-generation 
chemically defined cell culture medium.  IA is a second-generation chemically defined medium 
with a more restricted raw material content focusing on cell growth and productivity.  IA contains 
a streamlined composition so that customers can tailor the formulation later with various raw 
materials for increasing glycosylation complexity as desired. Cell culture was performed in a 
humidified 37 °C incubator with 5% CO2 and 130 rpm shaking speed. Cells were subcultured 
every 3-4 days at seeding density of 0.5 ×106 cells/ml media in 125 ml shake flasks with 30 ml 
media.  
To monitor cell growth rates, recombinant EPO-Fc cells were seeded at 0.3×106 cells/ml 
in 30ml culture EX and IA media separately.  Three biological repeats were performed. Cell density 
was measured every 24 h using a hemocytometer, and viability was determined by distinguishing 
live cells from dead cells using trypan blue staining (Thermo Fisher Scientific). During the cell 
growth study, cell supernatants were collected every 24 h and subject to metabolite analysis and 
EPO-Fc characterization using immunoblotting and Coomassie blue staining as described below. 
Metabolites (glucose and lactate) were measured by using an YSI 2700 D dual channel select 
biochemistry analyzer (YSI Life Sciences).    
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2.3.2 Immunoblots and Coomassie blue staining 
Equal volumes (40 µl) of daily supernatants from EX medium-cultured and IA medium-
cultured EPO-Fc cells in the growth study were denatured and reduced with 4x sample buffer by 
boiling at 95 °C for 5 mins. The 4x sample buffer was made of 90% 4x Laemmli Sample Buffer 
(Bio-Rad, Hercules, CA) and 10% 2-Mercaptoethanol (Millipore-Sigma). After cooling, 
supernatant samples were fractionated on 10% SDS-PAGE, followed by transfer to a PVDF 
membrane (Bio-Rad, Hercules, CA). Rabbit anti-human EPO (Abcam, Cambridge, MA) was used 
as the primary antibody in immunoblots. Horseradish peroxidase (HRP)-linked anti-rabbit IgG 
was used as secondary antibody for EPO detection (Cell Signaling Technology, Danvers, MA), as 
previously described [198]. Horseradish peroxidase (HRP)-linked anti-human IgG from Abcam 
(Cambridge, MA) was used to detect Fc protein expression. The HRP signal was detected using 
Immun-Star Western Chemiluminescent Kit (Bio-Rad, Hercules, CA) with imaging performed on 
a Molecular Imager® ChemiDoc™ XRS (Bio-Rad, Hercules, CA) with Quantity One Software 
(Bio-Rad, Hercules, CA). For Coomassie blue staining, the purified EPO-Fc protein was subjected 
to SDS-PAGE and followed by staining in Coomassie Blue solution (0.1% Coomassie Blue R250 
(ThermoFisher Scientific), 10% acetic acid, 50% methanol and 40% H2O) overnight and 
destaining in destaining solution (10% acetic acid, 50% methanol and 40% H2O) for 6 hours, 
replacing the solution every two hours.  
2.3.3 EPO-Fc protein purification 
The culture supernatant containing recombinant EPO-Fc protein was first filtered through 
a 0.22-µm-pore-size membrane, and then mixed with Protein A agarose bead slurry (Vector Lab) 
and incubated at room temperature for 3 hours on a rotator. Then the supernatant was loaded onto 
a column to retain the agarose beads. After three washes with PBS buffer, the bound EPO-Fc was 
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eluted with 0.1 M glycine, pH 2.7. The pH of eluate was neutralized by adding 1 M Tris-HCl, pH 
9.0. The EPO-Fc eluate was subsequently dialyzed against PBS buffer using Amicon ultra-flow 
filter with molecular weight cut-off (MWCO) 10 kDa (Millipore). The final protein concentration 
was measured by bicinchoninic acid (BCA) assay (Thermo Fisher Scientific). The purified EPO-
Fc protein purity was assessed by 10% SDS-PAGE followed by Coomassie blue staining.  
2.3.4 Enzymatic digestion of purified EPO-Fc protein 
2 mg of purified EPO-Fc protein from EX medium and IA medium respectively was 
denatured in 8.0 M urea/1.0 M ammonium bicarbonate buffer, and reduced in 10 mM 1,4-
dithiothreitol (DTT) at 37 °C for 1.0 h. Proteins were alkylated in 10 mM iodoacetamide at room 
temperature for 30 min in the dark. Samples were diluted 5-fold with nuclease-free water to 
decrease the concentration of urea. Endoproteinase GluC (New England BioLabs) for N-
glycopeptide or trypsin (New England BioLabs) for O-glycopetide (protein:enzyme = 50:1, w/w) 
were separately added to each sample to digest proteins overnight with shaking at 37 °C.  We chose 
Endoproteinase GluC and trypsin for N- and O-glycopeptide analysis respectively because: 1. 
GluC can divide EPO-Fc protein into individual glycopeptides with only one glycan site remaining 
on each glycopeptide, while trypsin cannot separate the first two N-glycosites of EPO-Fc; 2. The 
O-glycopeptide after GluC digestion was too large to be ionized for routine MS detection while 
trypsin digestion can generate O-glycopeptide of EPO-Fc with appropriate length for MS 
detection. After digestion, samples were centrifuged at 13000 x g for 15 mins to remove 
precipitates, followed by desalting on a C18 cartridge (Waters, Milford, MA) according to the 
manufacturer’s instructions. The peptide samples were dried in a Speed-Vac and stored at -80°C 
prior to LC−MS/MS analysis. 
2.3.5 MAX column for N-glycopeptide enrichment 
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Oasis MAX is an anion-exchange and reversed-phase polymer column (Waters Company). 
The protocol for using MAX column for N-glycopeptide enrichment was developed previously by 
Yang et al.[199]. Briefly, after C18 desalting, peptides were eluted in 60% acetonitrile (ACN), 
0.1% trifluoroacetic acid (TFA). Then the binding solution was adjusted to 95% ACN, 1% TFA for 
N-glycopeptide enrichment using Oasis MAX 1 cc vacuum cartridge (Waters, Milford, MA). 
Before loading samples, MAX columns were first equilibrated in 1 mL of ACN for three times, 
then 1ml 100 mM triethylammonium acetate for three times, 1ml water for three times, and finally 
1 ml 95% ACN, 1% TFA for three times. Next, the peptide samples in 95% ACN, 1% TFA solution 
were loaded and washed by 1 mL of 95% ACN, 1% TFA for three times. Finally, bound 
glycopeptides were eluted in 400 μL of 50% ACN, 0.1% TFA. Concentration of the eluted peptides 
were determined using Nanodrop spectrophotometer to measure 280 nm absorbance for tryptophan 
and tyrosine. The peptide samples were dried in Speed-Vac and stored at -80°C prior to 
LC−MS/MS analysis. The component percentage shown in this work is based on volume ratio 
(v/v) unless otherwise specified.   
2.3.6 Nano LC−MS/MS Analysis.  
The dried peptide sample was re-suspended in 3% ACN and 0.1% formic acid (FA). The 
samples were analyzed on a Q-Extractive mass spectrometer (Thermo Fisher Scientific, Bremen, 
Germany). The Nano LC-MS/MS parameters were described previously in Yang et al. [200]. First, 
samples were separated by a Dionex Ultimate 3000 RSLC nano system (Thermo Scientific) with 
a PepMap RSLC C18 column (75 μm × 50 cm, 2 μm, Thermo Scientific) protected by an Acclaim 
PepMapC18 column (100 μm × 2 cm, 5 μm, Thermo Scientific). For intact glycopeptides, the 
mobile phase consisted of 0.1% FA and 3% ACN in water (A) and 0.1% FA, 90% ACN in water 
(B) using a gradient elution of 0-2% B, 1 min; 2-8% B, 9 min; 8-31%B, 80 min, 31-38% B, 20 
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min; 38-95% B, 5 min; 95% B, 10 min; 95-2% B, 4 min [200]. The flow rate was kept at 0.3 
µl/min. Data-dependent higher-energy collisional dissociation (HCD) MS/MS fragmentation was 
performed on the 12 most abundant ions. The spray voltage was set to 1.5 kV. Spectra MS1(AGC 
(Automatic Gain Control) target 3x 106 and maximum injection time 60 ms) were collected from 
400-2000 m/z at a resolution of 70,000 followed by data-dependent HCD MS/MS (at a resolution 
of 35,000, NCE (Normalized Collision Energy) 32%, intensity threshold of 4.2x104,  AGC target 
2x105 and maximum injection time 120 ms) of the 12 most abundant ions  using an isolation 
window of 1.4m/z [200]. Charge state screening was enabled to reject singly charged ions and ions 
with more than eight charges. A dynamic exclusion time of 30 sec was used to discriminate against 
previously selected ions. For tryptic peptides, 110 m/z was set as the fixed first mass in MS/MS 
fragmentation to include all oxonium ions of glycopeptides [200]. 
2.3.7 Data Analysis  
For intact glycopeptide identification, the MS data were searched using an in-house 
glycopeptide analysis software, GPQuest 3.0, based on GPQuest (Toghi Eshghi et al. 2015). 
Acquired MS/MS spectra were searched against the RefSeq Cricetulus griseus protein database 
downloaded from the NCBI website with last update June 01, 2016, which contained 46,402 
proteins. The human erythropoietin fasta protein sequence and human IgG1 Fc region sequence 
were also added to the protein database. Database search parameters were set as follows: a 
maximum of two missed cleavage sites permitted from GluC or trypsin digestion, 10 ppm 
precursor mass tolerance, 0.06 Da fragment mass tolerance, carbamidomethylation (C, +57.0215 
Da) as a fixed modification, and oxidization (M, +15.9949 Da) and deamidation (N, +0.98 Da) as 
dynamic modifications. Spectral counting was used to quantify the peptides identified from LC-
MS/MS data. The parameters for mass tolerance of MS1 and MS2 were 10 ppm and 20 ppm, 
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respectively. The spectra containing an oxonium ion m/z 204.09 were chosen for further searching. 
Results were filtered based on the following criteria: (1) false discovery rate (FDR) less than 1%, 
(2) ≥ 3  glycopeptide spectra matches (PSMs) for each peptide were required, (3) all the PSMs 
should be annotated by at least one N-linked glycans. All the annotated intact glycopeptides were 
presented in Supplemental Figures S2-2. 
2.4 Results 
2.4.1 Comparison of  EX-CELL and imMEDIAte Advantage media on EPO-Fc CHO cell growth 
and protein production  
First, EPO-Fc expressing cell growth profiles cultured in EX-CELL (EX) medium and 
immediate Advantage (IA) medium were obtained for three biological repeats. As shown in Figure 
2-2A, EPO-Fc cells in IA medium exhibited an extended exponential growth phase (Day 2 –Day 
6) compared to that in EX medium (Day 2-Day 5) and as a result reached a higher cell density than 
those in EX-CELL medium. On Day 6, EPO-Fc cells in IA medium reached a maximum cell 
density around 13 million/ml on Day 7 while EX medium reached a maximum cell density of 
about 8.4 million/ml at Day 6. Furthermore, the viability in EX medium started to drop and 
declined gradually from Day 6 while the viability in IA medium started to drop on Day 8 but 
quickly declined to 0 by Day 9. In addition, as a complement to the growth and viability studies, 
we conducted metabolite analysis of lactate accumulation and glucose consumption (Figure 2-2C 
and 2D) to gain further insight into the relative impact of  EX and IA media on CHO cell 
metabolism. As shown in Figure 2-2D, IA medium had higher glucose level (5800mg/L) than that 
(5400 mg/L) in EX medium at Day 0. Cells in EX medium also exhibited a relatively slower 
glucose consumption and lactate accumulation rates compared to those in IA medium. By Day 8, 
EPO-Fc cells in IA medium had completely consumed all the glucose and taken up most of the 
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lactate, which correlated with the drop of cell number and viability observed at Day 9 in IA 
medium. At Day 9, small amounts of glucose and lactate remained in EX medium, which is also 
consistent with the more gradual decline in cell density and viability.  
Next, the abundance and quality of EPO-Fc protein secreted into EX and IA culture media 
was evaluated.  Briefly, equal amounts of supernatant were harvested every day of the growth 
study and subjected to SDS-PAGE followed by Coomassie blue staining. Purified EPO-Fc protein 
was used as a positive control. As shown in Supplemental Figure S2-3A, EPO-Fc protein was the 
most abundant protein in the supernatant from both EX and IA media cell culture during the growth 
cycle. In addition, anti-EPO and anti-IgG immunoblots were applied on the daily supernatant 
samples from the same EX and IA growth study respectively. In Supplemental Figure S2-3B, the 
intensity of EPO and IgG signal in their respective immunoblots increased gradually with 
increasing time in culture in both EX and IA media. However, we observed some degradation of 
the protein for the anti-IgG immunoblot from Day 6 to Day 8 in the IA medium cell culture but 
not in EX medium and no obvious degradation of EPO-Fc protein for the anti-EPO immunoblot 
results in both EX and IA media (Supplemental Figure S2-3B). Therefore, some degradation of 
recombinant EPO-Fc protein during the later days for batch cell growth in IA basal medium may 
be attributed to the changed concentration of secreted proteases and reductases in IA medium or 
an increase of truncated or missed glycosylation on EPO-Fc protein. Alternatively, recombinant 
EPO-Fc protein maintained its integrity in the EX medium.  This difference may have been due, 
in part, to the composition differences of the two media which can affect the cell state and secretory 
processes.  In particular, the IA medium was designed with a streamlined composition which may 
have affected secretion of certain components at later days for this simple batch cell culture 
process.   
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2.4.2 N-glycopeptide enrichment for improving intact glycopeptide MS identification 
Prior to the study of media influence on the glycan profile of EPO-Fc protein using intact 
glycopeptide analysis, in order to improve the EPO-Fc glycopeptide abundance for better MS 
capture and characterization,  chromatographic columns can be applied to concentrate the 
glycopeptide quantities from digested EPO-Fc peptides. Due to the hydrophilic features of glycans 
or glycopeptides, strong anion-exchange columns such as the MAX column can be used for highly 
sensitive and selective extraction of acidic compounds, such as N-glycopeptides [201].  In this 
work, we adopted the MAX column for EPO-Fc N-glycopeptide enrichment and conducted a 
comparison on the N-glycopeptide analysis for IA Day 6 culture supernatant with and without 
MAX column enrichment as shown in Figure 2-3A workflow. Briefly, conditioned media from 
Day 6 EPO-Fc cell culture in IA medium was harvested and subjected to protein A purification to 
obtain EPO-Fc protein. Then purified EPO-Fc protein from three biological repeats was digested 
using GluC endoproteinase individually followed by C18 column desalting of the digested 
peptides. Subsequently, some desalted peptides were subjected to the MAX column for N-
glycopeptide enrichment. Finally, equal amounts (0.4 µg) of peptides from before and after MAX 
enrichment were subjected to LC-MS/MS analysis.  
The characterization of N-glycopeptide mass spectrometric performance is tabulated in 
Table 2-1. On average, more glycopeptides and glycan types were detected using MAX column 
enrichment (51.67 ±1.25 PSM and 24 ± 0.81 glycan types detected before MAX enrichment; 85.33 
±4.78 PSM and 31 ± 0.81 glycan types detected after MAX enrichment). Importantly, the 
representative oxonium ion (m/z=204.09) signal intensity was increased nearly 10-fold using 
MAX column to enrich the N-glycopeptides.  Next, a fucosylation and sialylation comparison was 
performed as shown in Figure 2-3B. While the fucosylation content of EPO-FC protein (76%) was 
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slightly higher than the sample without MAX column enrichment (72%), there was no significant 
fucosylation level difference between MAX column sample and the control sample (Figure 2-3B). 
Moreover, the sialylation content of the EPO-Fc protein also displayed similar content with or 
without MAX enrichment (Figure 2-3B). We also explored the N-glycan branch distribution of 
EPO-Fc protein with and without MAX enrichment. The MAX column enrichment increased the 
tri- and tetra-antennary content of EPO-Fc protein slightly while decreasing the bi- antennary 
content, but this result is not significantly different for the three biological repeats. The high-
mannose type glycans present similar abundance with or without MAX column enrichment. 
Furthermore, with more N-glycopeptides and N-glycan types detected after MAX column 
enrichment, we acquired more consistent results among three biologic repeats compared to the 
control unenriched counterparts, which identified fewer N-glycopeptides and glycan types. 
Collectively, these results indicated that MAX column can efficiently enrich N-glycopeptides 
leading to a more in-depth profiling analysis of the glycans presenting on EPO-Fc glycoprotein.  
2.4.3 Comparison of media influence on EPO-Fc N-glycans using intact N-glycopeptide 
characterization  
After evaluating the performance of MAX column for N-glycopeptide enrichment, we next 
studied the EPO-Fc glycan profile in EX and IA media using the intact glycopeptide 
characterization method. The workflow is displayed in Supplemental Figure S2-1. Briefly, 
conditioned media from Day 5 (see Figure 2-2 growth phase) and Day 8 (see Figure 2- 2 stationary 
phase) in both EX and IA media cell culture were collected and recombinant EPO-Fc protein was 
obtained and purified from the culture broth. Next, equal amounts of EPO-Fc protein were 
subjected to GluC endoproteinase digestion followed by C18 column desalting and MAX column 
enrichment for N-glycopeptide preparation. Finally equal amounts (0.8 µg) of MAX-enriched 
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peptides were subjected to nano LC-MS/MS analysis.   
First, we assessed the size difference of purified EPO-Fc protein from EX and IA media 
culture. Equal amounts of the purified EPO-Fc protein from both Day 5 and Day 8 EX and IA 
media cell cultures were loaded onto a SDS-PAGE gel followed by Coomassie blue staining. The 
result shown in Figure 2-4A indicates that EX medium generated a more homogenous and slightly 
larger EPO molecule during both the growth and stationary phases compared to their 
corresponding counterparts from IA medium cell culture.   In order to further explore the effect of 
media on EPO-Fc protein glycan characteristics, for EPO-Fc N-glycopeptide analysis, the 
distribution of glycan antennary was studied and is displayed at each of the 4 N-glycan sites in 
Figure 2-4B. There were more combined bi-/ tri-antennary glycans present in IA medium than EX 
medium both in the growth phase and stationary phase at the first 3 N-glycan sites.  In contrast, 
the EX medium tended to include a larger fraction of tetra-antennary structures at both Day 5 and 
Day 8. As expected, at the 4th N-glycan site, both Day 5 and Day 8 samples in both EX and IA  
media present solely bi-antennary structures, consistent with previous studies noting that the N-
glycans on the antibody Fc region is predominantly a bi-antennary structure [202]. Alternatively, 
the prevalent N-glycan types on recombinant EPO protein expressed in CHO cells are often tri- 
and tetra-branched structures [7, 48, 172].  Therefore, as a fusion protein, EPO-Fc maintained their 
individual EPO and Fc N-glycan characteristics, which may be attributed to their structural 
inherence. The N-glycopeptide analysis was in keeping with Coomassie blue gel result with the 
shown in Figure 2-4A.   The EX media generated larger molecules including  a large fraction of 
tetra-antennary glycans in Figure 2-4B, consistent with the more uniform and slightly larger 
protein band observed for the Coomassie gel result. Alternatively, the IA medium generated a more 
diverse collection of bi- and tri-antennary branched glycans which is in accordance with broader 
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EPO-Fc band observed for the IA-derived samples on the Coomassie blue gel.    
We further evaluated the sialylation content (Neu5Ac and Neu5Gc) of N-glycans on the 
EPO-Fc protein. The total Neu5Ac sialylation site occupancy of Day 5 and Day 8 samples in both 
EX and IA media cell culture is shown in Figure 2-5A. In all tested samples, the Neu5Ac content 
in growth phase was similar to that in stationary phase for EX medium, while the Neu5Ac level 
decreased with cell culture time in IA medium. Site-specific analysis of Neu5Ac content on the 
four N-glycan sites (first 3 of EPO N-glycan sites, the 4th of Fc N-glycan site) is shown in Figure 
2-5B. The Neu5Ac sialylation content decreased gradually from the 1st to the 4th N-glycan sites, 
which is consistent with our analysis of wild-type EPO protein glycans from CHO cell cultures 
[7]. In the current study, the 4th N-glycan site was fully unsialylated (Figure 2-5B). Similar to the 
total Neu5Ac sialylation trend in Figure 2-5A, the Neu5Ac sialylation level in the growth phase 
was consistent with that in stationary phase at the first three N-sites for EX culture, while the 
Neu5Ac sialylation level decreased along with cell culture time in IA medium for the first three 
N-sites. Further details about the sialic acid content at the specific sites is summarized in 
Supplemental Figure S2-4. This analysis revealed that the most widely observed N-glycans include 
only one sialic acid (S1) for all tested samples at the first three N-glycan sites. N-glycans with two 
or three sialic acids (S2 and S3) represented a smaller fraction of the N-glycans at each site while 
N-glycans with four sialic acids (S4) were rare and only traceably detected at the first N-site on 
the Day 5 EX cultured and the 2nd N-site on the Day 8 IA cultured EPO-Fc samples. Therefore, 
EX medium can maintain the EPO-Fc protein Neu5Ac sialylation content along with cell culture 
time while sialylation content decreased slightly with culture duration for the IA medium. On the 
other hand, the total and site-specific Neu5Gc sialylation analysis is presented in Figure 2-5C and 
2-5D. The Neu5Gc sialylation analysis, shown in Figure 2-5C, revealed that low but detectable 
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amounts of Neu5Gc were detected in all tested samples with Day 8 cultured EPO-Fc protein 
exhibiting more Neu5Gc content than Day 5 culture samples in both EX and IA media. For site-
specific Neu5Gc analysis (Figure 2-5D), Neu5Gc content was highest at the 1st N-glycan site 
during stationary phase in both media. At 2nd N-site, Neu5Gc was only detected at the stationary 
phase in IA medium.  The 3rd N-glycan site also contained detectable Neu5Gc content with very 
low levels as the 2nd site and none detected at the 4th site.   
The total and site-specific fucosylation analysis is shown in Figure 2-6A and 2-6B, 
respectively. EPO-Fc from the IA cultured medium had a slightly higher fucosylation content than 
EX cultured samples during both growth and stationary phases (Figure 2-6A). For the site-specific 
analysis (Figure 2-6B), interestingly, in contrast to the sialylation analysis, the 1st N-glycan site 
had the lowest fucosylation occupancy compared to the other N-glycan sites. Furthermore, the 4th 
N-glycan site was fully fucosylated in all tested samples, and the fucosylation content also 
remained relatively  similar over time at the 2nd, 3rd and 4th N-glycan site for both EX and IA 
media. The culture media difference in fucosylation content mainly affected the 1st N-glycan site, 
in which the IA medium exhibited a higher fucosylation level compared to its counterparts in EX 
medium at same time points.  
2.4.4 Comparison of different media impact on EPO-Fc O-glycan profile using intact O-
glycopeptide characterization 
Finally, we studied the O-glycan profile of EPO-Fc protein cultured in both EX and IA 
media. The workflow of O-glycopeptide analysis is also illustrated in Supplemental Figure S2-1.   
After EPO-Fc protein purification, trypsin digestion and C18 desalting, equal amounts (0.8 µg) of 
two biological O-glycopeptide repeats were subjected to nano LC-MS/MS analysis.  The identified 
O-glycan are summarized in Table 2-2. In all tested samples, GalNAc-Gal, GalNAc-Gal-SA and 
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GalNAc-Gal-SA2 (N1F1F0SOG0, N1H1F0S1G0 and N1H1F0S2G0) represented the three major 
types of O-glycans identified on EPO-Fc protein. Moreover, more O-glycan types were identified 
in the EX medium in both the growth (7 types) and stationary phases (6 types) compared to the 
types observed at their corresponding time points in IA medium (5 types and 4 types for growth 
and stationary phases, respectively), indicating that EX medium results in a more diverse O-glycan 
profile on EPO-Fc protein than IA medium. 
2.5 Discussion 
Intact glycopeptide profiling characterizing the site-specific glycans has emerged as an 
alternative and complementary glycan analysis tool in recent years. Its application includes  
biomarker discovery, disease diagnosis and biopharmaceutical product quality control [203] [204] 
[205] [206]. Here we adopted this glycoproteomic method for evaluating the effects of different 
media compositions on the glycan profile of a recombinant protein, EPO-Fc, secreted from CHO 
cells. Compared to the traditional released glycan analysis method, this approach can elucidate the 
glycopeptide sequence, glycan site information, and the glycan structural composition 
simultaneously [193]. Moreover, this approach requires a less extensive sample preparation 
process with a turnover time for results in less than 2 days.  In this work, we applied two different 
media, EX-CELL (EX) medium and immediate Advantage (IA) medium from Millipore-Sigma, 
and compared the effects of the media on the EPO-Fc N- and O-glycan profiles using this intact 
glycopeptide method. For N-glycosylation, the sialylation content decreased for the 1st through 
4th N-glycan sites. Even as a fusion protein, EPO-Fc maintained the N-glycan characteristics that 
would be expected for the individual EPO (Sites 1 to 3) and Fc (4th site) elements. EPO N-glycans 
presented bi-, tri- and tetra-branched glycan structures with various sialylation and fucosylation 
levels at each sites, while the Fc N-glycan displayed mostly fully fucosylated, unsialylated bi-
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antennary N-glycans. For the O-glycans, there was a prominence of 3 main glycotypes 
(N1F1F0SOG0, N1H1F0S1G0 and N1H1F0S2G0) for both media compositions. 
For glycopeptide sample preparation, an enrichment step can serve to increase the abundance 
of glycopeptides among all the digested peptides. For N-glycans, we evaluated the MAX column 
for N-glycopeptide enrichment and the result shows that more N-glycopeptides and more 
consistent N-glycan types were detected after MAX column enrichment. For O-glycans, a 
HyperSep retain AX (RAX) (Thermo Fisher Scientific) column enrichment method was tested 
[199] but not implemented due to low capture efficiency. There are two possible reasons for this 
phenomenon: 1. The O-glycan on EPO-Fc protein has generally low occupancy and less diversity 
[207]. Indeed, using β-elimination method to release O-glycan, we only obtained three types 
(N1H0F0S0G0, F0N1H1S0G0 and N1H1F0S1G0) of O-glycan on EPO-Fc protein (data not 
shown), which is consistent with previous studies (Lauber et al. 2015). 2. RAX affinity may have 
binding bias, which is specific to a certain type of glycan structures and may be inefficient for 
enriching O-glycan-rare samples [195].   
We tested two different commercial culture media, EX and IA media from Millipore-Sigma, 
and their influence on the complexity of glycan profiles of recombinant EPO-Fc protein secreted 
from a CHO-GS cell line. Coomassie blue profiling (Figure 2-4A) indicated that the N-glycans 
produced by cells cultured in the EX medium varied more in size and produced a broader 
distribution of EPO-Fc protein than that in the IA medium.  Furthermore, the detailed glycopeptide 
antennary analysis (Figure 2-4B) based on glycopeptide spectra match (PSM) revealed a similar 
wider distribution of glycan types in the IA medium.  While the EX medium tended to produce 
predominantly tetra-antennary N-glycans on the 1st, 2nd, and 3rd sites, CHO cells in IA cell culture 
produced more bi and tri-antennary structures in addition to the tetra-antennary features at those 
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same three sites. We also summarized the total N-glycan types identified on the 4 N-sites of EPO-
Fc protein, which also revealed that more tetra-branched and fewer tri- and bi-branched glycan 
types were detected at both Day 5 and Day 8 in EX culture medium than those obtained in IA 
culture medium (Supplemental Figure S2-5). Interestingly, O-glycopeptide analysis revealed that 
both media produced highest relative amount of structures containing GalNAc-Gal, GalNAc-Gal-
SA and GalNAc-Gal-SA2 (N1H1F0S0G0, N1H1F0S1G0, N1H1F0S2G0) but the other structures 
varied somewhat in the two media compositions.  Collectively, our results indicate that IA medium 
produced more diverse N-glycopeptide profile while the EPO-Fc from EX medium tended to 
contain more tetra-antennary N-glycans. Previous studies by commercial vendors has indicated 
that the two media will produce different growth and glycan profiles for recombinant proteins 
generated from CHO cells, and CHO cells grown in the IA medium may produce a less complex 
glycosylation product than that in EX medium ( personal conversation with Dr. Frank 
Swartzwelder from Millipore-Sigma). Moreover, it is also worthwhile to note that the cell growth 
is enhanced in IA medium culture with higher cell densities, which may lead to less complete 
glycan modifications perhaps due to differing allocation of resources or protein transport rates 
through the Golgi apparatus.   
While Neu5Ac is the predominant sialylation type for recombinant glycoproteins in CHO cells, 
we still detected low amounts of Neu5Gc in all tested samples (Figure 2-5). Neu5Gc, as a side-
product in CHO cell culture, should be limited in the final drug product if possible.  Interestingly, 
from our intact glycopeptide analysis, the Neu5Gc amount increased significantly at later times 
(Day 8) compared with that in the earlier growth phase (Day 5) in both EX and IA media for EPO-
Fc cell culture (Figure 2-5C).  After CMP-Neu5Ac is synthesized and released from nucleus into 
the cytosol, CMP-Neu5Ac can be converted into CMP-Neu5Gc with the assistance of CMAH 
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enzyme [208]. Then both CMP-Neu5Ac and CMP-Neu5Gc in the cytosol will be transported to 
the Golgi by the same transporter SLC35A1 and involved in the protein glycosylation process 
[208]. The activity and availability of CMAH enzyme directly affect the incorporation of Neu5Gc 
into glycoproteins [209]. We propose that the prolonged cell culture time may serve to change 
CMAH and NADH (a cofactor for CMAH) levels in CHO cells and as a result, the distribution of 
Neu5Ac and Neu5Gc metabolites intracellularly, which further impacts the Neu5Gc content on 
glycoproteins.  
2.6  Conclusion 
In conclusion, we have demonstrated a rapid glycopeptide analysis method can reveal site-
specific glycan information on recombinant EPO-Fc protein secreted from CHO cells in different 
media compositions. Retaining glycans on the peptides enables users to simultaneously elucidate 
the glycan structure on the specific glycosylation sites and provide insights about how proteins are 
modified at different points along the polypeptide chain under different culture conditions. Using 
this intact glycopeptide characterization method, EX medium was revealed to produce a more 
complex tetra-antennary N-glycan profile than IA medium for EPO-Fc cell cultures. For N-
glycosylation analysis, the sialylation content decreased with increasing N-glycan sites of EPO-
Fc, which is opposite to the trend of fucosylation content at these same 4 N-glycan sites and 
consistent with the known profiles of the individual structural regions of the composite protein. 
EPO N-glycans from EPO-Fc protein presented bi-, tri- and tetra-branched glycans structures with 
various sialylation and fucosylation levels at each sites, while Fc N-glycan displayed mostly fully 
fucosylated, unsialylated bi-antennary glycans. O-glycan profiles indicated a predominance of the 
3 major structures in both the EX and IA media and lesser amounts of other glycans. In total, intact 
glycopeptide characterization may become increasingly important as an analytical tool for 
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biopharmaceutical manufacturing by producing protein therapeutics with well-defined physical 
properties.  
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Figures and Tables 
 
Figure 2-1. Illustration of intact glycopeptide characterization method applied in this work. 
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Figure 2-2. Growth study of EPO-Fc CHO-GS cells in EX-CELL (EX) and imMEDIAte  
ADVANTAGE (IA) media (left and right panels, respectively). (2-2A) The viable cell density (VCD) of 
EPO-Fc cells; (2-2B) The viability of EPO-Fc cells; (2-2C) The lactate level in the culture media (2-2D) 
The glucose level in the culture media. Please note that the EPO-Fc cell density declined on Day 8 in EX-
CELL medium cell culture but the viability remained more than 90%, so we still recognized Day 8 as the 
stationary phase in the cell growth cycle.  
 






Figure 2-3 The application of MAX column for N-glycopeptide enrichment. (3A) the workflow 
of MAX column comparison study, (3B) The EPO-Fc fucosylation and sialylation content before 
and after MAX column enrichment, (3C) The EPO-Fc N-glycan branch distribution before and 
after MAX enrichment.  The p-values for high-mannose, bi-, tri and tetra-antennary glycan types 






Figure 2-4.(2-4A) Coomassie blue staining result of purified EPO-Fc protein from both 
exponential and stationary phases in EX and IA media culture respectively. Equal amount of 
purified EPO-Fc protein were loaded. (2-4B)The site-specific N-glycan antennary analysis of 
EPO-Fc protein. CHO-GS EPO-Fc expressing cells were cultured in EX and IA media 












Figure 2-5. The N-glycan sialylation analysis of EPO-Fc protein. (2-5A) and (2-5C) The 
overall Neu5Ac and Neu5Gc content with 4 N-sites summed up together. (2-5B) and (2-5D) The 
site-specific Neu5Gc and Neu5Ac content.  
 
 
Figure 2-6. The N-glycan fucosylation analysis of EPO-Fc protein. (2-6A) the overall 
fucosylation content of EPO-Fc protein with 4 N-sites summed up together. (2-6B) the site-






Table 2-1. The comparison of MS characterization of EPO-Fc protein with and without MAX 






























Supplemental Figure S2-1. The workflow of experiments in this work.  
 
Supplemental Figure S2-2. Representative MS/MS spectra of the identified N- and O-
glycopetides in EPO-Fc protein. For example, in Figure S2-2A, Spectral title: AKEAENITTGCAE + 
N4H5F3S0G0/3. Glycopeptide sequence: AKEAENITTGCAE; N-glycan: N4H5F3S0G0 (N: HexNAc, 
H: Hex, F: Fuc, S: Neu5Ac, G: Neu5Gc); Charge: 3. The same labeling works for For (S2-2B)-(S2-
2E). Upper figure: highlight only oxonium ions in yellow; Lower figure: after removing oxonium 









Supplemental Figure S2-3. (S2-3A) The abundance of EPO-Fc protein in the supernatant per day 
in the growth study. 40ul supernatant sample was loaded each well. 2ug purified EPO-Fc 
protein from EX-CELL medium on Day 6 cell culture were collected and used as positive control. 
(S2-3B) Anti-EPO and Anti-IgG immunoblots for detection of EPO-Fc protein in the daily 
supernatant in the EX-CELL and imMEDIAte media growth studies individually.  15ul 
supernatant was loaded each well. 500 ng purified EPO-Fc protein from EX-CELL medium on 




Supplemental Figure S2-4, The site-specific Neu5Ac sialylation distribution of EPO-Fc protein. 
S1: glycans with one sialic acid, S2: glycans with two sialic acids, S3: glycans with three sialic 
acids, S4: glycans with 4 sialic acids. NITT, NIST and NSS are the amino acids at 1st, 2nd, and 3rd 
N-glycan sites. At the 4th N-glycan site (Fc N-site), no sialylation has been detected.  
 
Supplemental Figure S2-5. The N-glycan types analysis of EPO-Fc protein using intact 
glycopeptide characterization.  (S2-5A). The number of N-glycan types identified from each  
sample. The total glycan types were summarized from two biological runs. (S2-5B) The branch 
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distribution of glycan types of EPO-Fc protein cultured in EX and IA media harvested at growth 





Chapter 3 Comprehensive exploration of the effect of 1,3,4-O-
Bu3ManNAc as a novel sugar supplement on the quality and 




A desirable feature of many therapeutic glycoprotein production processes is to maximize the 
final sialic acid content. In the first part of this chapter, the effect of applying a novel chemical 
analog of the sialic acid precursor N-acetylmannosamine (ManNAc) on the sialic acid content of 
cellular proteins and a model recombinant glycoprotein, erythropoietin (EPO), was investigated 
in CHO-K1 cells. By introducing the 1,3,4-O-Bu3ManNAc analog at 200-300 μM into cell 
culture media, the intracellular sialic acid content of EPO-expressing cells increased ~8 fold over 
untreated controls while the level of cellular sialylated glycoconjugates increased significantly as 
well. Moreover, addition of 200-300 μM 1,3,4-O-Bu3ManNAc resulted in >40% increase in final 
sialic acid content of recombinant EPO, while feeding of ManNAc at almost 100 times higher 
concentration of 20mM concentration produced a less profound change in EPO sialylation. In the 
second part of this chapter, we also examined an alternative chemical additive, 1,3,4-O-
Bu3ManNAc, for its effect on recombinant protein production in CHO. Supplementation with 
1,3,4-O-Bu3ManNAc for two stable CHO cell lines, expressing human erythropoietin or IgG, 
enhanced protein expression for both products with negligible impact on cell growth, viability, 
glucose utilization, and lactate accumulation. In contrast, the chemical additive sodium butyrate 
(NaBu) has been applied in cell culture media as a direct and convenient method to increase the 
protein expression in Chinese hamster ovary (CHO) and other mammalian cells. Sodium 
butyrate treatment resulted in a ~20 % decrease in maximal viable cell density and ~30 % 
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decrease in cell viability at the end of cell cultures compared to untreated or 1,3,4-O-
Bu3ManNAc treated CHO cell lines for both products. While NaBu treatment enhanced product 
yields more than the 1,3,4-O-Bu3ManNAc treatment, the NaBu treated cells also exhibited 
higher levels of caspase 3 positive cells using microscopy analysis. Furthermore, the mRNA 
levels of 4 cell apoptosis genes (Cul2, BAK, BAX and BCL2L11) was up-regulated more in 
sodium butyrate treated wild-type, erythropoietin or IgG expressing CHO-K1 cell lines while 
most of the mRNA levels of apoptosis genes in 1,3,4-O-Bu3ManNAc treated cell lines remained 
equal or increased only slightly compared to the levels in untreated CHO cell lines.  In the last 
part of this chapter, we compared NaBu and 1,3,4-O-Bu3ManNAc on their effects on the glycan 
quality of recombinant proteins. The beneficial impact of 1,3,4‐O‐Bu3ManNAc on EPO glycan 
quality, while evident in wild‐type CHO cells, was particularly pronounced in glycoengineered 
CHO cells with stable H Supplementation of 1,3,4‐O‐Bu3ManNAc achieved approximately 30% 
sialylation enhancement on EPO protein in wild‐type CHO cells. Overexpression of 
GnTIV/GnTV/ST6 in CHO cells increased EPO sialylation about 40%. Combining 1,3,4‐O‐
Bu3ManNAc treatment in glyocengineered CHO cells promoted EPO sialylation about 75% 
relative to EPO from wild‐type CHO cells. Moreover, a detailed mass spectrometric ESI‐LC‐
MS/MS characterization of glycans at each of the three N‐glycosylation sites of EPO showed 
that the 1st N‐site was highly sialylated and either the negative impact of NaBu or the beneficial 
effect 1,3,4‐O‐Bu3ManNAc treatments mainly affects the 2nd and 3rd N‐glycan sites of EPO 
protein. In summary, these results indicate inclusion of butyrate-derivatized side chains on 
ManNAc likely improves the capacity of cells to uptake the analog and incorporate exogenous 
ManNAc into recombinant glycoproteins such as EPO. This study establishes 1,3,4-O-
Bu3ManNAc as a novel chemical supplement to improve glycoprotein quality and sialylation 
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levels at concentrations orders of magnitude lower than alternative approaches. These findings 
also demonstrate that 1,3,4-O-Bu3ManNAc has fewer negative effect on cell cytotoxicity and 
apoptosis, perhaps as a result of a more deliberate uptake and release of the butyrate compounds, 
while simultaneously increasing the expression of multiple recombinant proteins and improving 
the glycosylation characteristics when applied at comparable molarity levels to NaBu. Thus, 
1,3,4-O-Bu3ManNAc represents a highly promising media additive alternative in cell culture for 
improving protein yields without sacrificing cell mass and product quality in future 
bioproduction processes. Moreover, 1,3,4‐O‐Bu3ManNAc can compensate for the negative effect 
of NaBu on EPO glycan quality while simultaneously enhancing recombinant protein yields. In 
this way, a platform that integrates glycoengineering with metabolic supplementation can result 




Protein glycosylation is a critical quality attribute in biopharmaceutical manufacturing. The 
glycosylation patterns of recombinant proteins directly affect these drugs’ clinical efficacy and 
safety by modulating their stability, biological activity, circulatory half-life, and 
pharmacokinetics (PK) [210] [211]. Numerous strategies have been investigated to control the 
glycan profiles of recombinant proteins including glycoengineering on the glycosylation 
pathways and metabolite supplementation to the culture media. Glycoengineering involves the 
modulation of glycogene expression in CHO cells, which includes overexpression of 
sialyltransferases to enhance terminal sialylation and N-acetylglucosaminyltransferases to 
improve branching [43, 52] [212]. Chemical supplementation of the culture media provides a 
convenient way to tailor the glycosylation profiles of recombinant proteins. For example, the 
addition of 20 to 40 mM N-acetylmannosamine (ManNAc) to culture medium improved 
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sialylation of recombinant interferon-  and EPO produced in CHO cells by ~20% [50]. A 
desirable feature of many therapeutic glycoprotein production processes is to maximize the final 
sialic acid content. One way to improve sialylation is feeding to the media of nucleotide sugar 
precursors such as the widely utilized substrate, N-acetylmannosamine (ManNAc), an 
intermediate metabolite along the sialic acid pathway as shown in Figure 3-1 [213, 214].  Our 
group as well as other groups detected no significant difference on protein expression level 
between ManNAc treated and non-treated cells [50]. 
Another major goal of the biomanufacturing industry is to improve the productivity of 
mammalian cell cultures, especially Chinese hamster ovary (CHO) cells. To meet this goal, 
multiple strategies have been implemented to increase therapeutic protein production in CHO 
cells, including host cell engineering [215, 216], expression vector engineering [217], and culture 
medium optimization[218-221].  One approach is addition of small chemical molecules 
including glycerol [222], DMSO [223, 224] and sodium butyrate [225, 226]. Among these 
strategies, chemical supplementation, sometimes using sodium butyrate (NaBu)- a known yield 
enhancer, has been considered as a most convenient way to increase protein production.  
Sodium butyrate, a short chain fatty acid, was originally identified as a product of anaerobic 
bacterial fermentation. The impact and molecular mechanisms of sodium butyrate on 
recombinant protein expression have been evaluated in several studies [227, 228]. Sodium 
butyrate regulates gene expression by inhibiting cell proliferation in cell cultures. As a result of 
sodium butyrate treatment, the expression of several genes involved in the cell cycle is changed, 
which inhibits or halts cell growth [227, 228]. Inhibition of histone deacetylase (HDAC) is 
another of the consequences of sodium butyrate activation of gene expression in cell culture. Due 
to the resulting hyperacetylated histones, the relaxed chromatin complexes are more readily 
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accessed by regulatory factors and thus can be more efficiently transcribed [229]. Because of its 
positive effects on protein expression in mammalian cell culture, sodium butyrate has been 
extensively used to achieve the high-level production of several recombinant therapeutic proteins 
in CHO cells such as antibodies and other pharmaceutical proteins (erythropoietin, factor VIII, α-
interferon, interleukin-2, and human follicle stimulating hormone) [225, 230-234]. However, the 
beneficial effects of sodium butyrate on protein expression comes with some potentially 
compromising side-effects, one of which is the induction of apoptosis. In addition, the presence 
of sodium butyrate can have additional potentially problematic effects, either directly or 
indirectly due to its cytotoxicity, on glycosylation processing and especially sialylation [226, 
235, 236]. More recently, we developed and applied butyrated alternatives to ManNAc, 
including 1,3,4-O-Bu3ManNAc, as a “high-flux” precursor for increasing sialic acid production 
at much lower concentrations compared to natural ManNAc [5, 237]. Given the expression-
enhancing effect of sodium butyrate on proteins, including butyrate “delivered” through ester-
conjugation to ManNAc [238], we wanted to examine if 1,3,4-O-Bu3ManNAc exhibited any 
effects on recombinant protein production and cell growth in Chinese hamster ovary (CHO) cells 
as well.  
On the other side, considering the unsatisfactory impact of NaBu on the glycosylation quality of 
recombinant proteins, especially with respect to sialylation, we propose supplying butyrate to 
cells using the analog 1,3,4-O-Bu3ManNAc, which is composed of a core ManNAc moiety 
linked to three butyrate groups (Figure 3-1B). 1,3,4-O-Bu3ManNAc has several key features that 
make it attractive for cell culture supplementation. First, the regioisomeric placement of the three 
butyrate groups at the 1, 3, and 4 positions of the core monosaccharide avoids cytotoxicity 
associated with fully acylated hexosamines [239] [240] [241]. After efficiently entering cells, a 
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process assisted by the lipophilic butyrate groups that facilitate diffusion of the hydrophilic core 
monosaccharide through the plasma membrane, 1,3,4-O-Bu3ManNAc is disassembled into three 
equivalents of butyrate and one equivalent of ManNAc by non-specific esterase activity [242] 
[243]. 1,3,4-O-Bu3ManNAc has been reported to increase the sialylation of endogenous proteins 
in different cell types including  Jurkat (lymphoma) cells, human breast cancer cells, SW1990 
pancreatic cancer cells, and CHO-K1 cells [244] [245].  These previous studies focused on 
characterizing sialylation.  Alternatively, given the wide use of NaBu as a supplement in 
mammalian cell culture, the comparison of 1,3,4-O-Bu3ManNAc and NaBu on recombinant 
protein production and quality would be of interest to biotechnologists.  
In the past, glycoengineering strategies and chemical supplementations typically have been 
pursued independently to tailor the glycan profiles of recombinant proteins, leaving the 
combined benefits of these two approaches largely untested.  In this study we fill this void by 
combining metabolic supplementation with glycoengineering in CHO cells, as illustrated in 
Figure 3-1C. The glycoengineered CHO cell line was developed by overexpression of human β-
1,4-N-acetylglucosaminyltransferase (GnTIV), human β-1,6-N- acetylglucosaminyltransferase 
(GnTV) and human α-2,6-sialyltransferase (ST6) in wild-type EPO-expressing CHO cells [246]. 
In comparison with EPO from wild-type CHO cells (wt-EPO), the EPO from glycoengineered 
CHO cells (which we refer to as “glycoengineered-EPO”) has higher levels of sialylation and 
increased display of highly branched (tri- and tetra-antennaries) N-glycans. Recombinant EPO 
combined with these CHO systems provides an ideal test platform to compare the influence of 
NaBu and 1,3,4-O-Bu3ManNAc on the glycan quality of recombinant proteins. In tandem, given 
the abundance and importance of EPO N-glycan, we employed intact glycopeptide analysis 
using mass spectrometry (MS) to decipher the site-specific N-glycan microheterogeneity of wt-
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EPO and glycoengineered-EPO proteins treated with 1,3,4-O-Bu3ManNAc or NaBu at 
equivalent butyrate concentrations.  
 
3.3 Materials and Methods 
 
3.3.1 Cell lines and cultures 
Wild-type CHO-K1 cells were purchased from Sigma-Aldrich (European Collection of Cell 
Culture, ECACC). The CHO-K1 with human erythropoietin (EPO) expressing cell line was 
established previously as described in Yin et al [5]. The establishment of recombinant wild-type 
human EPO and recombinant glycoengineered human EPO cell lines was previously described in 
Yin et al [246]. Briefly, human EPO cDNA was fused with a 6x His tag at its C terminus and 
codon-optimized for expression in CHO cells. Wild-type and glycoengineered CHO lines that 
expressed human EPO were cultured in conditions widely used for CHO-K1 cell culture, except 
that Zeocin (300 g/ml) was added to the wild-type cell cultures to maintain EPO gene 
expression and Zeocin (300 g/ml), hygromycin (200 g/ml), and blasticidin (8.0 g/ml) were 
added to the glycoengineered-EPO cell cultures to maintain expression of the recombinant 
glycogenes (i.e., GnTIV, GnTV, and ST6, respectively) [246]. Plasmids contained grass pollen 
Phlp7 IgG1 sequences were from Dr. Beavil’s lab and obtained from Addgene [247]. Then the 
IgG1 sequences were subcloned into a mammalian expression vector pBudCE4.1 (Thermo 
Fisher Scientific). Ham’s F12-K medium (Thermo Fisher Scientific) supplemented with 10 % 
(v/v) fetal bovine serum (FBS, Gibco) was used for CHO cell growth in a humidified atmosphere 
containing 5% CO2 at 37 ℃. Zeocin (300 μg/ml) was added to both EPO and IgG expressing cell 
line individually to maintain stable expression.  
Human EPO and IgG-expressing cell lines were seeded at the cell density 0.2×106 cells/ml to 
determine the cell growth curve and metabolite changes. Samples were collected every 12 h. Cell 
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number was counted using a hemocytometer and metabolites measure using a YSI 2700 D 
dual-channel select biochemistry analyzer (YSI Life Sciences).   Viable cells were distinguished 
from dead cells using trypan blue (Thermo Fisher Scientific) stain.    
3.3.2 Treatment of cultures with Bu3ManNAc and ManNAc 
Sodium butyrate (≥ 98.5 purity GC) was purchased from Sigma-Aldrich. 1,3,4-O-Bu3ManNAc 
was synthesized as previously described [240]. NaBu was dissolved in sterile water and 1,3,4-O-
Bu3ManNAc was dissolved in ethanol. Appropriate amounts of NaBu solution and 1,3,4-O-
Bu3ManNAc solution were added in F-12K media with 10% FBS individually to achieve the 
final concentrations of  1.0 mM NaBu or 0.333 mM  1,3,4-O-Bu3ManNAc in the culture media 
(these concentrations were selected to provide the same molar equivalents of butyrate and were 
used throughout this study based on previous optimization). In certain experiments, recombinant 
EPO cells were seeded and cultured in F12-K media with chemical supplements for two-day 
incubation. The cells then were collected and counted for intracellular sialic acid analysis. In 
alternate experiments, after the two-day incubation (as described) culture media was changed to 
serum-reduced Opti-MEM media (Thermo Fisher Scientific) with chemical supplements 
maintained correspondingly and the cells were incubated for an additional two days.  Then 
culture supernatant was collected and subjected to EPO protein purification and the following 
analysis described below. In other experiments, CHO-K1 cells were seeded at 1×106 cells per 
dish in 10cm dishes in 10 ml Ham’s F-12K media untreated or treated with 20mM ManNAc or 
various concentrations of Bu3ManNAc (50µM, 100 µM, 150 µM, 200 µM, 250 µM, 300 µM, 
350 µM). Cells were collected at confluency above 90% after 3 days. Similarly, a CHO-EPO cell 
line was grown in 10ml Ham’s F-12K media followed by Opti-MEM (ThermoFisher) 
supplemented with 20mM ManNAc or Bu3ManNAc (200 and 300 µM Bu3ManNAc) after 3 days 
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in culture.  Supernatants were collected after 48-hour incubation with or without treatment and 
then subjected to EPO purification.  
3.3.3 Quantitative real-time PCR 
 Wild-type CHO-K1, IgG- and EPO-expressing cell lines were treated with NaBu (1 mM) or 
1,3,4-O-Bu3ManNAc (0.33 mM). The three untreated  cell lines together with the treated cells 
were then separately harvested and homogenized using TRIzol reagent (Thermo Fisher 
Scientific) containing polyacryl-carrier (Molecular Research Center). RNA was extracted by 
phase separation and precipitated by addition of isopropanol, followed by reverse-transcription 
by the SuperScript III First-Strand Synthesis System (Thermo Fisher Scientific). Quantitative 
RT-PCR was performed with Absolute Blue SYBR Low ROX Master Mix (Thermo Fisher 
Scientific) in an Applied Biosystems 7500 Real-Time PCR system. Actin was used as an internal 
control using 2-ΔΔCt calculation. Primers for quantitative real-time PCR (qRT-PCR) were 
designed according to the CHO genome sequences as follows: Bcl2L11(5'- 
TGACACGGCGTGGTCAAGAG -3' and 5'- TCCGGAGTTGTCACTGGGC -3'),  BAX (5′- 
AGGCCCTGTGTACCAAAGTGC -3′ and 5′- TCAGCCCATGTTCTTCCAGATCGT -3′), 
BAK (5'- TTTGACCGGCTTCCTGGGC -3' and 5'- AGAATCTGTGTACCACGTACTGGCC -
3'), Cul2(5'- TCCAAGCTGCTATCGTCCGC -3' and 5'- ACCCACATCAGAGACGGTGTCA -
3') and CHO Actin(5'- TGACCGGATGCAGAAGGAGATCA -3' and 5'- 
AGAAGCATTTGCGGTGGACGA TG -3'). 
3.3.4 Immunohistochemistry  
Wild-type CHO-K1 cells were grown on glass cover slips coated with 0.1% gelatin, NaBu (1 
mM) and 1,3,4-O-Bu3ManNAc (0.33 mM) treated cells were cultured for 6 days prior to 
immunohistochemistry. For fluorescent staining, cells were fixed for 10 min at room temperature 
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in 4% paraformaldehyde in PBS and incubated with Caspase-3 antibody (Cell Signaling, 1:800 
dilution) followed by fluorescein isothiocyanate-conjugated donkey anti-Rabbit IgG (Thermo 
Fisher Scientific, 1: 400 dilution). Mounting medium with DAPI (Vector Laboratories) was 
added before fluorescence microscopic imaging to determine the cell nucleus.  
3.3.5 EPO protein purification 
The culture supernatant containing recombinant EPO protein was first filtered through a 0.22-
m-pore-size membrane to remove cell debris, and then loaded onto an affinity column packed 
with Ni-NTA agarose (Qiagen). After several washes of 20 mM imidazole in PBS buffer, the 
bound EPO was eluted with PBS buffer supplemented with 250 mM imidazole, and the EPO 
eluate was subsequently dialyzed against PBS buffer. The final protein concentration was 
measured by bicinchoninic acid (BCA) assay (Thermo Fisher Scientific). The purified EPO 
protein purity was assessed by 10% SDS-PAGE followed by Coomassie blue staining.  
3.3.6 Immunoblots and lectin blots 
For immumoblots, chemically-treated cells were lysed using RIPA buffer (Thermo Fisher 
Scientific) following protocols supplied by the manufacturer. After measuring protein 
concentrations in cell lysates, equivalent amounts from each sample were fractionated on 10% 
SDS-PAGE, followed by transfer to a PVDF membrane (Bio-Rad, Hercules, CA). Primary 
antibodies detecting GnTIV protein expression (rabbit anti-Mgat 4), and β-galactoside α-2,3-
sialyltransferase 4 (ST3Gal4) protein expression (rabbit anti-ST4Gal4) were obtained from 
Abcam (Cambridge, MA), and β-Galactosamide α-2,6-sialyltranferase 1 (ST6) protein 
expression (mouse anti-ST6) was purchased from Sigma (St. Louis, MO). Horseradish 
peroxidase (HRP)-linked anti-mouse IgG or anti-rabbit IgG was used as secondary antibodies 
individually (Cell Signaling Technology, Danvers, MA), as we previously described [246].  IgG 
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expression was detected using horseradish peroxidase-linked goat anti-human IgG antibody 
(Abcam). HRP signal from the antibodies was detected by adding an enhanced 
chemiluminescent (ECL) substrate (Millipore).  
For lectin blots, purified EPO proteins were quantified by BCA assay (Thermo Fisher Scientific) 
and fractioned on 10% SDS-PAGE, followed by transfer to a PVDF membrane (Bio-Rad, 
Hercules, CA). Membranes were blocked by Carbo-free blocking solution (Vector Labs, 
Burlingame, CA) and then incubated with biotinylated Sambucus nigra Lectin (SNA), or 
Maackia amurensis Lectin II (MAL II) individually and then continuously incubated in 
horseradish peroxidase-avidin (Av-HRP) (Vector Labs, Burlingame, CA), as previously 
described [246]. The HRP signal from either the bound antibodies or conjugated lectins was 
detected using Immun-Star Western Chemiluminescent Kit (Bio-Rad, Hercules, CA) on the 
Molecular Imager® ChemiDoc™ XRS (Bio-Rad, Hercules, CA) with Quantity One Software 
(Bio-Rad, Hercules, CA).  
3.3.7 Anti-EPO enzyme-linked immunosorbent assay (ELISA) 
To monitor EPO production, EPO present in the supernatants obtained on a daily basis from the 
growth study were measured by enzyme-linked immunosorbent assay (ELISA). Briefly, 5.0 l 
supernatants from each sample were loaded in a 96-well plate to test biological triplicates. 
Subsequently, samples were coated with carbonate/bicarbonate buffer overnight at 4 °C, 
followed with 5% BSA blocking solution,  chicken anti-EPO antibody (Thermo Fisher 
Scientific) and goat anti-chicken IgY antibody linked with HRP (Abcam, Cambridge, MA) were 
used as capture and detection antibodies, respectively. 3,3',5,5'-Tetramethylbenzidine (TMB, 100 
l, Thermo Fisher Scientific) was added as a chromogenic substrate for HRP into each well and 
the plate was incubated at room temperature for 5 min followed by the addition of H2SO4 
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solution (2.0 M) to stop the reaction. Absorbance OD values at 450 nm were then measured 
immediately. 
3.3.8 Intracellular free sialic acid assay 
Intracellular sialic acid content was quantified by using the periodate resorcinol method 
developed by Jourdian et al [248]. In brief, cell pellets consisting of 2 x 106 cells from each 
sample were resuspended in 300 l PBS, followed with freeze/thaw cycle three times for cell 
lysis. The cell lysate was oxidized with 5 µl of 0.4 M periodate acid and kept on ice for 10 min. 
Then 500 µl resorcinol mixture was added to each sample and heated at 100 °C for 10 min. After 
the sample cooling, 500 µl of tert-butyl alcohol was added and the samples were vortexed and 
centrifuged to precipitate cell debris. The supernatants were transferred immediately to a 96-well 
plate and the absorbance was measured at 630 nm.  Sialic acid concentrations were calculated by 
comparison with a standard curve. 
 
3.3.9 Quantitative determination of EPO sialic acid content 
The sialic acid content of purified recombinant EPO was quantified by the fluorescence-labeling 
method as developed by Hara et al. [249]. Briefly, sialic acid was hydrolyzed in 25-mM sulfuric 
acid for 1 h at 80 °C and derivatized with 1,2-diamino-4,5-methylenedioxybenzene, 
dihydrochloride (DMB, Dojindo, Rockville, MD) for 2.5 h at 60 °C. Next, DMB-labeled sialic 
acids were separated on a Poroshell120-EC-C18 (150MM, 2.7 m) reverse-phase column 
(Aglient, Santa Clara, CA) and detected by a fluorescence detector (G1316A, Agilent) with the 
excitation and emission wavelength at 367 nm and 445 nm.  
 
3.3.10 Intact glycopeptide LC-MS/MS analysis 
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Equal amounts of purified recombinant EPO obtained from wild-type or glycoengineered CHO 
lines treated with 0.33 mM 1,3,4-O-Bu3ManNAc or 1.0 mM NaBu was denatured using 8.0 M 
urea/1.0 M ammonium bicarbonate buffer, reduced with 10 mM tris (2-chloroethyl) phosphate at 
37 °C for 1.0 h and alkylated with 15 mM iodoacetamide at room temperature in the dark for 30 
min [250]. The protein sample then was diluted 5-fold with nuclease-free water and digested 
with endoproteinase GluC (New England BioLabs) (protein:enzyme = 50:1, w/w) overnight with 
shaking at 37 °C. Sample was centrifuged at 13000 x g for 10 min to remove precipitates and 
desalted with C18 SPE column (Waters, Milford, MA) as described in Jia et al [250].  The EPO-
derived glycopeptides were further enriched by anion-exchange, reversed-phase Oasis MAX 
column (Waters, Milford, MA) as described in Yang et al [251]. Subsequently, samples were 
dried in speed-vac and 1 g each sample was subjected to LC-MS/MS analysis. The LC 
conditions and MS parameters were described in Jia et al [250]. For EPO intact glycopeptide 
identification, the MS data were analyzed by an in-house software called GPQuest 3.0 with 




3.4.1 Compare the effects of 1,3,4-O-Bu3ManNAc and ManNAc on recombinant protein 
sialylation 
In order to evaluate the effect of Bu3ManNAc on CHOK1 cells, total cell lysates from treated 
and untreated cells were subjected to HPLC quantification for evaluation of sialic acid content on 
glycoproteins and glycolipids (Figure 3-2A). Treatment with 100 μM Bu3ManNAc increased the 
bound sialic acid by ~20 fold compared to untreated cells. Furthermore, the sialic acid content 
increased following addition of higher concentrations, reaching a level 60 fold higher than the 
untreated cells for 350 μM Bu3ManNAc. Compared with 20mM ManNAc treatment, 200 μM of 
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Bu3ManNAc served to increase the lysate sialic acid content to a similar level at 100 fold less 
concentration. Moreover, sialic acid content was ~35% and ~56% higher for 300 μM and 350 
μM Bu3ManNAc relative to the 20 mM ManNAc treatment. 
To assess the effect of Bu3ManNAc feeding on intracellular glycoproteins, CHO-K1 cell cultures 
were introduced with increasing concentrations of Bu3ManNAc (from 0 to 350 μM)[253]. After 
a 96-hour incubation, CHO-K1 cells were lysed and subjected to lectin blot using Maackia 
amurensis lectin II (MAL II), which specifically binds to α2,3 sialylation linkages. As shown in 
Figure 3-2B, the lectin binding to the oligosaccharide of total glycoproteins increased 
significantly with Bu3ManNAc treatment compared to the untreated negative control (0 μM 
Bu3ManNAc). Interestingly, MAL II binding efficiency was highest at Bu3ManNAc 
concentration between 100 and 350 μM. More importantly, the MAL II binding levels from cell 
cultures treated with higher concentrations of Bu3ManNAc (>= 150 μM) exhibited stronger 
binding signals than that for supplementation with 20mM ManNAc. Combining the results of the 
lectin blot analysis and HPLC quantification indicates that Bu3ManNAc addition can enhance 
sialylation levels in CHO cells with feeding concentrations of Bu3ManNAc approximately 100 
fold lower than that of ManNAc.   
Since the total cell lysate contains numerous glycoproteins, subsequent analysis was undertaken 
to investigate further the role of Bu3ManNAc on the intracellular sialic acid levels and sialylation 
of a CHO-K1 expressing a recombinant glycoprotein, erythropoietin (EPO). We first 
investigated the effect of Bu3ManNAc feeding on the total intracellular sialic acid content of the 
EPO-expressing cell line with or without Bu3ManNAc supplement. As shown in Figure 3-3A, 
feeding of 200 or 300 μM Bu3ManNAc resulted in a greater than 8-fold increase in total 
intracellular sialic acid which exceeded the increase obtained by addition of 20 mM ManNAc. 
81  
200-300 μM Bu3ManNAc feeding can achieve comparable and even higher intracellular sialic 
acid level than ManNAc feeding at nearly two order of magnitude lower concentration for the 
analog. Thus, Bu3ManNAc treatment is more efficient in its conversion into sialic acid in the 
intracellular pool than supplementation with ManNAc. 
 Moreover, recombinant EPO was purified from a stable EPO-expressing CHO cell line treated 
with 0 μM, 200 μM, and 300 μM Bu3ManNAc as well as 20 mM ManNAc. As is shown in 
Figure 3-3B, the sialic acid content of EPO from cells following addition of 20mM ManNAc 
increased ~20%, while the sialylation level increased even more with the treatment of 200 μM or 
300 μM Bu3ManNAc (~40%), compared to the untreated cells. This result suggests that 
Bu3ManNAc supplementation can clearly increase the sialic acid content of specific recombinant 
glycoproteins and the enhancement is consistent with the improvement in total intracellular sialic 
acid content detected in the cell lysates treated with Bu3ManNAc. 
3.4.2 Butyrated ManNAc analog improves protein expression in Chinese hamster ovary cells 
1. Effect of 1,3,4-O-Bu3ManNAc on recombinant protein production in CHO cells 
This novel sugar analog-1,3,4-O-Bu3ManNAc is composed of a core ManNAc moiety with three 
ester-linked butyrate groups (Figure 3-1A). Given the expression-enhancing effect of sodium 
butyrate on proteins, we reasoned that 1,3,4-O-Bu3ManNAc may also have the potential to affect 
recombinant protein expression. To examine the impact of this novel analog on recombinant 
protein production, two stable CHO cell lines, one expressing human EPO and the other 
producing human IgG, were treated with 0, 100, 200, and 300 μM 1,3,4-O-Bu3ManNAc 
followed by collection of the cell culture supernatants for immunoblot analysis. As we expected, 
expression levels of both EPO and IgG increased progressively with 1,3,4-O-Bu3ManNAc 
treatment compared to the corresponding untreated cells (Figure 3-4) with addition of 300 μM 
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1,3,4-O-Bu3ManNAc showing the highest expression level of EPO and IgG.  
To further assess the effects of 1,3,4-O-Bu3ManNAc on protein productivity, EPO and IgG cell 
culture supernatant from unmodified medium and medium supplied with a series of 1,3,4-O-
Bu3ManNAc concentrations (100, 200, 300 μM) were harvested and subjected to Ni-NTA (EPO) 
or protein A (IgG) purifications followed by SDS-PAGE analysis. As shown in Figure 3-5A, the 
IgG purified from 1,3,4-O-Bu3ManNAc treatment exhibited increased productivity with 
increasing concentrations of the additive compared to the purified IgG from untreated cells. Both 
in reducing conditions (separate heavy chain and light chain) and non-reducing conditions (full-
size antibody), the protein profile of purified IgG displayed a similar pattern of increased 
productivity for 1,3,4-O-Bu3ManNAc treated cells with the highest antibody levels produced in 
cells treated wtih 300 μM of 1,3,4-O-Bu3ManNAc. For purified EPO, the protein productivity 
was augmented in higher concentrations (200 and 300 uM) of analog as well (Figure 3-5B). Due 
to band spreading as a result of glycosylation, the purified EPOs at different 1,3,4-O-
Bu3ManNAc medium levels were treated with the glycosidase PNGase F, which also exhibited 
higher levels of deglycosylated EPO for the treated samples versus the untreated control.  
2. Effects of 1,3,4-O-Bu3ManNAc on cell growth and metabolism  
We further investigated the cell culture growth and metabolic changes in the presence or absence 
of this novel analog. Cell lines stably expressing IgG (Figure 3-6A and 3-6B) and EPO (Figure 
3-6C and 3-6D) were cultured in the media with or without addition of 0.33 mM 1,3,4-O-
Bu3ManNAc and 1mM NaBu respectively and analyzed for cell numbers and viability on a daily 
basis. Untreated cells entered an exponential growth phase that persisted for 3 days and then the 
viable cell numbers declined. With the addition of 1,3,4-O-Bu3ManNAc, both the EPO and IgG 
expressing cell lines exhibited similar growth patterns and daily viability as the untreated control. 
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Moreover, the non-treated and 1,3,4-O-Bu3ManNAc treated cells were able to reach a similar 
maximum cell density (~3×106 mL-1) for both the EPO and IgG expressing cell lines in batch 
cell culture (Figure 3-6).  Another set of cells were treated with 1mM NaBu. For both the EPO 
and the IgG production cell lines, the NaBu treated cells followed a similar initial growth 
trajectory as the 1,3,4-O-Bu3ManNAc treated and untreated control cells.  However, the 
maximum cell densities following NaBu treatment were reduced relative to these other cell lines 
for both IgG and EPO expressing CHO lines and this culture also exhibited lower viable cell 
densities during the stationary and death phases relative to the other two cultures.  A similar 
pattern was detected in the viabilities in which the cell cultures treated with NaBu showed 
progressively lower percent viabilities after 4 and 5 days in culture.     
Concentrations of glucose and lactate in the cell culture medium were also monitored throughout 
the cell culture time course. As shown in Figure 3-6E and 3-6G, the concentration of glucose 
dropped dramatically in the exponential phase while the concentration of lactate increased over 
time (Figure 3-6F and 3-6H). In all experiments, there was a negligible effect of the presence of 
1,3,4-O-Bu3ManNAc additives on the overall glucose consumption and lactate accumulation for 
both the EPO and IgG cell cultures. The glucose levels in the NaBu-treated cells declined at a 
slightly slower rate for the IgG expressing cell lines. Furthermore, lactate increased more slowly 
in NaBu treated cells by day 2 and maintained a lower overall level in the cultures up until day 5 
of the cultures. Thus, the combined results exhibited that addition of 1,3,4-O-Bu3ManNAc did 
not appear to change the overall growth rates, cell viability as well as metabolite consumption 
and accumulation compared to the untreated cells in both EPO and IgG expressing cell lines. 
Alternatively, the addition of NaBu had a discernibly negative impact on final cell densities and 
viabilities in the stationary and growth phases of both CHO cell cultures.  The influence of NaBu 
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was also reflected in lower lactate accumulation levels for the CHO cultures treated with NaBu 
during the growth and stationary phases. 
Recombinant protein accumulation during cell growth 
Next, the expression levels were determined over the cell culture process for cells treated with 
1,3,4-O-Bu3ManNAc.  Total accumulation levels of EPO and IgG were evaluated daily from 
conditioned medium of expressing CHO cell lines in the presence or absence of 300 μM 1,3,4-O-
Bu3ManNAc in order to monitor the protein profile over the culture period and define the time 
for product harvest. As is shown in Figure 3-7, EPO and IgG accumulation levels were at a very 
low concentration in lag phase and early exponential phases for the untreated (NC) cells, but 
increased in the late exponential phase and stationary phase to a maximum on the final day at 5 
post-inoculation. The product accumulation of EPO in 300 μM 1,3,4-O-Bu3ManNAc exhibited a 
more rapid accumulation pattern with times compared to the untreated cells. By day 3, the EPO 
levels were substantially elevated in the untreated cells and this increase sustained through the 
duration of the batch process. The IgG production profiles are also elevated in the IgG producing 
cell line by day 4 and reached a higher final titer at day 5 compared to the untreated cells. 
Recombinant protein accumulation during cell growth 
Sodium butyrate is widely used as a commercial media supplement to increase protein 
productivity. The presence of butyrate groups on 1,3,4-O-Bu3ManNAc may serve a role 
analogous to NaBu in cell cultures (Figure 3-1). Therefore, another experiment was undertaken 
to compare the impact of NaBu and 1,3,4-O-Bu3ManNAc on CHO cell cultures. As shown in 
Figure 3-8, EPO expression levels were gradually enhanced along with increasing 1,3,4-O-
Bu3ManNAc concentrations from 0.1, 0.2, 0.33 until 0.5 mM. Because 1,3,4-O-Bu3ManNAc can 
generate 3 equivalents of butyrate, NaBu was added at 3-fold higher concentrations (0.3, 0.6, 1 
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and 1.5 mM) than the corresponding 1,3,4-O-Bu3ManNAc concentrations. The supplementation 
of NaBu exhibited higher relative EPO expression levels for same molar amount of butyrate 
compared to the 1,3,4-O-Bu3ManNAc treatment. 
Next, the effect of 1,3,4-O-Bu3ManNAc and NaBu on cumulative EPO protein production from 
day 1 to day 5 over the batch cell culture process was examined for comparative levels of molar 
butyrate, 0.33 mM of 1,3,4-O-Bu3ManNAc and 1mM NaBu, added at the beginning for EPO 
expressing cell lines  followed by immunoblot analysis. The increase in EPO expression for the 
0.33 mM 1,3,4-O-Bu3ManNAc treated cells was once again observed in mid to late growth stage 
(day 3 to day 5) as observed previously  (Figure 3-7). One mM NaBu treatment of the cells 
revealed a similar pattern of expanded EPO expression during the exponential phase with a slight 
increase in protein production compared to 0.33mM 1,3,4-O-Bu3ManNAc treatment (Figure 3-
8B) The viable cell density (VCD) and cell viability were examined as well to assess the cell 
cytotoxicity of 1,3,4-O-Bu3ManNAc and NaBu treatments as shown in Figure 3-6. As noted 
previously, cell culture with 1,3,4-O-Bu3ManNAc added contained more viable cells and 
maintained higher cell viability than NaBu at the end of exponential and during the stationary 
and death phases. 
      Further, quantitative EPO production analysis was investigated. Briefly, along with the 
growth study equal amounts of supernatant were collected twice a day and the relative EPO 
production in the supernatant was measured by enzyme-linked immunosorbent assay (ELISA) 
with anti-EPO antibody. As shown in Figure 3-9E, the relative production of recombinant EPO 
over the time period demonstrated increased for both 1,3,4-O-Bu3ManNAc and NaBu 
supplement compared to cells not subject to chemical supplementation. Based on the equivalent 
butyrate concentrations used, 1,3,4-O-Bu3ManNAc showed a ~ 27% improvement above 
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untreated cells while NaBu increased recombinant EPO expression by ~ 71% relative to the 
untreated producer CHO cells.   
5. Comparison of 1,3,4-O-Bu3ManNAc to NaBu on cell apoptosis 
A major concern for NaBu applications in mammalian cell culture is its effect on cell viability as 
well as cell apoptosis [254, 255]. To examine -the effects of these additives on apoptotic cell 
death, CHO-K1 cells were treated with 1 mM NaBu or 0.33 mM 1,3,4-O-Bu3ManNAc or left 
untreated, then fixed and stained with anti-Caspse3 antibody. Caspse 3 protein is an important 
indicator for cell apoptosis and remarkably active in cell death phase [256].  Stained cells were 
then incubated by DAPI (4',6-diamidino-2-phenylindole) for showing the nuclei areas and 
observed under a florescent microscope. The population of anti-caspase3 stained cells numbered 
as apoptotic cells was observed to increase following the addition of 1 mM NaBu, as compared 
to the untreated control (Figure 3-9A and 3-9B). Alternatively, no statistical variation (n=10) was 
observed between 0.33 mM 1,3,4-O-Bu3ManNAc treated cells and untreated cells in the 
percentage of apoptotic cells in the population under the fluorescence microscope. 
In order to investigate further the activation of cell apoptosis, quantative RT-PCR was used to 
determine mRNA expression of 4 apoptotic marker genes (Cul2, BAK, BAX and BCL2L11) at 
day 3 in wild-type and IgG or EPO expressing CHO cell lines left untreated or treated with 1 
mM NaBu or 0.33 mM 1,3,4-O-Bu3ManNAc. The addition of 1,3,4-O-Bu3ManNAc exhibited 
comparable and slightly elevated levels (1 to 1.5 fold) of mRNA expression of pro-apoptotic 
marker genes when compared to untreated cells for wild-type and IgG or EPO expressing CHO 
cell lines. Alternatively, the addition of 1 mM NaBu resulted in the highest relative expression 
levels of all pro-apoptotic genes across all the three cell cultures when compared to both 
untreated cultures and those treated with 0.33 mM 1,3,4-O-Bu3ManNAc. In particular, NaBu 
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addition up-regulated BCL2L11 1.7-2.5 fold, BAK 1.2-3.2 fold, BAX 1.1-2 fold and Cul2 1.5-
1.8 fold for each of these three different cell lines. Collectively, the combined results of Figure 3-
9 and 3-10 showed that both 1,3,4-O-Bu3ManNAc and NaBu are able to significantly increase 
the recombinant protein productivity in CHO cells. Although NaBu displays a higher 
enhancement of protein expression, 1,3,4-O-Bu3ManNAc showed less cell cytotoxicity and 
apoptosis induction in CHO cell culture at equivalent butyrate levels. 
 
3.4.3 Combining Butyrated ManNAc with Glycoengineered CHO Cells Improves EPO Glycan 
Quality  
1. Intracellular sialic acid levels increased in 1,3,4-O-Bu3ManNAc-treated recombinant EPO-
expressing CHO cells 
We next investigated the impact of the two chemical supplements on intracellular sialic acid 
content. Wild-type and glycoengineered EPO stably expressing CHO cells (wt-EPO and 
glycoengineered-EPO) were cultured in F12K media supplemented with 1,3,4-O-Bu3ManNAc or 
NaBu using equivalent butyrate concentrations. The CHO-K1 cells were also cultured as a 
control. After a 2-day incubation, 2 million cells were collected from each culture and subjected 
to the periodate/resorcinol assay to detect intracellular sialic acid content [248]. As shown in 
Figure 3-11, 1,3,4-O-Bu3ManNAc treatment substantially increased the intracellular sialic acid 
concentrations in both the wild-type and glycoengineered EPO-expressing CHO cell lines (by ~ 
7.2- to 8.0-fold in the wild-type and glycoengineered CHO cells, respectively) compared to 
untreated controls. Sodium butyrate treatment did not measurably change intracellular sialic acid 
levels compared to untreated controls in either the wild-type or glycoengineered EPO cells. 
Together, these comparisons confirmed that ManNAc (a key metabolic precursor of sialic acid 
biosynthesis in mammalian cells) generated from 1,3,4-O-Bu3ManNAc is efficiently converted 
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into the sialic acid biosynthesis pathway and enhance intracellular pools of this sugar.   
 
2. Combining chemical supplementation and glycoengineering strategies altered recombinant 
EPO sialylation  
Next, we assessed the effect of 1,3,4-O-Bu3ManNAc and NaBu addition on the sialylation 
content of recombinant EPO. The EPO protein was purified from both wild-type and 
glycoengineered EPO-expressing CHO lines that had been treated with 1,3,4-O-Bu3ManNAc, 
NaBu, or left untreated. In order to analyze the alterations on sialic acid linkage specificity, equal 
amounts of purified EPO were subject to lectin blot analysis using Maackia amurensis lectin II 
(MAL II) that recognizes α-2,3-linked sialic acid or Sambucus nigra lectin (SNA) that 
preferentially binds to α-2,6-linked sialoglycoconjugates (Figure 3-12A). The lectin blots 
revealed that EPO from 1,3,4-O-Bu3ManNAc treated wild-type CHO cells showed stronger 
MALII binding compared to EPO produced in comparable cells that were either untreated or 
supplemented with NaBu. Similarly, EPO produced by the glycoengineered CHO cells 
supplemented with 1,3,4-O-Bu3ManNAc displayed stronger binding for MALII and higher 
binding to SNA compared to NaBu treated or untreated control samples. In contrast, NaBu 
treated EPO produced in the glycoengineerined cells showed weaker binding of both MALII and 
SNA compared to untreated controls. These results indicated that 1,3,4-O-Bu3ManNAc not only 
increased EPO production (as shown above in Figure 3-4 and 3-5 ) but measurably enhanced α-
2,3-sialylation for EPO from wild-type CHO cells and both α-2,3- and α-2,6-sialylation for EPO 
from the glycoengineered cells. Sodium butyrate treatment (at 1.0 mM), slightly decreased 
sialylation of recombinant EPO, especially from glycoengineered cell line in accordance with the 
literature indicating that NaBu treatment can lower glycan quality[257] [258].  
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Thus, in order to further investigate the combinatorial effect of chemical supplement with 
glycoengineering strategies on EPO sialylation, the influence of equivalent levels of butyrate 
delivered via NaBu or 1,3,4-O-Bu3ManNAc on sialic acid levels of recombinant EPO produced 
in the wild-type and glycoengineered CHO cells was performed . Sialic acids on EPO in each 
sample were derivatized with 1,2-diamino-4,5-methylenedioxybenzene dihydrochloride (DMB) 
and quantified by HPLC using fluorescence detection (Figure 3-12B).  In the absence of 
chemical supplementation, overexpression of GnTIV, GnTV, and ST6 in the glycoengineered 
CHO cells increased EPO (glycoengineered-EPO) sialylation by 42%. In chemically-
supplemented cells, 1,3,4-O-Bu3ManNAc enhanced EPO sialylation by 29% in the wild-type 
CHO cells and by approximately 32% in the cells compared to the respective untreated controls; 
in contrast, treatment with NaBu reduced sialyation by between  6% and 14%. When the benefits 
of 1,3,4-O-Bu3ManNAc supplementation and glycoengineering were combined by comparing 
EPO produced in untreated wild-type CHO cells (633 ng/ml sialic acid) with EPO produced in 
1,3,4-O-Bu3ManNAc supplemented glycoengineered cells (1,114 ng/ml), a dramatic 75% 
enhancement in sialic acid content  was observed.  In summary, lectin blots and HPLC 
quantification demonstrate that 1,3,4-O-Bu3ManNAc supplementation enhanced sialylation of 
recombinant EPO consistent with the increased intracellular sialic acid content in the respective 
cells (Figure 3-11) and furthermore that combining glycogene overexpression with our 
metabolite supplementation method  increased these levels even more. 
 
3. N-Glycan profiles of wild-type and glycoengineered EPO determined by intact glycopeptide 
LC-MS/MS analysis 
To elucidate N-glycan profiles from EPO produced in wild-type and glycoengineered EPO-
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expressing CHO cells treated with 1,3,4-O-Bu3ManNAc or NaBu, we performed intact 
glycopeptide analysis using nano LC-MS/MS. The unique fragmentation signatures obtained 
from the MS/MS spectra of intact EPO glycopeptides analyzed by high energy C-trap 
disassociation (HCD) fragmentation, including oxonium ions (m/z 138, 163, 204, 274 , 292, and 
366), peptide fragmentation ions (b- and y-ions), and peptide and peptide+HexNAc fragment 
ions, were integrated to identify the glycopeptides. Representative EPO glycopeptide MS/MS 
spectra at each EPO N-glycan site are provided in the Supplemental Results, Figure S3-1.  The 
number of peptide spectral matches (PSM) was used to calculate the overall abundance of 
different glycoforms or at specific glycosylation sites with two biological repeats. 
The EPO glycoforms were first analyzed and organized by antennary distribution (Supplemental 
Results, Figure S3-2). The antennary distribution of wt-EPO and glycoengineered-EPO glycans 
showed that overexpressing GnTIV/GnTV genes in glycoengineered CHO cells significantly 
increased the tetra-antennary structures and simultaneously reduced the tri- and bi-antennary 
content on the glycoprofile of recombinant EPO. However, treatments with 1 mM NaBu resulted 
in fewer tetra-antennary structures and an increased fraction of tri-antennary glycans on EPO 
from glycoengineered CHO cells.  Indeed,  3mM NaBu has previously been shown to lower the 
EPO branch complexity in unmodified CHO cells [259]. Alternatively, 0.333 mM treatment with 
1,3,4-O-Bu3ManNAc resulted in an increase in the tetra-antennary and fewer tri-antennary 
structures on EPO from both wild-type and CHO cells. Treatment with 1 mM NaBu and 0.333 
mM 1,3,4-O-Bu3ManNAc did not alter the abundance of oligomannose, mono- and bi-antennary 
glycans distribution in wild-type and glycoengineered CHO cells. 
Next, we explored the impact of NaBu and 1,3,4-O-Bu3ManNAc on the sialylation of EPO from 
wild-type and glycoengineered CHO cells. The overall (∑ 𝑠𝑖𝑎𝑙𝑦𝑙𝑎𝑡𝑒𝑑 𝑔𝑙𝑦𝑐𝑜𝑝𝑒𝑝𝑡𝑖𝑑𝑒 𝑃𝑆𝑀
∑ 𝑡𝑜𝑡𝑎𝑙 𝑔𝑙𝑦𝑐𝑜𝑝𝑒𝑝𝑡𝑖𝑑𝑒 𝑃𝑆𝑀
) and site-
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specific sialylation occupancy 
 (∑ 𝑠𝑖𝑎𝑙𝑦𝑙𝑎𝑡𝑒𝑑 𝑔𝑙𝑦𝑐𝑜𝑝𝑒𝑝𝑡𝑖𝑑𝑒 𝑃𝑆𝑀 𝑎𝑡 𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝑠𝑖𝑡𝑒
∑ 𝑡𝑜𝑡𝑎𝑙 𝑔𝑙𝑦𝑐𝑜𝑝𝑒𝑝𝑡𝑖𝑑𝑒 𝑃𝑆𝑀 𝑎𝑡 𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝑠𝑖𝑡𝑒
) are shown in Figure 3-13A and 3-13B. The sialylation 
occupancy is defined by the percentage of sialylated glycopeptides detected at a specific site as 
showed in the raw MS data in the Supplemental Results. With this method we achieved exquisite 
resolution of the glycan profile at each of the three N-glycan sites of EPO. We first compared 
EPO produced in wild-type and glycoengineered cells not subject to chemical supplementation. 
In this case (the first column in Figure 3-13A) we observed that the first N-glycan site (-N51ITT-
) of EPO had highest sialylation occupancies of ~ 85% and 77% in EPO from their 
corresponding two cell lines.  A feature of the glycoengineered CHO-derived EPO glycosylation 
profile was approximately equivalent sialylation at each of the three sites (77, 73, and 76% for 
sites 1, 2, and 3, respectively) compared to the gradually lower occupancy at three N-sites in wt-
EPO. We next compared sialylation occupancy after supplementation with NaBu and found that 
there was negligible impact to the 1st and 3rd (-N110SSQ) N-glycan sites for wild-type EPO 
compared with the untreated controls (shown in Figure 3-13A). Supplementation of the 
glycoengineered cells that produce glycoengineered EPO with NaBu, however, caused 
measurably decreased sialylation at each site (from 77% to 68% at the 1st N-glycan site, from 
73% to 52% at the 2nd, and from 76% to 51% at the 3rd). By comparison, 1,3,4-O-Bu3ManNAc 
(Figure 3-13A)  increased sialylation occupancy at the 2nd (-N65ITV-) and 3rd N-glcyan sites on 
both wt-EPO and glycoengineered-EPO compared to untreated controls. These analyses of site-
specific sialylation occupancy indicate that the 1st N-glycan site was already highly sialylated 
under “wild type” conditions, perhaps because in the glycosylaiton process, the first N-site on the 
nascent EPO peptide is the first one to be glycosylated in Golgi or perhaps the first N-glycan site 
has less structural hindrance than the other two sites to interact with glycosyltransferases. 
92  
Glycosylation difference at different sites have been observed previously by Liu et al., who were 
looking at Influenza A virus hemagglutinin and the first two N-sites were fully glycosylated 
while the rest N-sites were not completely glycosylated [260].The study of secretory 
immunoglobulin A from human colostrum also revealed that for secretory component (SC), the 
first two N-sites have higher glycosylation and sialylation occupancy than other N-sites and the 
second N-site has higher glycosylation and sialylation than other N-sites for IgA1/IgA2 perhaps 
due to structural hindrance to interact with available glycosyltransferases [261].The positive 
impact of 1,3,4-O-Bu3ManNAc supplementation primarily contributes to enhanced sialyation of 
the 2nd and 3rd N-glycan sites of recombinant EPO.  Importantly, 1,3,4-O-Bu3ManNAc 
supplementation either avoids, or reverses, the deleterious impact of butyrate on glycan quality 
when this chemical agent is delivered and complexed with ManNAc as opposed to NaBu.  
Lastly, the overall impact of chemical supplementation on EPO sialylation occupancy with 1 to 4 
sialic acids (S1 to S4) is shown in Figure 3-13B where the net effect is summed across all three 
sites; this combined data shows that NaBu decreases sialylation occupancy in both the wild-type 
and especially in the glycoengineered CHO lines compared to untreated controls while 1,3,4-O-
Bu3ManNAc increases overall occupancy. In Figure 3-13B, we also classified the glycan 
structures based on the number of sialic acids found on each of these EPO samples based on the 
MS analysis. NaBu treatment reduced the proportion of N-glycans with 2, 3, or 4 sialic acids 
while increasing the fraction of N-glycans with 0 or 1 copies of this sugar for wt- and 
glycoengineered CHO derived EPOs. By contrast, treatment with 1,3,4-O-Bu3ManNAc 
increased the proportion of S2 to S4 sialylated glycans  while decreasing the percentage of 





Previously Gu et al reported that feeding of ManNAc to CHO cells can improve the interferon-γ 
sialylation [50]. Furthermore, the study also determined that 20mM was the best concentration to 
supplement ManNAc in CHO cells because lower levels like 0.2 mM or 2 mM were insufficient 
while no further improvement in sialylation was achieved when adding more than 40mM 
ManNAc [50]. Our lectin blot and sialic acid content analysis revealed that the novel 
Bu3ManNAc analog can greatly increase total protein sialylation in CHO cells at much lower 
concentrations compared to ManNAc. 
Unlike subsequent sialylation pathway metabolites, ManNAc is able to permeate across the cell 
membrane, albeit inefficiently [253]. High exogenous addition of ManNAc is required primarily 
due to the lack of plasma membrane transporters for this monosaccharide. To circumvent the low 
metabolic uptake of natural ManNAc, acetylated monosaccharides (and disaccharides) were 
observed to increase cellular uptake efficiency by up to three orders of magnitude [232, 262]. A 
problem with completely acetylated monosaccharides, however, is that modification of the C6-
OH groups results in unacceptable levels of off-target effects such as increased toxicity. Our 
group has overcome challenges with lipophilicity and toxicity by substituting acetate with the 
longer chain SCFA (short chain fatty acid) n-butyrate, rendering tri-substituted monosaccharides 
fully membrane permeable and leaving the C6-OH group unmodified. Specifically, 1,3,4-O-
Bu3ManNAc represents a novel “high-flux” precursor for increasing sialic acid production in 
mammalian cells at low concentrations compared to natural ManNAc with negligible 
cytotoxicity[240]. Once inside a cell, non-specific esterases rapidly remove the butyrate groups 
regenerating natural ManNAc, which enters the sialic acid biosynthetic pathway [242].  
Improving recombinant protein production in mammalian cell culture is a major objective of 
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biopharmaceutical manufacturing. Viable strategies including cell line selection, cell 
engineering, vector design, medium optimization, and feeding strategies have been employed to 
maximize the productivity of therapeutic proteins [217, 219, 263]. One strategy used in the 
biopharmaceutical industry is the addition of chemical compounds to the culture medium in 
order to improve recombinant protein production using the CHO platform. Chemical 
modifications of media are convenient and easily implemented.  Indeed, additions to the media 
represent a modification that can be incorporated readily at a later stage in product development 
or when updating a current production process.  
 NaBu is one of the most widely used additives in mammalian cell culture to improve the 
productivity of recombinant proteins. Unfortunately, these enhancements in product yields often 
come at the expense of product quality. Indeed, while the addition of NaBu provides a number of 
advantages in terms of yield improvements,  its inclusion can be problematic in terms of product 
quality and  cell viability resulting from the effect of this additive on cellular physiology.   
In this study,  we have characterized the impact of a potentially useful chemical additive, 1,3,4-
O-Bu3ManNAc, on the expression of recombinant proteins in CHO cells. In comparison to the 
extensively used additive-NaBu, 1,3,4-O-Bu3ManNAc exhibited several advantages, including 
decreased cell cytotoxicity, lowered apoptosis and reduced expression of pro-apoptotic genes 
combined with superior sialylation. Its application may be beneficial as a media supplement and 
replacement for NaBu both for improved protein yields and enhanced glycosylation with a lower 
or negligible impact on growth.   
N-Acetylmannosamine (ManNAc) is an intermediate in the sialic acid synthesis pathway. Given 
that ManNAc exhibits low metabolic efficiency and cellular uptake in previous studies, 1,3,4-O-
Bu3ManNAc was designed initially as a substitute for ManNAc. Chemical modifications were 
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made to this known glycosylation supplement including extending the fatty acid chain length 
(acetate to n-butyrate) to increase lipophilicity and membrane permeability while leaving the C6-
OH group unmodified to negate the toxicity found in fully conjugated hexosamine analogs [237]. 
The resulting chemical analog, 1,3,4-O-Bu3ManNAc represents a “high-flux” alternative for 
incorporating the ManNAc precursor into the cells in order to increase the cellular production of 
sialic acid used in the sialylation of glycoproteins. Indeed, sialic acid levels in cells incubated 
with 1,3,4-O-Bu3ManNAc increased ~2500-fold compared to cells incubated with natural 
ManNAc [237, 240]. Moreover, application of 1,3,4-O-Bu3ManNAc in CHO cells and other cell 
lines improved sialylation of cellular glycoproteins and a recombinant glycoprotein, EPO, at 
concentrations as much as 100 fold lower compared to natural ManNAc [5].   
While this chemical analog has been utilized previously only in the context of enhancing 
intracellular sialic acid and protein sialylation [5, 240], the current study was initiated to evaluate 
its capacity to increase recombinant protein production for multiple target proteins. Stable EPO 
and human IgG-expressing CHO cell lines were selected to investigate the influence of 1,3,4-O-
Bu3ManNAc supplement on recombinant protein expression in CHO cell culture.  Increasing the 
concentration of 1,3,4-O-Bu3ManNAc supplemented in the cell culture media led to the 
enhancement of production for two therapeutic protein (EPO and IgG) targets. This capacity to 
improve production of the two varied proteins suggests that 1,3,4-O-Bu3ManNAc can be 
generally applicable for other expressed proteins and potentially in different cell lines. Indeed, 
HEK 293 cells, treated with 1,3,4-O-Bu3ManNAc have also shown improved expression of 
membrane proteins relative to untreated cells (data not shown).  Thus, treatment with 1,3,4-O-
Bu3ManNAc appears to be generally applicable for improving recombinant protein production 
across multiple mammalian cell types and for various therapeutic protein targets. Since the 
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organic component, ManNAc, has been shown not to alter protein production in CHO cell 
cultures [50], the yield enhancing activity of 1,3,4-O-Bu3ManNAc was most probably 
contributed by the butyrate groups. Indeed, butyrate is known to act as a histone deacetylase 
inhibitor, and facilitate “opening” the chromatin area for enhanced accessibility to transcription 
factors [264],  The widely-used butyrate chemical-NaBu and this new chemical analog, 1,3,4-O-
Bu3ManNAc, both greatly increased protein production in EPO expressing cells at same 
concentration of butyrate. While NaBu was more effective than 1,3,4-O-Bu3ManNAc in 
enhancing EPO production (Figure 3-9), this chemical is also known for its negative effects on 
cell growth and activation of cell death.  Thus, the impact of 1,3,4-O-Bu3ManNAc on cell 
growth and apoptosis in CHO cell culture was an equally important consideration to be 
examined. As shown in Figure 3-9, both EPO and IgG expressing cell lines with 1,3,4-O-
Bu3ManNAc treatment displayed similar growth profiles as the corresponding untreated controls 
respectively. 1,3,4-O-Bu3ManNAc-treated cells were able to reach an equivalent maximum cell 
density as the untreated control, while no significant differences in cell viability or changes in 
glucose consumption and lactate production were observed between control cells and cells with 
1,3,4-O-Bu3ManNAc treatment. Alternatively, NaBu-treated cells exhibited a decrease of ~20% 
in viable cell density as well as >30% decrease in viability compared to control cell lines and 
1,3,4-O-Bu3ManNAc-treated cells. 
To address this phenomenon further, we examined the expression of several cell apoptosis genes 
at the mRNA level for 1,3,4-O-Bu3ManNAc- and NaBu-treated cells at equivalent butyrate 
concentration (1mM) and compared these levels to untreated control cells. The two compounds 
exhibited varying impacts on wild-type CHO, EPO or IgG expressing cell lines. In particular, the 
mRNA level of 4 cellular apoptosis genes (Bcl2L11, BAK, BAX and Cul2) was substantially up-
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regulated (1.2 to >3 fold) with NaBu addition compared to untreated cells in all three CHO cell 
lines. In contrast, most of the mRNA levels of apoptotic marker genes in 1,3,4-O-Bu3ManNAc 
treated cell lines were equal or only slightly increased compared to the levels in untreated cells, 
with the two exceptions of BAK, which was increased ~2 fold in the IgG expressing cell line, 
and BAX, up-regulated ~1.5 fold in CHO-K1. These findings indicate that addition of 1,3,4-O-
Bu3ManNAc provides a much milder apoptotic signaling compared to NaBu in CHO cell culture. 
It is interesting to note that 1,3,4-O-Bu3ManNAc and NaBu display a varied influence on cell 
apoptosis and cytotoxicity despite both of them containing the same levels of the active butyrate 
groups. One possible explanation is that NaBu diffuses into the cytosol more rapidly and is 
utilized almost immediately.  Alternatively, 1,3,4-O-Bu3ManNAc is larger and likely exhibits a 
slower and more gradual permeability through the cell membrane  (although much superior to 
natural ManNAc). Moreover, an ester enzyme is required to release the butyrate group from 
1,3,4-O-Bu3ManNAc which may yield a slower-releasing dosage of the butyrate into the cellular 
cytosol over time.  
In this study, we combined 1,3,4-O-Bu3ManNAc supplementation with glycoengineering in 
CHO cells in order to construct an integrated production platform which provides synergies for 
improving quality and simultaneously increasing yields. Applying CHO cells previously 
engineered to express GnTIV/GnTV was observed to increase the tri- and tetra-antennary 
structures (Supplemental Figure S3-2), which increases the sialic acid binding sites[246]. In 
conjunction, overexpressing ST6 can increase α-2,6-sialyltransferase expression in CHO, which 
facilitates the transfer of sialic acid from the CMP-sialic acid donors to these specific acceptors 
[265]. Indeed, the combined overexpression of GnTIV/GnTV/ST6 increased sialylation of 
glycoengineered-EPO about 42% compared to wt-EPO (Figure 3-12B). Alternatively, feeding 
98  
1,3,4-O-Bu3ManNAc significantly increased the intracellular sialic acids which in turned 
improved  sialic acid content on wt-EPO by 29% and by 32% for the glycoengineered-EPO.  
Furthermore, 1,3,4-O-Bu3ManNAc  as a high-flux precursor is capable of augmenting 
recombinant protein sialylation at culture concentrations 100-fold lower than natural ManNAc 
feeding [5]. Furthermore, combining analog sugar feeding of 1,3,4-O-Bu3ManNAc with 
glycoengineering of CHO cells (overexpressing GnTIV/GnTV/ST6 ) achieved the highest 
sialylation levels, fully 75% higher compared to the wt-EPO control without chemical treatment.   
These results suggest that both glycosyltransferases activity and sialic acid substrate availability 
are limiting the sialylation content for recombinant proteins produced in CHO cells.  
Meanwhile, the impact of 1,3,4-O-Bu3ManNAc was compared with NaBu for their impact on 
production and glycan quality of EPO proteins expressed from CHO cells. We observed that 
under equivalent butyrate concentrations, 1,3,4-O-Bu3ManNAc and NaBu both increased the 
EPO expression in CHO cells, but NaBu exhibited a higher yield enhancement than 1,3,4-O-
Bu3ManNAc treatment. In addition, the NaBu treatment negatively affected GnTIV and ST6 
expressions while 1,3,4-O-Bu3ManNAc showed much less impact on expression of GnTIV and 
ST6 in CHO cell lines (Supplemental Figure S3-34). Moreover, as demonstrated in Figure 3-9, 1 
mM NaBu resulted in a 33% decrease in maximal viable cell density and ~30 % decrease in cell 
viability while 0.333 mM 1,3,4-O-Bu3ManNAc had a negligible impact on CHO cell growth and 
viability as compared to the untreated control. A recent report from our group also showed that 
the mRNA levels of 4 cell apoptosis genes (Cul2, BAK, BAX and BCL2L11) were up-regulated 
in sodium butyrate treated CHO cells while most of the mRNA levels of apoptosis genes in 
1,3,4-O-Bu3ManNAc treated cells remained constant or increased only slightly compared to 
untreated CHO cells [266]. These findings suggests that NaBu can induce CHO cell cytotoxicity 
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and apoptosis while 1,3,4-O-Bu3ManNAc has a limited or negligible impact on CHO cell 
cytotoxicity and apoptosis. The reduction in some glycotransferase expression in NaBu treated 
cells may be linked to the activation of cell apoptosis, which has led to the degradation of 
glycosylation in the Golgi [267]. Indeed, the mechanism by which NaBu impairs glycosylation 
may be through multiple mechanisms including activation of cell death pathways and regulation 
of gene expression. Moreover, proteomics and transcriptomics studies have revealed that sodium 
butyrate can affect gene expression in CHO cells in both directions (up-regulation and down-
regulation), and some genes showed an opposite trend at the transcriptional and translational 
levels [268] [269]. A comprehensive investigation of NaBu and 1,3,4-O-Bu3ManNAc on N-
glycosylation at both transcriptional and translational levels is warranted to further elucidate the 
various mechanisms by which NaBu and 1,3,4-O-Bu3ManNAc impact protein glycosylation in 
CHO.   
A critical finding in this study was that the delivery of butyrate via 1,3,4-O-Bu3ManNAc rather 
than by using its sodium salt (NaBu) circumvented diminishing glycan quality, in particular the 
reduction of sialylation.  Indeed, the negative effect of NaBu on protein glycosylation was more 
evident on heavily glycosylated and sialylated EPO from the glycoengineered CHO than wt-
EPO.  The HPLC sialic acid quantification (Figure 3-12B) revealed that NaBu decreased the 
sialic acid content on wt-EPO about 6% and on the glycoengineered EPO about 14%, while 
1,3,4-O-Bu3ManNAc  increased the sialic acid content on wt-EPO about 29% and on the 
glycoengineered EPO about 32% . Detailed intact glycopeptide analysis revealed that NaBu 
reduced the sialylation occupancy on all 3 N-glycan sites on glycoengineered EPO while 1,3,4-
O-Bu3ManNAc significantly increased sialylation occupancy of both wt-EPO and 
glycoengineered EPO on both the 2nd and 3rd N-glycan sites. These analyses of site-specific 
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sialylation occupancy indicate that while the 1st N-glycan site was already highly sialylated 
under “wild type” conditions, the positive impact of either glycotransferase overexpression or 
1,3,4-O-Bu3ManNAc supplementation primarily contributes to enhanced sialyation of the 2nd 
and 3rd N-glycan sites of recombinant EPO.  Previous reports [270] also demonstrated that 
NaBu diminished the sialylation content on recombinant proteins from CHO cells and to a lesser 
extent, the antennary complexity of glycans [270]. These alterations of glycosylation due to 
NaBu are potentially attributed to two factors:  1. NaBu induces a faster protein biosynthesis rate 
in cells and this may exceed glycosylation processing at high flux rates through Golgi and 2. 
NaBu addition triggers cell apoptosis, which can increase ER stress [271] [272] and initiate the 
degradation of glycosylation and other processing enzymes in Golgi [267]. In contrast, at the 
same butyrate conditions, 1,3,4-O-Bu3ManNAc may not impact the glycosylation activity in 
Golgi as severely as NaBu treatment. Most importantly, 1,3,4-O-Bu3ManNAc can increase the 
availability of substrates  in order to maintain or increase sialylation levels in CHO cells.   
 
3.5. Conclusion 
The current study has expanded the potential applicability of this analog by demonstrating its 
capacity to improve sialylation of cellular glycoproteins in CHO-K1 cells, and, more 
importantly, the sialic acid content of a recombinant glycoprotein, EPO, secreted from CHO 
cells. Furthermore, Bu3ManNAc is a more effective chemical additive to improve sialylation 
than widely-used ManNAc with comparable and even superior improvement at concentrations as 
much as 100 fold lower. Furthermore, the reduced cytotoxicity compared to other chemical 
analogs suggest this chemical additive may be a valuable supplement for enhancing the 
glycosylation and sialylation profiles of recombinant proteins produced from CHO and other 
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mammalian production hosts in the coming decades. 
In summary, we present 1,3,4-O-Bu3ManNAc as a new chemical supplement for enhancing 
production for a diverse collection of recombinant proteins in cell cultures.  Furthermore, our 
data indicate that 1,3,4-O-Bu3ManNAc addition has a negligible impact on cell growth, 
cytotoxicity, apoptosis and metabolite utilization while simultaneously enhancing the sialylation 
properties of target secreted glycoproteins. All of these properties are valuable attributes for its 
use as a cell culture additive in CHO cells and other mammalian production hosts. In this way, 
1,3,4-O-Bu3ManNAc can represent a useful replacement to NaBu in future biotechnology efforts 
to improve protein yields without sacrificing undue negative impacts on the cell growth, 
viability, apoptosis, and glycosylation.  Its capacity to be added as a direct supplement to culture 
media should allow it to be incorporated readily into current bioproceses as well as those under 
development.   
In conclusion, in this work, we compared two butyrate-based chemical supplementation 
strategies (NaBu and 1,3,4-O-Bu3ManNAc ) by evaluating their impact on protein production 
and glycan quality of recombinant EPO expressed from wild-type and glycoengineered CHO 
cells. 1,3,4-O-Bu3ManNAc promoted recombinant protein production while increasing 
sialylation. NaBu, although achieving a higher protein yield than 1,3,4-O-Bu3ManNAc 
treatment, induced cell cytotoxicity and resulted in deteriorated EPO glycan sialylation. These 
findings position 1,3,4-O-Bu3ManNAc as an attractive chemical supplement for recombinant 
protein production in biotherapeutics manufacturing. Furthermore, by combining metabolite 
supplementation with glycoengineering strategies, enhanced glycan quality, and especially 
sialylation profiles, can be achieved with their potential positive impacts on functional in vivo 
activity for target glycoproteins [273]. 
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Figures and Tables 
Figure 3-1.  (3-1A) Structures of 1,3,4-O-Bu3ManNAc, NaBu and ManNAc, (3-1B) The simplified 





Figure 3-2. Effect of 20 mM ManNAc and increasing Bu3ManNAc levels on the sialic acid content of the 
total protein. (3-2A) HPLC quantification of sialic acid content for total proteins from wild type CHO-K1 
treated with ManNAc and various Bu3ManNAc concentrations. (3-2B) MAL lectin blot of total 




Figure 3-3. (3-3A) Intracellular sialic acid content in untreated parental wild type CHO-K1, NC (negative 
control, EPO-expressing cell line growing in regular F-12K media), EPO cell line treated with 20mM 
ManNAc, with 200 and 300 μM Bu3ManNAc. (3-3B) Sialic acid content on recombinant EPO from 
CHO-K1 in the presence and absence of supplements: NC (negative control, EPO-expressing CHO-K1 
cell line growing in regular untreated F-12K media), EPO-expressing cell line fed with 20mM ManNAc, 






Figure 3-4.  Immunoblot of protein expression in EPO- or IgG-expressing cell lines with increasing 
concentrations of 1,3,4-O-Bu3ManNAc treatment. EPO- and IgG-expressing cell lines were treated with 
100, 200, 300 μM 1,3,4-O-Bu3ManNAc along with untreated cells as a control. Twenty microliters of 
supernatant from each sample were loaded into an SDS-PAGE and then anti-EPO or anti-IgG antibodies 




Figure 3-5. Western blot of IgG and EPO purified from expressing CHO cell lines treated with increasing 
levels of 1,3,4-O-Bu3ManNAc. EPO- and IgG-expressing cell lines were treated with 100, 200, or 300 
μM of 1,3,4-O-Bu3ManNAc with untreated cells used as the control. Supernatant (2ml) from each EPO or 
IgG sample were collected and subjected to protein purification. EPO proteins were purified using Ni-
NTA resin because of the fused his-tag on the C-terminus, and IgGs were separated using a protein A 
resin. (A) Purified IgGs were treated with DTT in the loading buffer for SDS-PAGE as the reducing 
condition and compared to samples without DTT (non-reducing) addition; (B) Purified EPOs were 





Figure 3-6. Cell growth and metabolite changes in EPO- and IgG-expressing stable CHO cell lines from 
untreated controls and cells exposed to 1,3,4-O-Bu3ManNAc (0.33 mM) or NaBu (1 mM). (A) Viable cell 
densities (VCD) for IgG-expressing lines; (B) Cell viabilities for IgG-expressing cell lines; (C) Viable 
cell densities for EPO-expressing cell lines; (D) Cell viabilities for EPO-expressing cell lines; (E) Glucose 
levels for IgG-expressing cell lines; (F) Lactate levels for IgG-expressing cell lines; (G) Glucose levels 








































































































Figure 3-7. The effect of 1,3,4-O-Bu3ManNAc addition on recombinant protein accumulation with days. 
Daily aliquots (20 μl) of conditioned media from EPO- and IgG-expressing CHO cell  lines were 
collected in the presence or absence of 300 μM 1,3,4-O-Bu3ManNAc addition, and subjected to anti-EPO 
and anti-IgG immunoblot analysis individually in order to monitor the recombinant protein accumulation 















Figure 3-8. Comparison of the effects of 1,3,4-O-Bu3ManNAc and NaBu on recombinant protein 
production. (A) The expression level of EPO in the presence of different levels of 1,3,4-O-Bu3ManNAc 
and NaBu treatment at equivalent molar butyrate concentration conditions; (B) The accumulation of 
recombinant EPO from day 1 to day 5 over the batch cell culture process following 0.33 mM of 1,3,4-O-
Bu3ManNAc and 1 mM NaBu addition, which provide comparative levels of molar butyrate. Daily 
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Figure 3-9. Cell growth and EPO productivity in wt-EPO-expressing CHO cell line from untreated 
controls and 1,3,4-O-Bu3ManNAc (0.333 mM) or NaBu (1 mM) treatments. (3-9A) Viable cell densities 
(VCD) for wt-EPO-expressing line with chemical treatments; (3-9B) Cell viabilities for wt-EPO-
expressing line with chemical treatments; (3-9C) Glucose levels for wt-EPO-expressing cell line with 
chemical treatments; (3-9D) Lactate levels for wt-EPO-expressing cell line with chemical treatments; (3-
9E) Relative EPO productivity in the growth cycle in the wt-EPO-expressing line treated with 1,3,4-O-
Bu3ManNAc (0.333 mM) or NaBu (1 mM) individually.   
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Figure 3-10. Comparison of the impact of 1,3,4-O-Bu3ManNAc and NaBu on apoptosis and expression 
of apoptosis-related genes in CHO cells. (A) Microscopic analysis of Caspase 3 protein activity in 1 mM 
NaBu or 0.33 mM 1,3,4-O-Bu3ManNAc treated and untreated CHOK1 cells. After fixing and staining 
with anti-Caspase3 antibody, cells were then incubated with DAPI for showing the nuclei areas and 
observed under a 20× magnification of a florescence microscope; (B) The mRNA expression of 4 
apoptosis marker genes (Cul2, BAK, BAX and BCL2L11) in 1 mM NaBu or 0.33 mM 1,3,4-O-







Figure 3-11. Intracellular sialic acid content of  EPO expressed in wild-type and glyco-engineered CHO 
cells supplemented with 1.0 mM NaBu and 0.33 mM 1,3,4-O-Bu3ManNAc (n=3). wt-EPO: EPO 
expressed in wild-type CHO cells, branch-EPO: EPO expressed in glyco-engineered CHO 
(overexpression of GNTIV/GNTV/ST6) with higher sialylated and complex glycans. NC: negative 
control as no-chemical supplemented sample. CHOK1 cells were also analyzed under same condition as 
control. After two days of incubation with each supplement, 2 x 106 cells were collected from each 
culture batch and subjected to the periodate/resorcinol assay to measure intracellular sialic acid.  
 
 
Figure 3-12. Comparison of 1,3,4-O-Bu3ManNAc  and NaBu on the sialylation content of recombinant 
EPOs expressed in wild-type and glyco-engineered CHO cells. (3-11A) Lectin blot analysis of sialylation 
of EPO from wild-type and glyco-engineered CHO cells treated with 1.0 mM NaBu and 0.333 mM 1,3,4-
O-Bu3ManNAc. Purified EPOs from untreated or treated cells were subjected to lectin blot analysis with 
Maackia amurensis Lectin II (MAL II) for α2,3 sialylation and Sambucus nigra Lectin (SNA)  for α2,6 
sialylation. Coomassie blue staining was used to quantify the purified EPO amount as a loading control. 
Coomassie blue staining was used to ensure equal amounts of purified EPO proteins  loaded in each 
lane.  EPO samples from the lectin blots showed similar molecular size as the purified EPO from 
Coomassie blue staining result.   (3-11B) HPLC quantification of sialic acid content of EPO from wild-
type and glyco-engineered CHO cells treated with 1.0 mM NaBu and 0.333 mM 1,3,4-O-Bu3ManNAc. 
1.5ug of purified EPO for each sample were labeled by 1,2-diamino-4,5-methylenedioxybenzene 





Figure 3-13. Comparison of NaBu and 1,3,4-O-Bu3ManNAc treatments on the overall and site-specific 
sialylation occupancies of N-glycans on EPO expressed in wild-type and glyco-engineered CHO cells. (3-
12A). The sialylation occupancy at each N-glycan site of wt-EPO and branch-EPO treated with NaBu and 
1,3,4-O-Bu3ManNAc individually. The site-specific sialylation percentage is calculated by sialylated 
glycopeptide PSM number in the total identified glycopeptide PSM number at each N-glycan site of EPO.  
(3-12B). The overall sialylation occupancy  ( the percentage of total sialylated glycopeptide PSM number 
in the total identified glycopeptide PSM number). The identified sialylated/ total glycopeptide PSM ratio 





Supplemental Figure S3-1. Representative MS/MS spectra of the 5 identified N-glycopetides in 
EPO control sample. (S3-1A)Spectral title: AKEAENITTGCAE + N4H5F3S0G0/3. 
Glycopeptide sequence: AKEAENITTGCAE; N-glycan: N4H5F3S0G0 (N: HexNAc, H: Hex, F: 
Fuc, S: Neu5Ac, G: Neu5Gc); Charge: 3. The same labeling works for For (S3-1B)-(S3-1E). 
Upper figure: highlight only oxonium ions in yellow; Lower figure: after removing oxonium 








Supplemental Figure S3-2. The N-glycan antennary distribution of EPO expressed in wt-EPO 






Supplemental Figure S3-3. Comparison of 1,3,4-O-Bu3ManNAc  and NaBu supplementations 
on some glycotransferases expression in CHO cells. Wild-type EPO- and glyco-engineered EPO-
expressing CHO cells treated with 1.0 mM NaBu and 0.333 mM 1,3,4-O-Bu3ManNAc  for 2-day 
culture. Then, chemically-treated and untreated cells were lysed using RIPA buffer and 
equivalent cell lysate from each sample was subjected to immunoblot analysis to detect some 
glycotransferases expressions in cells under chemical treatments (n=3). Actin serves as an 
internal control. GNTIV: β-1,4-N-acetylglucosaminyltransferase, GNTV: β-1,6-N- 
acetylglucosaminyltransferase, ST6: α2,6-sialyltransferase 1,  ST3: α2,3-sialyltransferase   
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Chapter 4 Exploration of B3GNT2 and B4GALT1 for their 





β-1,3-N-acetylglucosaminyltransferase 2 (B3GNT2) and β-1,4-galactotransferase 1 (B4GALT1) 
have been identified as two critical gene for the initiation and elongation of repeated N-
acetyllactosamine (poly-LacNAc) units in mammalian cells. Poly-LacNAc serves various 
cellular functions in differentiation, metastasis, immune response and tumorigenesis Moreover, it 
also affects recombinant EPO enzymatic activity and circulatory half-life. In this work, we 
explored the single and dual-incorporation of two LacNAc primary genes-B3GNT2 and 
B4GALT1 for their roles in the initiation and elongation of LacNAc units in recombinant EPO-
expressing CHO cells. However, challenges exited for incorporation of B4GALT1 into 
B3GNT2-overpressig CHO cells. Furthermore, we also investigated if the capping terminal 
sialylation impacts the LacNAc elongation or not by eliminating sialylation in CHO cells. To our 
surprise, the overexpression of B3GNT2 in EPO-expressing CHO cells did not increase the 
LacNAc content on recombinant EPO protein, but also resulted in nearly 100% elimination of 







As a common and complex protein post-translational modification, glycosylation has long been 
known to play major metabolic, structural and physical roles in mammalian cells [274]. Many 
complex and hybrid N-glycans on glycoproteins and glycolipids have elongated branches, which 
is composed of repeated N-acetyllactosamine units (LacNAc) and often presented as the poly-
LacNAc glycan epitope [275] [276] [277], as shown in Figure 4-1A. The LacNAc glycan is 
initiated by the addition of a β-linked galactose (Gal) to N-acetylglucosamine (GlcNAc) to 
generate the ubiquitous building block Galβ1-4GlcNAc. LacNAc can be further extended by the 
sequential addition of GlcNAc and Gal residues, resulting in tandem repeats of LacNAc (Galβ1–
4GlcNAc)n. Poly-LacNAc is identified  as a scaffold for other oligosaccharides to display, such 
as sialyl Lewis X, and also as a binding motif for galectins [276] [278]. In addition, poly-
LacNAc also serves various cellular functions in differentiation, metastasis, immune response 
and tumorigenesis [278]. Moreover, it has also been reported that poly-LacNAc extensions affect 
recombinant EPO enzymatic activity and circulatory half-life [279] [280]. 
For LacNAc extension, the polymerization of the alternating GlcNAc and Gal residues is 
catalyzed by the successive action of two glycotransferases in Golgi--UDP-GlcNAc: βGal β-1,3-
N-acetylglucosaminyltransferase  and UDP-Gal:βGlcNAc β-1,4-galactosyltransferase, 
individually [277], as shown in Figure 4-1B. For the β-1,3-N-acetylglucosaminyltransferase 
family (iGNTs),  among 8 homologs, β3Gn-T2 has been reported to be the most effective on an 
oligosaccharide substrate of polylactosamine structures from in vitro enzyme reaction studies 
[281]. Furthermore, the individual knockout study of B3GNT1/2/8 individually by zinc finger 
nucleases (ZFNs) revealed that B3GNT2 as the key gene controlling the LacNAc initiation in 
CHO cells by Lycopersicon esculentum lectin (LEL) immunocytology [279]. Thus,  β-1,3-N-
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acetylglucosaminyltransferase 2 (B3GNT2) has been identified a major poly-lactosamine 
synthase for the poly-LacNAc initiation and extension in CHO cells. On another hand, for β-1,4-
galactotransferase (B4GalT) family, there are two major B4GalTs forms related to LacNAc 
extension based on sequence similarity-- β-1,4-galactotransferase 1 (B4GALT1) and β-1,4-
galactotransferase 2 (B4GALT2). Between these two β-1,4-galactotransferases, B4GALT1 has 
been widely studied and indicated as the primary β-1,4-galactotransferase for transferring Gal to 
GlcNAc residue through β-1,4 linkage [276, 279, 282]. The individual B4GalT knockout study 
by ZFNs demonstrated that knockout of B4GALT1 eliminated immunoreactivity for LacNAc, 
whereas knockout of B4GALT2 or B4GALT3 or B4GALT4 had no substantial effects [279]. In 
vitro enzyme reaction study also revealed that LacNAc is an acceptor substrate of B4GALT1 
[282]. 
Although ploy-LacNAc is of significance for various cellular functions and the therapeutic 
recombinant protein properties, limited understanding in the literature for the biosynthesis and 
influence of poly-LacNAc on N-glycans is available. Interestingly, one recent study reported that 
the knockdown of B3GNT2 by siRNA slightly increased the sialylation content of recombinant 
EPO in CHO cells [275]. Typically, the terminal sialylation capping for human glycans is 
Neu5Ac and the N-glycans on proteins generated from CHO cells are covered with one to four 
sialic acids per N-glycan often with zero or one at maximum LacNAc elongation group. 
Therefore, in this study, we examined if capping the glycans with terminal sialylation impacts 
the LacNAc elongation or not by eliminating sialylation in CHO cells. We also explored the 
single and dual-incorporation of two LacNAc primary genes-B3GNT2 and B4GALT1 for their 
roles in the initiation and elongation of LacNAc units in recombinant EPO-expressing CHO 
cells. Our results showed that the overexpression of B3GNT2 in EPO-expressing CHO cells 
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surprisingly did not increase the LacNAc content on EPO protein, and further resulted in nearly 
complete elimination of sialylation on recombinant EPO.  
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4.3 Materials and Methods 
 
4.3.1 Plasmid construction 
The sequence of codon-optimized human EPO was described in Yin et al [246]. pcDNA-EPO 
plasmid was constructed by inserting the EPO sequence with a 6xhis tag at its C-terminal 
through the Hind III and Bam HI restriction sites. Human B3GNT2 gene (NCBI Gene ID: 
10678) cDNA was codon-optimized and purchased from Biomatik (Wilmington, Delaware) and 
subcloned into pCHO1.0 vector through Avr II and BstZ17I. Human B4GALT1 gene (NCBI 
Gene ID: 2683) codon-optimized and purchased from Biomatik (Wilmington, Delaware) and 
subcloned into pEF6/V5 vector through BamH I and Not I restriction sites. There are two 
transcripts, which differ only at the 5' end, with approximate lengths of 4.1 kb and 3.9 kb encode 
the same protein. We used the longer transcript which encodes the type II membrane-bound, 
trans-Golgi resident protein involved in glyco-conjugate biosynthesis. While the shorter 
transcript encodes a protein which is cleaved to form the soluble lactose synthase.  
For protein expression study, cloned human B3GNT2 and B4GALT1 cDNAs were further 
introduced into pBudCE4.1 through the Hind III /Bam HI sites under CMV promoter and Not I / 
Xho I sites under EF1apromoter, respectively. GNT4A cDNA was described previously in Yin et 
al [246]. Meanwhile, cloned human GNT4A and B4GALT1 cDNAs were further introduced into 
pBudCE4.1 through the Hind III /Bam HI sites under CMV promoter and Not I / Xho I sites 
under EF1apromoter simultaneously. 
4.3.2 Cell culture and transfection 
The generation of wild-type EPO-expressing CHO cells was described in Yin et al [246] and is 
abbreviated as WTEPO. The generation of sialylation-deficient CHO-K1 cells was described in 
Chung et al. [283] and is abbreviated as asialylated-CHO cells (dual knockouts of β-galactoside 
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α-2,3-sialyltransferase 4 (ST3GALT4) and β-galactoside α-2,3-sialyltransferase 6 (ST3GALT6)). 
We introduced the EPO gene in asial-CHO cells. With limited dilution (LDC), we generated the 
sialylation-deficient EPO cells and is abbreviated as asialylated-EPO cells. Subsequently, the 
introduction of B3GNT2, B4GALT1 individually and together in WT-EPO and asialylated-EPO 
cell lines was performed and abbreviated as WT-EPO-B3GNT2, asialylated-EPO-B3GNT2, 
WT-EPO-B4GALT1, asialylated-EPO-B4GALT1, WT-EPO-B3GNT2-B4GALT1 and 
asialylated-EPO-B3GNT2-B4GALT1 cell lines. For transfection, cells were seeded onto a 6-well 
plate at appropriate densities and transfected 24 h later using lipofectamine 3000(Thermo  Fisher  
Scientific),  according  to  the  manufacturer’s instructions. After two-day incubation, transfected 
stable pools were obtained based on drug selection using zeocin (EPO), puromycin  (B3GNT2) 
and blasticidin (B4GALT1).  Stable single  clones  were established by seeding 0.7 cell/well in 
96-well plates (Corning,Tewksbury, MA) for limited dilution. All CHO cells were maintained in 
Ham’s F12K media supplied with 10% FBS and 2 mM L-glutamine. 
4.3.3 Reverse transcription PCR (RT-PCR) and Quantitative real-time PCR (qRT-PCR) 
Wild-type CHO, WT-EPO, asialylated-EPO, WT-EPO-B3GNT2, asialylated-EPO-B3GNT2, 
WT-EPO-B4GALT1, asialylated-EPO-B4GALT1, WT-EPO-B3GNT-B4GALT1 and 
asialylated-EPO-B3GNT2-B4GALT1 cell lines were then harvested respectively. 10 million 
cells from each cell line were subjected to RNA extraction using RNeasy Mini Kit followed by 
manufacturer’s protocol (Qiagen, Gaithersburg, MD). The isolated RNA concentration was 
determined by Nanodrop 2000. 1 µg of total RNA from each sample was used as the template for 
RT-PCR to determine the mRNA expression of the corresponding genes. Then the reverse-
transcription reaction was performed by phase separation and precipitated by addition of 
isopropanol, followed by reverse-transcription by the SuperScript III First-Stand Sysnthesis 
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System (Thermo Fisher Scientific). For RT-PCR, the primer sequences for B3GNT2 were 5’-
AGGAGGATCAAGCTGCTG-3’ and 5’- TCATCATCAGCACTTCAGG-3’. The primer 
sequences for B4GALT1 were 5’- ATGAGGCTTCGGGAGC-3’ and 5’- 
CTAGCTCGGTGTCCCG-3’. The primer sequence for internal control gene GAPDH were 5’-
ATGGTGAAGGTCGGCG-3’ and 5’-TTACTCCTTGGAGGCCATGTA-3’. The PCR products 
were further analyzed by electrophoresis on a1% agarose gel and visualized by ethidium bromide 
staining. Quantitative RT-PCR was performed with Absolute Blue SYBR low ROX Master Mix 
(Thermo Fisher Scientific) in an Applied Biosystems 7500 Real-time PCR system. GAPDH was 
used as an internal control using Cq value. The primers designed for qRT-PCR were the same as 
the ones for RT-PCR.  
4.4.4 Protein purification  
For purification purpose, one the cells became confluent, the media was replaced with Opti-
MEM I reduced serum media (Thermo Fisher Scientific) with 2 extra culture days. Then the 
culture supernatants were filtered through a 0.22-mm-pore-size membrane, then concentrated 
and dialyzed with PBS by ultra-filtration (AmiconUltra; Millipore). With a 6xHis tag at the C-
terminal of recombinant EPO, EPO from the supernatant was purified by Ni-NTA resin 
(Qiagen). The bound EPO were eluted with PBS supplemented with250mM immidazole, and the 
fractions were immediately dialyzed with PBS.  The concentration of purified EPO was 
quantified by the bicinchoninic acid (BCA) assay and the purity of purified EPO was evaluated 
using 10% SDS–PAGE followed by Coomassie blue staining. 
4.3.5 HPLC sialic acid quantification 
The sialic acid content of purified EPO was quantified by the MDB-labeling method as described 
previously [249]. Briefly, 2 µg of purified EPO was hydrolyzed in 200 µL of 25 mM sulfuric 
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acid at 80 °C for an hour and was derivatized with 7 mM of 4,5-methylenedioxy-1,2-
phenylenediamine dihydrochloride (DMB) (Dojindo, Kumamoto, Japan) at 60 °C for 2.5 hours. 
10 µl of treated samples were injected onto the Agilent 1260 HPLC system with the excitation 
and emission at 373 and 448 nm wavelengths respectively.  
4.3.6 MALDI-TOF N-glycan analysis 
We applied the method of glycoprotein immobilization for glycan extraction (GIG) alone with 
sialic acid protection by p-toluidine [284]. 300 µg of purified EPO were denatured using 
Glycoprotein denaturing buffer (New England BioLabs, B1704S) and conjugated to AminoLink 
resin (Thermo Fisher Scientific). To protect the sialic acid groups, N-glycans were incubated 
with a p-toluidine (Sigma) solution and then washed sequentially with 10% formic acid, 10% 
acetonitrile, 1 M NaCl and H2O. For N-glycan detachment, 2mL of PNGase F (New England 
BioLabs, Ipswich, MA) was added to the bead mixture and incubated at 37°C for 2 h. The 
extracted glycans were subjected to MALDI-TOF glycan analysis. The purified glycan was 
analyzed by a Bruker AutoFlex MALDI-TOF spectrometer in the positive mode.  The MALDI-
TOF-MS parameters were set as following: mass range 500~6000 Da, laser 70%, reflective-
positive-mode, and 8000 shots per sample, and CID (collision-induced dissociation) MS/MS. We 





4.4.1 The incorporation of B3GNT2 and B4GALT1 into EPO-expressing CHO cell lines 
In order to examine the single- and dual-incorporations of β-1,3-N-acetylglucosaminyltransferase 
2 (B3GNT2) and β-1,4-galactosyltransferase 1 (B4GALT1) genes in wild-type EPO (WT-EPO) 
and sialyation-deficient EPO (asialylated-EPO) cell lines, stable clones (WT-EPO, asialylated-
EPO, WT-EPO-B3GNT2, asialylated-EPO-B3GNT2,WT-EPO-B4GALT1, asialylated-EPO-
B4GALT1, WT-EPO-B3GNT2-B4GALT1, asialylated-EPO-B3GNT2-B4GALT1) were 
generated and these eight stable cell lines along with CHOK1 control cells were subjected to  
RT-PCR  and real-time quantitate PCR  analysis for targeted gene expression at transcriptional 
level (Figure 4-2) and immunoblots using anti-B4GALT1 and anti-B3GNT2 antibodies for 
protein expression at the translational level (Figure 4-3).  
In Figure 4-2A, the RT-PCR analysis revealed that the single-gene incorporation of individual 
B3GNT2 and B4GALT1 in WT-EPO and sialylation-deficient EPO cell lines (WT-EPO-
B3GNT2, asialylated-EPO-FB3GNT2,WT-EPO-B4GALT1, asialylated-EPO-B4GALT1) 
showed obvious mRNA expression of  targeted genes compared to their individual untreated 
EPO-expressing cell lines (WT-EPO and asialylated-EPO) and CHO-K1 control cells. However, 
the subsequent stable incorporation of B4GALT1 in B3GNT2-overexpressing cell lines resulted 
in very weak B4GALT1 mRNA signal, in contrast to the strong B3GNT2 signal in the RT-PCR 
analysis. This result indicates that the B4GALT1 gene is not expressed at the high transcriptional 
levels in B3GNT2-overexpressing cells. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
mRNA expression were also tested in RT-PCR analysis as an internal mRNA loading control. In 
order to confirm this finding, we also performed real-time quantitative PCR analysis of the 
single-gene and dual-gene incorporation of B3gnt2 and B4galt1 in WT-EPO and sialylation-
deficient EPO cell lines, as displayed in Figure 4-2B. In accordance with the RT-PCR result 
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(Figure 4-2A), the real-time quantitative PCR analysis showed that the B3GNT2 mRNA level in 
B3GNT2 overexpressing cells (WT-EPO-B3GNT2, asialylated-EPO-FB3GNT2, WT-EPO-
B3GNT2-B4GALT1 and asialylated-EPO-B3GNT2-B4GALT1) was one order of magnitude 
higher than the control cells (WT-EPO, asialylated-EPO and CHO-K1). The B3GNT2 mRNA 
content in B4GALT1-overexpressing cells (WT-EPO-B4GALT1 and asialylated-EPO-
B4GALT1) showed similar level as the control CHOK1 cells. B4GALT1 mRNA expression in 
B4GALT1 singe-gene overexpressing cells (WT-EPO-B4GALT1 and asialylated-EPO-
B4GALT1) is also higher than the control cells (WT-EPO, asialylated-EPO, WT-EPO-B3GNT2, 
asialylated-EPO-FB3GNT2 and CHOK1) and B3GNT2-B4GALT1 dual-gene overexpressing 
cell lines (WT-EPO-B3GNT2-B4GALT1, asialylated-EPO-B3GNT2-B4GALT1). Consistent 
with the finding in Figure 4-2A, the B4GALT1 content in B3GNT2-B4GALT1 dual-
overexpressing cells (WT-EPO-B3GNT2-B4GALT1, asialylated-EPO-B3GNT2-B4GALT1) 
demonstrated similar B4AGLT1 mRNA content as the untreated and control cells (WT-EPO, 
asialylated-EPO, WT-EPO-B3GNT2, asialylated-EPO-FB3GNT2 and CHOK1). Both results in 
Figure 4-2 suggests that there is some inhibition for expressing B4GALT1 gene in B3GNT2-
expressing cell lines at the transcriptional level. 
Furthermore, immunoblot detection of B3GNT2 and B4GALT1 protein expression was 
performed and is presented in Figure 4-3. There was obvious B3GNT2 protein expression in 
B3GALT2-overexpresiing cells (WT-EPO-B3GNT2, asialylated-EPO-FB3GNT2, WT-EPO-
B3GNT2-B4GALT1 and asialylated-EPO-B3GNT2-B4GALT1) but B4GNT1 protein only 
strongly expressed in B4GALT single-gene expressing cell lines (WT-EPO-B4GALT1, 
asialylated-EPO-B4GALT1). Very weak B4AGLT1 protein signal was detected in B3GNT2-
B4GALT1 dual-overexpressing cell line (WT-EPO-B3GNT2-B4GALT1 and asialylated-EPO-
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B3GNT2-B4GALT1), indicating that B4GALT1 expression was hampered in B3GNT2 
overexpressing cell lines at protein level.  The house-keeping gene GAPDH protein was also 
detected as an internal loading control. Combined the results from Figure 4-2 and Figure 4-3 
together, it is reasonable to hypothesize that B3GNT2 inhibits B4GATL1 for gene expression at 
both transcriptional and translational levels. 
4.4.2 The exploration of B4GALT1 and B3GNT2 expression in CHO cells 
In order to further explore the relationship between B4GATL1 and B3GNT2, a bi-expression 
plasmid designed to simultaneously express B3GNT2 (under the EF1a promoter) and B4GALT1 
(CMV promoter) was constructed (Pbud-B3GNT2-B4GALT1) along with the B3GNT2 (Pbud-
B3GNT2) and B4GALT1 (Pbud-B4GALT1) single-expression using the same vector backbond 
and same corresponding promotors. Besides, B4GALT1 (CMV promoter) and GNT4A (EF1a 
promoter) bi-expressing plasmid was also constructed as a control. The illustration of plasmids 
constructions was presented in Figure 4-4A. Equal amount of each plasmid was transfected in 
equal amount of CHOK1 cells and the transient transfection result was analyzed via immunoblot 
two-day post-transfection. As shown in Figure 4-4B, equivalent amount of transfected cell lysate 
along with untransfected control CHOK1 lysate was loaded. Transfection of Pbud-B3GNT2 and 
Pbud-B3GNT2-B4GALT1 resulted in B3GNT2 protein expression. Transfection of Pbud-
B4GALT1 and Pbud-GNT4A-B4GALT1 resulted in B4GALT1 protein while only trace 
B4AGLT1 protein expression was detected from Pbud-B3GNT2-B4GALT1 sample. Anti-
GNT4A immunoblot only detected GNT4A protein overexpression in Pbud-GNT4A-B4GALT1 
transfected cells. The transient transfection result suggests that B3GNT2 inhibits B4GALT1 
expression in CHO-K1 cells, while GNT4A and B4GALT1 did not impact each other’s 
expression. Further, amino acid homology analysis revealed that B3GNT2 and B4GALT1 
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exhibit 24.56% similarity, B3GNT2 and GNT4A contain 46.15% similarity and B4GALT1 and 
GNT4A have 35.00% similarity through the NCBI Blast protein sequence alignment tool 
(https://blast.ncbi.nlm.nih.gov).  
4.4.3 Characterizing the purified EPO protein from glyco-engineered CHO cell lines 
Furthermore, the recombinant EPO from the 8 tested CHO cell lines was purified and equal 
amounts of purified EPO protein was loaded for SDS-PAGE followed with Coomassie Blue 
staining (Figure 4-5A). We observed that wild-type EPO from CHO cells had a molecular weight 
around 37 kilodalton (kDa), which is in accordance with previous publications [7, 172]. The 
elimination of sialic acid on recombinant EPO (asialylated-EPO) reduced the molecular weight 
of EPO, which showed a faster migration rate on Figure 4A. Surprisingly, the EPO band from 
WT-EPO-B3GNT2 as well as asialylated-EPO-B3GNT2 cell lines both presented significantly 
lower and similar band size (approximately 25 kDa), indicating a faster migration rate compared 
to wild-type EPO and asialylated-EPO proteins. Moreover, the single introduction of 
B4GTALT1 in WT-EPO and asialylated-EPO (WT-EPO-B4GALT1 and asialylated-EPO-
B4GALT1) cell lines obviously increased the EPO protein size, showing a slower migration rate 
than other tested samples (Figure 4-5A).   
To our surprise, the overexpression of B3GNT2 significantly decreased the molecular weight of 
recombinant EPO both from wild-type and sialylation-deficient CHO cell lines. To investigate 
this phenomena, HPLC sialic acid quantification was applied to detect the sialic acid content on 
each EPO sample. Briefly, sialic acids were released from equal amounts of purified 
recombinant EPO samples, derivatized with a fluorescence-labeling compound, 1,2-diamino-4,5-
methylenedioxybezene dihydrochloride (MDB), and then separated on a reversed-phase C18 
column. Interestingly, as shown in Figure 4-5B, recombinant EPO proteins from the B3GNT2-
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expressing cell line (WT-EPO-B3GNT2) showed similar levels of sialylation content as EPO 
from sialylation-deficient cell line (asialylated-EPO). Plus, the sialic acid content of EPO from 
B3GNT2-expressing sialylation-deficient cell line (asialylated-EPO-B3GNT2) was even lower 
among all the tested samples. Overexpression of B4GALT1 in WT-EPO cell line increased the 
sialylation content about 32% compared with wild-type EPO. While overexpression of 
B4GALT1 in a sialylation-deficient cell line (asialylated-EPO-B4GALT1) did not have an 
obvious change on the sialylation level compared to the EPO-expressing sialylation-deficient cell 
line (asialylated-EPO). This HPLC result indicates the change in sialic acid content of total 
glycans on recombinant EPO, including both N- and O-glycans. 
4.4.4 Elucidation of recombinant EPO protein N-glycan profile from glyco-engineered CHO cell 
lines 
Given the changes in protein size and sialylation levels following expression of 
glycosyltransferases, the next step was to elucidate the specific N-glycan structures attached to 
recombinant EPO from different cell variants. N-glycan structures were released from purified 
recombinant EPO derived from PNGase F digestion, and then analyzed on a matrix assisted laser 
desorption ionization-time of flight mass spectrometry (MALDI-TOF) mass spectrometer. The 
N-glycan profiles derived from recombinant EPOs produced in wild-type and glycoengineered 
cell lines are displayed in Figure 4-6. Each peak was labeled with its corresponding predicted 
structure. The decrease in the larger N‐glycans observed in the mass spectra following an 
increase in transferase modification is qualitatively consistent with the faster migration rates 
observed on the Commassie blue staining result (Figure 4-5A) for the recombinant EPO from the 
B3GNT2-containning cell lines. 
In order to evaluate the LacNAc changes for individual sugars, the LacNAc analysis was 
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classified based on the number of GlcNAc-Gal units per N-glycan in each sample, overall 
LacNAc coverage, and average LacNAc unit per N-glycan (Table 4-1). The removal of sialic 
acid capping increased the average LacNAc units slightly and coverage on the EPO sample 
(asialylated-EPO). Furthermore , the overexpression of B4GALT1 in both WT-EPO and 
asialylated-EPO samples enhanced the average LacNAc units slightly compared to their 
corresponding control samples, with which asialylated-EPO-B4GALT1 showed more LacNAc 
units and coverage than WT-EPO-B4AGLT1. This finding is in accordance with our hypothesis 
that the terminal Neu5Ac suppressed the LacNAc elongation on glycoproteins in CHO cells. In 
contrast, and also consistent with the coomassie blue and HPLC results, the overexpression of 
B3GNT2 surprisingly reduced the number of LacNAc units and LacNAc coverage for both wild-
type EPO and sialylation-deficient EPO. As the overexpression of B4GALT1 in B3GNT2-
expressing cells is very weak, EPO protein from WT-EPO-B3GNT2-B4AGLT1 and asialylated-
EPO-B3GNT2-B4GALT1 cell lines displayed a LacNAc profile consistent to the one for their 
counterparts in WT-EPO-B3GNT2 and asialylated-EPO-B3GNT2 cell lines.  
Finally, the sialylated N-glycans on recombinant EPO were classified according to the numbers 
of terminal sialic acid residues on the observed N-glycan structures for the eight cell lines (Table 
4-2). The overexpression of B4GALT1 led to a decrease in the recombinant EPO levels with 2 
and 3 sialic acid and an increase in the N-glycans with 0 and 1 sialic acids on wild-type EPO. 
The dual-knockout of st3gal4 and st3gal6 results in 100% asialylatedylated EPO (asialylated-
EPO).  Nevertheless, the overexpression of B3GNT2 in both wild-type and sialylation-deficient 
CHO cell lines led to 99% and 99% asialylatedylated EPO individually. The introduction of 
B4GALT1 in sialylation-deficient CHO cell line also slowed almost completely asialylatedylated 




In this study, the impacts of B3GNT2 and B4AGLT1 along with the terminal sialylation in EPO-
expressing CHO cells was investigated. The sialic acid is capped at the terminal of N-glycan 
structure in mammalian cells with LacNAc elongation. We first explored whether the capping 
terminal sialylation inhibit the LacNAc extension on recombinant glycoprotein or not by 
knocking out two critical sialyltransferases in CHO cells. The dual-knockout of ST3GALT4 and 
ST3GALT6 significantly decreased Neu5Ac sialylation content with almost undetectable 
sialylation level on recombinant EPO proteins from MS N-glycan analysis (Figure 5 and Table 
2). Compared to WT-EPO, the removal of sialic acid capping increased the average LacNAc 
units per N-glycan from 3.54 to 4.02 and coverage from 93.46% to 97.44% on recombinant EPO 
protein (asialylated-EPO). Also, the overexpression of B4GALT1 in both WT-EPO and 
asialylated-EPO samples enhanced the LacNAc units slightly compared to their corresponding 
control samples, with which asialylated-EPO-B4GALT1 showed more LacNAc units and 
coverage than WT-EPO-B4AGLT1 sample. This results revealed that elimination of terminal 
sialic acid promoted the LacNAc elongation on N-glycans in CHO cells.  
From previous publications, B3GNT2 and B4AGLT1 are identified as two critical genes for the 
initiation and elongation of LacNAc units in mammalian cells. We explored the individual and 
dual-incorporation of these two LacNAc primary genes-B3GNT2 and B4GALT1-for their roles 
on the initiation and elongation of LacNAc units on recombinant EPO protein expressed from 
CHO cells. To our surprise, unexpected results were revealed with the single gene 
B3GNT2introduction. The overexpression of B3GNT2 in both WT-EPO and asialylated-EPO 
cell lines both didn’t increase the LacNAc units on recombinant EPO proteins. Otherwise, it 
displayed adverse effect on N-glycan profile: 1.The overexpression of B3GNT2 reduced the 
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average LacNAc number per N-glycan on EPO (Table 1); 2.  The sialyation nearly completely 
disappeared after B3GNT2 incorporation in wild-type EPO cell line (Figure 4B and Figure 5 and 
Table 2), which is consistent with the smaller EPO size and faster migration rate on Figure 4A. 
Regarding to asialylated-EPO sample, overexpression of B3GNT2 in wild-type EPO cells 
showed a similar sialic acid content as the sialylation-deficient EPO protein from both HPLC 
sialic acid quantification (Figure 4B) and MS N-glycan characterization (Figure 5 and Table2), 
indicating B3GNT2 overexpression served a sialylation inhibition function, as similar as α2,3 
sialyltransferases-knockout did in CHO cells, which is consistent with a previous study that the 
knockdown of B3GNT2 increased the sialylation on recombinant EPO protein. Meanwhile, the 
overexpression of B3GNT2 in asialylated-EPO cell line completely achieved sialylation-free 
EPO proteins. Moreover, we evaluate the effect of B3GNT2 and B4GALT1 overexpression on 
the sialylation of total glyco-conjugates (glycoproteins and glycolipids) in wild-type and 
asialylated-CHO cells. Total cell lysates from wild-type and glyco-engineered CHO cells were 
subjected to HPLC quantification for evaluation of sialic acid content on glycoproteins and 
glycolipids (Supplemental Figure S4-1). The result revealed that B3GNT2 overexpression 
reduced the sialylation content at total cell lysate level both in CHOK1 and asialylated-CHO 
cells, which matches the recombinant EPO protein result in Figure 4-5B.In order to further 
explain this phenomena, we investigated the expression of sialyltransferases ( β-galactoside α-
2,3-sialyltransferase 3,4 and 6 ST3GALT3, ST3GALT4 and ST3GALT6)) in wild-type and 
glyco-engineered CHO cells at transcriptional level, as shown in supplemental Figure S4-1 and 
S4-2. The RT-PCR and qPCR quantification results demonstrated that no significant difference 
detected on the mRNA expression of ST3GALT3 enzyme in all tested 8 samples. No great 
discrimination were observed on ST3GALT4 and ST3GALT6 mRNA expression among cell 
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lines developed from wild-type CHO (WT-EPO, WT-EPO-B3GNT2 and WT-EPO-B4AGLT1 
and CHO cell lines). Similar results also observed among cell lines developed from sialylation-
deficient CHO (asialylated-EPO, asialylated-EPO-B3GNT2, asialylated-EPO-B4GALT1 and 
asialylated-CHO).  In accordance with a recent paper from our group {Chung, 2017 #348}, the 
knockout of SY4GALT1 resulted in the absence of ST4GALT4 mRNA signal on Figure S 4-1 
and S4-2. The knockout of ST3GALT6 changed ST4GALT6 mRNA size on Figure S 4-2 and 
S4-3. Thus, we concluded the overexpression of B3GNT2 did not interfere with the 
sialyltransferase expression at translational level, although it inhibited the sialylation both on 
glycoprotein and glycolipids in CHO cells. 
Another interesting finding in this project is B4GALT1 cannot be incorporated in B3GNT2-
overexpressing CHO cell lines (Figure 4-2 and 4-3). We attempted to introduce human 
B4GALT1 in both WT-EPO-B3GNT2 and asialylated-EPO-B3GNT2 cell lines twice, but were 
still unable to generate a dual-overexpression cell line with appropriate B4GALT1 expression 
compared to their corresponding WT-EPO-B4GALT1 and asialylated-EPO-B4GALT1 control 
cell lines. For example, the immunoblotting result of WT-B3GNT2-B4GALT1 clone selection 
was presented in Supplemental Figure S4-4. Therefore, we choose clones with the strongest 
B4GALT1 expression in B3GNT2-B4GALT2 candidates, although its B4GALT1 expression 
was dramatically low compared to B4GALT1-expressing CHO cells. As shown in Supplemental 
Figure S4-4, the B4GALT1 expression in the top WT-EPO-B3GNT2-B4GALT1 clones is 
relatively very weak compared to the B4GNT1 expression in WT-EPO-B4GALT1 clone. 
Besides, MALDI-TOF N-glycan elucidation also revealed that the GlcNac/Gal ratio increased 
nearly one fold for EPOs expressed in B3GNT2-expression CHO and asialylated-CHO cells, 
while GlcNac/Gal ratio declined a little for EPOs expressed in B4GAT1-expression CHO and 
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asialylated-CHO cells (Table 4-3). A recent paper {Sumit, 2019 #753} pointed out that the 
nucleotide sugar donor (NSD) transport protein  in Golgi encoded by SLC35A2 serves as a 
transporter for UDP-Gal, UDP-GalNAc, UDP-GlcNAc {Song, 2013 #754} {Hartley, 2018 
#755}. In other words, these three nucleotide sugar substrates competes for each other for 
transporting into Golgi and further integration on the glycan structure.  For LacNAc extension, 
UDP and UDP are indispensable substrate, even though the levels of average GlcNc per N-
glycan on WT-EPO-B3GNT2 and asialylated-EPO-B3GNT2 were similar to the levels on WT-
EPO and asial-EPO, the reduction of average Gal per N-glycan definitely hampered the 
elongation of LacNAc synthesis for WT-EPO-B3GNT2 and asialylated-EPO-B3GNT2. The 
reduction of LacNAc content on WT-EPO-B3GNT2 and asial-EPO-B3GNT2 was attributed to 
the lack of galactose on N-glycan.  
 
 
Contributions from Collaborators: 
 
 
Dr. Xiaozhi Ren contributed to qPCR experimental design. Dr. Eric Sakowski and Dr. Sarah 
Preheim at Environmental Engineering department at JHU for providing the qPCR machine. 
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Figures and Tables 
Figure 4-1. (4-1A) The typical complex N-glycan structures with bi-, tri- and tetra-branches found on 
glycoproteins from mammalian cells. (4-1B.) The synthesis of poly-LacNAc chain in Golgi through the 




Figure 4-2. RT-PCR (4-2A)  and qPCR (4-2B) analysis for B3GNT2 and B4GALT1 expressions in both 





Figure 4-3. Immunoblotting of transfected human glycotransferases in different recombinant EPO-
expressing CHO cell lines. GAPDH serves as internal control. 
 
Figure 4-4. The single- and dual-expression of B3GNT2 and B4GALT1 in CHOK1 cells. (4-4A). The single-
and bi-expression plasmid constructions. (4-4B).The immunoblotting analysis of B3GNT2 and B4GALT1 
expressions in CHO-K1 cells at transient transfection level.  
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Figure 4-5. (4-5A) Coomassie blue staining of purified recombinant EPO protein from glyco-engineered 
CHO cell lines. Equal amount of purification protein were loaded. (4-5B) The HPLC sialic acid analysis. 
Sialic acids were released from equal amount of purified recombinant EPO samples, derivatized with a 
fluorescence-labeling compound, 1,2-diamino-4,5-methylenedioxybezene dihydrochloride (MDB), and 









Figure 4-6. N-glycosylation MALDI-MS profiles of different recombinant EPO proteins in this work. 






















Table 4-1 LacNAc analysis 
 














Supplemental Figure 4-1. HPLC sialic acid quantification of overall glyco-conjugates. Total cell 
lysate were loaded from glyco-engineered and wild-type CHO cells at equal amount level.  
Supplemental Figure 4-2. The expression of sialyltransferases at transcriptional level. (S4-2A). 

































Supplemental figure S4-3. The immunoblotting of B3GNT2 and B4GALT1 expression in WT-EPO-





Chapter 5 Application of the CRISPR/Cas9 gene editing 





Genetic engineering plays an essential role in the development of cell lines for 
biopharmaceutical manufacturing. Advanced gene editing tools can improve both the 
productivity of recombinant cell lines as well as the quality of therapeutic antibodies. Antibody 
glycosylation is a critical quality attribute for therapeutic biologics because the glycan patterns 
on the antibody fragment crystallizable (Fc) region can alter its clinical efficacy and safety as a 
therapeutic drug. As an example, recombinant antibodies derived from Chinese hamster ovary 
(CHO) cells are generally highly fucosylated; the absence of fucose significantly enhances 
antibody dependent cell-mediated cytotoxicity (ADCC) against cancer cells. This chapter 
describes a protocol applying clustered regularly interspaced short palindromic repeats 
(CRISPR) and CRISPR-associated protein 9 (Cas9) to disrupt the α-1,6-fucosyltranferase 




Targeted gene knockout has been extensively studied and widely used in mammalian cell line 
development. Traditionally, targeted gene editing is achieved by homologous recombination 
[285], but due to inherently low recombination rates, homologous recombination can be less 
efficient and more time-consuming [108]. The emergence of advanced genetic engineering 
technologies, such as zinc finger nucleases (ZFNs), transcription activator-like effector nucleases 
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(TALENs), and clustered regularly interspaced short palindromic repeats (CRISPR) with 
CRISPR-associated protein 9 (Cas9), has dramatically accelerated the gene editing process and 
significantly improved gene knockout efficiency [286]. These advanced gene editing tools are 
based on the use of engineered nucleases comprised of programmable and sequence-specific 
DNA-binding domains fused to a non-specific DNA cleavage module [285]. Specifically, ZFNs 
and TALENs employ a protein-DNA binding domain fused to a FokI endonuclease and require a 
pair of ZFNs or TALENs to generate a DNA double-strand break (DSB). More recently, the 
development of the CRISPR/Cas9 system, utilizing a guided RNA complementary to the target 
DNA sequence fused to a Cas9 nuclease, exhibits higher target binding specificity than ZFNs or 
TALENs and only requires RNA-binding to a single strand of DNA in order to generate a nick in 
the sequence [285]. The evolutionary origin of CRISPR stems from an adaptive immunological 
response in some bacteria and archaea to protect the host against foreign DNA [285]. Among the 
three identified CRISPR systems, the Type II CRISPR/Cas9 system of Streptococcus pyogenes 
(SpCas9) has been studied most extensively (Figure 5-1A). In this system, short segments of 
foreign DNA (approx. 20 nucleotides) known as “protospacers” are integrated within the 
bacterial CRISPR genomic loci; individual protospacers are separated by short palindromic 
repeats [285]. To generate short CRISPR-targeting RNA (crRNA), protospacers are transcribed 
as pre-crRNA, which anneals to trans-acting crRNA (tracrRNA) via a conserved dinucleotide 
protospacer adjacent motif (PAM) upstream of the target region [285]. The CRISPR/Cas9 
system can thereby direct sequence-specific cleavage to excise foreign DNA by Cas9 proteins. 
By re-designing the crRNA sequence, CRISPR can be engineered to target any DNA sequence 
of interest in the host genome. For the CRISPR/Cas9 gene editing system, there are two 
prerequisites: the targeted sequence must be unique in the host genome and the target sequence 
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must be present immediately upstream of a protospacer adjacent motif (PAM). 
Monoclonal antibody (mAb) therapeutics comprise a multi-billion dollar market [287]. The 
wide-ranging applications of mAb biologics not only treat major diseases such as cancer, 
autoimmune diseases, inflammation and Alzheimer’s disease [287], but also provide diverse 
types of therapies, including radioimmunotherapy [288], antibody-directed enzyme prodrug 
therapy [289], antibody-drug conjugates [290], immunoliposome therapy [291] and checkpoint 
inhibitor therapy [292]. Except for neutralization with pathogens, antibodies (especially IgGs) 
oftentimes execute their functions by phagocytosis of antibody-bound pathogens. In particular, 
antibody dependent cell-mediated cytotoxicity (ADCC) is triggered when pathogen-bound 
antibodies interact with Fc receptors of lymphocytes (mainly natural killer cells) [186]. The 
conserved N-glycan on the IgG Fc domain greatly affects this binding affinity. The core-fucose 
residue of the heavy chain constant region (CH)-associated N-glycans plays a critical role in 
regulating antibody effector function in ADCC [105-109, 112, 211, 293]. Compared to the 
fucosylated antibodies from wild-type CHO cells, defucosylated antibodies exhibited 100-fold 
higher ADCC in vitro [110, 114] as a result of a subtle conformational change [109, 111, 112]. 
Inactivation of the α-1,6 fucosyltransferase, encoded by the FUT8 gene in mammals, represents 
the most efficient single modification to inhibit the addition of fucose to the core of the complex 
N-glycan [116, 184].  
In this chapter, we describe a robust method for generating a single-gene knockout CHO cell line 
with an engineered glycosylation pathway using the CRISPR/Cas9 system. The biological 
significance of the FUT8 gene makes it an ideal target for our proof-of-concept study. 
Importantly, we employed the lectin selection methodology to isolate specific glycan types in 
antibody-expressing clones, which is a unique step in the knockout cell line development 
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process. The choice of stable antibody-expressing CHO cells as our parental cells makes our 
protocol practical and useful for industrial purposes.  
 
5.3. Materials  
5.3.1 Reagents and Kits 
1. Plasmid Miniprep kit  
2. 1.5 mL Eppendorf microcentrifuge tubes 
3. 12 × 75 mm tubes with cell strainer cap (FACS tubes) 
4. Nuclease-Free Water  
5. BbsI restriction enzyme (New England Biolabs) 
6. NEBuffer 2.1. (New England Biolabs) 
7. QIAquick Gel Extraction Kit (Qiagen) 
8. QIAquick PCR Purification Kit (Qiagen) 
9. S.O.C. Medium  
10. LB Broth (Miller)  
11. LB Agar powder (Lennox)  
12. NEBuffer 4 (New England Biolabs) 
13. T4 DNA ligase buffer  
14. Ampicillin  
15. T4 DNA ligase  
16. Taq DNA polymerase with standard Taq buffer  
17. PCR tubes  
18. NEB 5-alpha component E. coli (New England Biolabs) 
19. Opti-MEM™ I Reduced Serum Medium (ThermoFisher Scientific) 
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20. Lipofectamine™ 3000 Transfection Reagent. (ThermoFisher Scientific) 
21. Lens Culinaris Agglutinin (LCA) (Vector Laboratories) 
22. Biotinylated Lens Culinaris Agglutinin (LCA) (Vector Laboratories) 
23. Fetal Bovine Serum (FBS)  
24. L-Glutamine (200 mM)  
25. T25 flask  
26. T75 flask  
27. Dimethyl sulfoxide (DMSO) 
28. 6-well cell culture plate  
29. 12-well cell culture plate  
30. 96-well cell culture plate  
31. Ham's F-12K (Kaighn's) Medium (ThermoFisher Scientific) 
32. Trypan Blue Solution  
33. UltraPure™ Agarose  
34. 50× TAE buffer  
35. Phusion High-Fidelity DNA Polymerase (New England Biolabs) 
36. Cryovial tubes 1.2 ml  
37. Surveyor mutation detection kit (Integrated DNA technologies (IDT)) 
38. Phosphate buffered saline (PBS) solution  
39. Ethylenediaminetetraacetic acid (EDTA)  
40. HEPES Buffer  
41. Zero Blunt™ TOPO™ PCR Cloning Kit (ThermoFisher Scientific) 
42. 17 mm × 100 mm round-bottom snap-capped tubes for E. coli culture 
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43. Petri dishes  
44. Qiagen DNeasy Blood & Tissue Kit (Qiagen) 
45. GeneRuler 1kb DNA ladder (ThermoFisher Scientific) 
5.3.2  Formulas 
1. CHOK1 cell culture: F12K medium with 10% FBS and 2 mM L-glutamine 
2. FACS sorting buffer: 1× PBS with 1 mM EDTA, 25 mM HEPES and 1% FBS  
3. 1% agarose gel: 1 g agarose powder in 100 ml 1x TAE buffer, boil the solution to 
dissolve the agarose 
4. 1000× ampicillin stock: 1 g ampicillin powder in 10 ml sterile water 
5. LB-agar (ampicillin): 35 g LB agar powder in 1 L deionized water, then autoclave it. 
After LB-agar solution cools to 50 °C, add ampicillin stock in 1000× dilution ratio.  
6. 1× TAE buffer for DNA gel electrophoresis:  dilute 50× TAE buffer with deionized water 
 
5.3.3 Equipment 
1. Forma™ Series II 3110 Water-Jacketed CO2 Incubators (  ThermoFisher Scientific) 
2. Microcentrifuge  
3. Laboratory water bath 
4. Heat block 
5. NanoDrop™ 2000 Spectrophotometer (  ThermoFisher Scientific) 
6. Fluorescence-activated cell sorter (FACS) 
7. Hemocytometer 
8. Microscope 
9. PCR thermocycler  
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10. ChemiDoc™ XRS+ System (Bio-rad) 
11. Horizontal DNA Electrophoresis System (Bio-rad) 
12. Protein blot Electrophoresis System (Bio-rad) 
13. Microwave oven 
5.4. Methods 
5.4.1 Design sgRNAs against targeted gene  
The sequence specificity of the CRISPR/Cas9 system is determined by choosing 20 nucleotides 
(nts) from the target gene to serve as the single guide RNA (sgRNA) sequence [294]. In order to 
express the small chimeric sgRNA, an RNA pol III promoter, such as U6, is required [295, 296]. 
Since the U6 promoter initiates transcription at guanine (G), this base must be present in the 5’ 
end of the gene target site. Thus, the 20 nts from target DNA site located immediately at 5’ of a 
protospacer-adjacent motif (PAM, 5’-NGG-3’) are in the form of 5’-
GNNNNNNNNNNNNNNNNNNN-NGG-3’ (N can be A,G, C ,or T) [294, 297]. 
1. Search your gene of interest using the CHO Cas9 target Finder 
http://staff.biosustain.dtu.dk/laeb/crispy [129] (see Note 1). Be aware that your gene of 
interest may have multiple variants in CHO cells. For example, FUT8 gene (Gene ID: 
100751648) has two variants in CHO: one variant (protein ID: XP 003501783.1) 
containing 11 exons as a full-size α-1,6-fucosyltransferase, the other variant (protein ID: 
XP 007640580.1) containing 9 exons as a truncated α-1,6-fucosyltransferase. 
2. A list of target sequences will be presented. We choose the target sequence from Exon 9 
because Exon 9 exists in both CHO α-1,6-fucosyltransferase variants and its amino acid 
sequence covers the active region of the FUT8 enzyme [298, 299]  (see Note 2).  
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3. From the CHO Cas9 target Finder search result, two target sequences in Exon 9, each 
followed by a PAM sequence (5’-NGG-3’) was chosen, as shown in Table 5-1 (see Note 
3).  
4. Design sgRNA primers 
Based on the target sgRNA sequences from Subheading 3.1.3, we designed the sgRNA 
cloning primers according to the px458 CRISPR protocol from Dr. Feng Zhang’s lab at 
Addgene http://www.addgene.org/crispr/zhang/[129]. The target sequence minus the “5’-
NGG-3’” PAM sequence is the varying region that primers overlap with each other, as 
described in Table 5-1 and illustrated in Figure 5-1C. 
 
5.4.2 Construction of px458 plasmid with designed sgRNAs 
5.4.2.1 Preparation of px458 vector 
1. The construct plasmid px458 was kindly provided by Dr. Feng Zhang (MIT) [300]. 
Subclone this plasmid into E. coli to make a bacterial glycol stock.  
2. Inoculate a small amount of E. coli from the frozen bacterial glycol stock in LB medium 
supplemented with 100 μg/ml ampicillin.  
3. Culture overnight at 37°C with shaking at 250 rpm.  
4. Extract plasmid DNA from E. coli culture using a plasmid purification kit (depending on 
the culture volume to choose mini-, midi- or maxi- plasmid purification kit and follow the 
manufacturer’s protocol). Elute the empty px458 plasmid in nuclease-free water (NFW) 
and measure the DNA concentration using the Nanodrop 2000 (see Note 4)  
5.4.2.2 Digestion of px458 plasmid 
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1. Based on the px458 empty plasmid concentration, digest an appropriate amount of px458 
plasmid with Bbsl enzyme and 1× NEBuffer 2.1 digestion buffer as shown in Table 5-2. 
2. Analyze digested product by DNA electrophoresis on 1% agarose gel and check the size 
and linearization of px458 plasmid.  
3. Cut the DNA band (containing linearized px458 plasmid) with appropriate size (~9.3 kb) 
to remove primer dimers and isolate the linearized px458 plasmid by using a gel 
extraction kit following the manufacturer’s protocol.  
4. Elute the linearized px458 plasmid in nuclease-free water (NFW). 
5. Measure the DNA concentration using a Nanodrop 2000.  
5.4.2.3 Anneal sgRNA primers for the sgRNA construct (see Note 5) 
1. The primers are synthesized by a custom primer service and dissolved in NFW to a 
concentration of 100 μM. 
2. Mix the sense and anti-sense primers (100 μM) with following components in a tube as 
shown in Table 5-3.  
3. Boil the primer mixture at 95°C for 5 min using a heating block or thermocycler and 
allow the oligo duplex to slowly cool to room temperature. Freshly annealed oligo duplex 
is recommended for the sgRNA plasmid construction.  
5.4.2.4 The sgRNA plasmid construction (ligation) 
 Mix components in a tube according to Table 5-4. If not immediately used, store at -20°C. 
5.4.2.5 Transformation of sgRNA plasmid in E.coli 
1. Take the DH5-alpha component E. coli vials out from -80°C freezer and thaw them on 
ice.  
2. After E. coli thaws, add 1-3 μl ligation product into one vial of competent cells.  
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3. Mix gently by flicking the bottom of the tube with your finger twice.  
4. Prepare another vial of competent cells without adding ligation product as a negative 
control.  
5. Incubate the competent E. coli cells on ice for 30 min 
6. Heat shock the vial in a 42 °C water bath for 30 sec  
7. Place the vial in ice for 5 min.  
8. Add 950 μl room temperature SOC medium to each vial and incubate in a shaker at 250 
rpm at 37°C for 1 h.  
9. Centrifuge at 5000 g for 5 min and remove the supernatant.  
10. Add 150 μl fresh SOC media to each vial, pipette up and down to resuspend the E. coli 
pellet. 
11. Spread two densities (high and low) of transformed E. coli onto 10 cm LB agar plates 
containing 100 μg/ml ampicillin.  
12. Incubate the agar plates overnight at 37 °C. Very few colonies should be expected on the 
negative control agar plate. 
5.4.2.6 Analyze transformation colony 
1. Pick a few colonies using a pipette tip and individually transfer  to 4 ml LB medium 
supplemented with 100 μg/ml ampicillin in an E. coli culture snap-capped tube.  
2. Place tubes in shaking incubator at 250 rpm at 37°C overnight 
3. Purify the sgRNA plasmid using a plasmid purification kit following the manufacturer’s 
protocol and measure the DNA concentration using the Nanodrop 2000.  
4. Sequence the constructed plasmid using Sanger sequencing. 
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5. After confirming the sequence of the constructed sgRNA plasmid, store sgRNA plasmid 
at -20°C for further transfection (see Note 6). 
5.4.3 Transfection of sgRNA plasmids into an IgG expressing CHO cell line 
5.4.3.1 Day 0: seed cells for transfection 
1. Use healthy IgG expressing CHO cell line (viability >97%) at early passage, for higher 
transfection efficiency. The IgG expressing CHO cell line was previously described 
[301].  
2. Count cells using a cell counter or hemocytometer. 
3. Plate cells at a density 7 × 105 cells per well in a 6-well plate, add culture medium to 2 ml 
per well. At least two wells are needed: one well for transfection and another well for 
control. 
4. Incubate cell cultures at 37°C in a humidified incubator with 5% CO2 for 24 h. 
5.4.3.2 Day 1: transfection with lipofectamine 3000 
1. Check cell confluency. Cells should be 80-90% confluent at the time of transfection. 
Replace the old culture medium with 2 ml reduced serum Opti-MEM medium in each 
well.  
2. Use lipofectamine 3000 for transfection following the manufacturer’s protocol. Warm 
lipofectamine  3000 reagent to room temperature and thaw sgRNA plasmids from -20°C 
freezer. Flick the tube a couple times and quick spin before using. 
3. Place two sterile tubes, each containing 125 μl of Opti-MEM medium, and label them 
Tube 1 and Tube 2 
4. Lipofectamine 3000/Opti-MEM mixture: Add 5 μl Lipofectamine 3000 reagent into Tube 
1  
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5. Diluted DNA mixture:  Add 2.5 μg sgRNA plasmids (sgRNA1 plasmid: sgRNA2 
plasmid=1:1 (w/w)) into Tube 2. And then add 5 μl P3000 reagent. Gently pipet up and 
down to mix them well.  
6. Add Lipofectamine 3000/Opti-MEM mixture to the plasmid-P3000 reagent mixture.  
7. Incubate for 20 min at room temperature  
8. Add the transfection mixture into a well in the 6-well plate.   
9. Gently shake the 6-well plate to evenly distribute the transfection mixture.  
10. Incubate cells for 2 days at 37°C in 5% CO2 with humidity.  
5.4.4 LCA lectin selection of the transfected cells 
1. Two days post-transfection, the supernatant from transfected cells is collected and 
subjected to LCA lectin blot analysis to detect fucosylation of the recombinant antibody. 
An example of LCA lectin result is shown in Figure 5-3A.  
2. For transfected cells, selection of FUT8 knockout cells was performed by supplementing 
the culture medium with 50 μg/ml lens culinaris agglutinin (LCA). The transfected pool 
in one well of 6-well plate was passed into a T25 flask with F12K culture medium 
containing 50 μg/ml unconjugated LCA for a week to select the transfected cells with 
reduced fucosylation. The same amount of untransfected parental cells supplemented 
with equal concentrations of LCA is also performed as a negative control (see Note 7).  
5.4.5 (Optional) Fluorescence activated cell sorting to enrich for sgRNA plasmid expression (see 
Note 8) 
1. Prior to LCA selection, the transfected pool is seeded at 1 × 106 cells per 100 mm culture 
dish for overnight incubation. 
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2. When the confluency is above 90%, cells are collected by trypsinization and centrifuged 
at 500 × g for 15 min to obtain a cell pellet.  
3. Wash the cells twice using sterile PBS and resuspend the cell pellet in sorting buffer 
using a 12 × 75 mm tube with cell strainer cap.  
4. Cells are then subjected to FACS.  
5. Cells expressing GFP within the top 5% intensity of signal are sorted and collected in 
culture medium. 
6. Sorted cells are transferred to a 50 ml tube with culture medium up to 40 ml.  
7. Centrifuge 2100 × g for 5 min and remove sorting buffer and culture medium.  
8. Resuspend cells in a T75 flask with 50 μg/ml LCA for selection.  
9. Incubate the sorted cells for 3 days at 37°C in 5% CO2 with humidity. 
10. When the sorted cells grow, this indicates a successful sorting process. Passage the cells 
and allow them to grow to >80% confluency for the following analysis or 
cryopreservation. 
5.4.6 Surveyor mutation assay to check the knockout efficiency  
The Surveyor enzyme can cleave the mismatch in the DNA duplex where a mutated sequence is 
hybridized with the wild-type sequence. The PCR product after cleavage will produce bands of 
different size that are separable on an agarose gel (see Note 9).  
1. After 2-3 passages, harvest 1 × 106 cells from the LCA selected stable pool.  
2. Centrifuge at 1000 × g and remove the supernatant.  
3. Extract the genomic DNA from the cell pellet using DNeasy blood & Tissue kit 
following the manufacturer’s protocol. Also extract the genomic DNA from 
untransfected parental cells for use as a negative control. 
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4. Design sequencing forward and reverse primers: Design your primers using ApE 
software (http://biologylabs.utah.edu/jorgensen/wayned/ape/) or NCBI primer-BLAST 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/). Please see Note 10 for primer design 
instructions. The sequencing primers can be used for Surveyor mutation detection as 
described here or for Sanger sequencing as described in Subheading 3.8. 
5. Mix the following components (Table 5-5) in a 1.5 ml Eppendorf tube (master mix) and 
add 25 µl from the master mix to each PCR tube. Prepare 4 tubes for the knockout 
sample and 4 tubes for the control sample. 
6. Place the PCR tubes in a thermocycler, and run the program outlined in Table 5-6 (see 
Note 11): 
7. After PCR amplification, pool 4 PCR repeats together and take 5 μl of the PCR product 
from knockout and control samples and run them individually on 1% agarose gel. There 
should be only one clear band from your control sample (if not, redo your PCR or 
troubleshoot your primer design). 
8. Check the PCR product on the gel, if not much primer dimer is present, the PCR product 
can be purified by a PCR purification kit following the manufacturer’s protocol; if primer 
dimers are abundant, the PCR product has to be processed through a gel extraction step to 
remove primer dimers before proceeding to the next step.  
9. Combine purified knockout PCR product with control wild-type PCR product in a new 
PCR tube as shown in Table 5-7.  
10. Place the combined PCR mixture in a thermocycler and run the DNA hybridization 
protocol as shown in Table 5-8. When the PCR amplification is done, put the sample on ice 
immediately.  
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11. Mix the components for the following two reactions as outlined in Table 5-9. 
12. Incubate the PCR tubes for 60 min at 42 °C.  
13. Then add 1.3 µl Stop solution to each PCR tube to terminate the surveyor endonuclease 
reaction. Put the samples on ice.  
14. Load the products on a 2% agarose gel and run for 30 min. Your results should be similar 
to what is shown in Figure. 5-3B.  
5.4.7 Limited dilution cloning (clone isolation) (see Note 12) 
1. Trypsinize the cells from the stable knockout pool and count the cell density. 
2. Perform a 1:10 serial dilution with fresh medium to a final concentration of ~ 1,000 
viable         cells/ml.  
3. Transfer 160 µl of 1,000 cell/ml solution to 39.8 ml fresh medium to bring the 
concentration to about 4 cell/ml. Low LCA lectin concentration (10-20 ug/ml) in the 
medium is preferred in this step.  
4. Add 200 µl of the 4 cells/mL solution into each well of the 96-well plate, allowing each 
well to be seeded at an average density of 0.8 cells/well. 
5. Leave the cells undisturbed in an incubator until Day 7 or 8, then start to check cell 
growth to identify single colonies in the 96-well plates. Wells with more than one colony 
should not be marked. 
6. After 11 or 12 days, check the growth of single-cell clones daily.  
7. Before the cultures become over-confluent, trypsinize the clonal cells from each well and 
expand them to 12-well plates individually. 
5.4.8 Clonal cell line selection 
After the isolated clones grow, make three repeats of each. One culture serves a maintenance 
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purpose. One culture is subjected to screen the clonal cells for FUT8 knockout efficiency by using 
surveyor mutation detection assay (Figure 5-4A) and Sanger sequencing (Figure 5-4B). The other 
culture is subjected to LCA lectin blot and western blot analysis against α1,6 fucosylation and 
antibody titer analysis.  
5.4.8.1 Sanger sequencing to analyze gene mutation 
1. After the clones in 6-well plate become confluent, the genomic DNA from each clone 
is extracted using a Qiagen DNeasy Blood & Tissue Kit DNA extraction kit 
following the manufacturer’s protocol. 
2. Measure the extracted genomic DNA concentration and use the designed sequencing 
primers in Subheading 3.6 to perform the PCR amplification and PCR product 
purification.  
3. Check the PCR product quality by DNA gel electrophoresis and measure the purified 
PCR product concentration using a Nanodrop.  
4. Perform a Surveyor mutation analysis to detect FUT8-knockout efficiency in each 
clone.  
5. The mutant clones from the analysis are chosen and processed as in the next step.  
6. For sequencing the mutated region in each clone, TOPO cloning of the PCR product 
is performed following the manufacturer’s protocol. Alternative methods are also 
provided in Note 13.  
7. The TOPO plasmids constructed with the mutated region from each clone are purified 
and mixed with the forward and reverse sequencing primers as in Subheading 3.6, 
individually based on the Sanger sequencing service company’s instructions.  
8. Analyze Sanger sequencing results using ApE software.  
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5.4.8.2 LCA lectin blot to check FUT8 knockout efficiency 
 A LCA lectin blot against potential FUT8 knockout clone cell lysates can also be used to 
verify the FUT8 knockout efficiency (Please see Figure 5-5 for an example of LCA lectin 
blot result).  
5.4.8.3 Antibody titer analysis 
The antibody productivity in each clone is analyzed by enzyme-linked immunosorbent assay 
(ELISA) or high-performance liquid chromatography (HPLC).  
5.5. Notes 
 
Note 1. Other CRISPR sgRNA design software are also available [302], such as CRISPR 
MultiTargeter (http://www.multicrispr.net/), E-CRISP (http://www.e-crisp.org/E-CRISP/) and 
CRISPRseek (http://bioconductor.org/packages/release/bioc/html/CRISPRseek.html). We chose 
CRISPY because this Cas9 target finding software is built on the CHO-K1 genome.  
Note 2. For improving gene disruption efficiency, we chose two sgRNAs targeting two close 
sites in one exon in the targeted gene (as shown in Figure 5-1B). The exon or exons covering the 
activity domain of the targeted protein are recommended. This protocol is also applicable for one 
target site using one sgRNA.  
Note 3. sgRNA selection criteria are as follows: 
a. If the targeted protein’s activity domain has been defined, design the sgRNA within the 
activity domain coding sequence. For example, Exon 9 covers the active site of both variants 
of FUT8 in CHO cells. If the targeted protein’s activity domain has not yet been determined, 
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it is preferable to design multiple sgRNAs targeting different exons and test the sgRNA 
knockout efficacy of each one.  
b. The sgRNA should be unique in the CHO genome with minimum off-target effects. Given that 
Cas9 digests between 3 and 4 nts upstream of the PAM sequence of the targeted knockout 
sequence [297], it is important to make sure the first 10 nts in the selected sgRNA has no off-
target activity. Many sgRNA software programs also predict the off-target activity for each 
sgRNA. Alternatively, you can manually align your sgRNA sequence with the CHO genome 
using NCBI BLAST (https://blast.ncbi.nlm.nih.gov/Blast.cgi). No or low off-target activity is an 
important consideration for sgRNA selection.  
Note 4. It is recommended to check the px458 vector sequence before BbsI digestion, especially 
the BbsI digestion region for sgRNA insertion.  
Note 5. It is not necessary to phosphorylate the oligo duplex. The oligo duplex without 
phosphorylation can also work well. 
Note 6. For transfection purposes, it is suggested to use sterile NFW to elute the sgRNA plasmid. 
Note 7. LCA is a plant lectin which preferentially binds to the α-linked mannose of N-glycans. 
LCA can cause cytotoxicity in cells expressing core-fucosylated proteins [108].  
Note 8. The px458 plasmid contains the GFP marker, which can be used for cell analysis by 
FACS to enrich for cells with a high  plasmid expression level. Given that the CRISPR system is 
efficient and LCA selection alone is enough to generate FUT8-/- cells, we provide the FACS 
protocol here as a supplement. FACS should be performed prior to LCA lectin blot selection 
because after LCA selection, transient px458 plasmid expression may be terminated.  
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Note 9. Other enzymes can also detect mismatched DNA sequences, such as T7 endonuclease. 
For an example of a detailed mutation assay methodology, please refer to the Surveyor mutation 
detection protocol from Integrated DNA Technologies (IDT).  
Note 10. Generally, a PCR product between 600-1000 bp is a suitable length for PCR 
amplification. This product should span the knockout binding site in your targeted gene. Primers 
should be placed ≥ 50 bp outside the region of interest and have 18-25 bp in length with a GC 
content around 45-60%. 
Note 11. The annealing temperature is dependent on the length and GC content of your primers.  
Note 12. For a more detailed CHO limited dilution protocol, please refer to the Freedom™ CHO-
S™ protocol. As an alternative to the limited dilution protocol, single cell sorters can also be 
applied to perform clone isolation.  
Note 13. The uracil-specific excision reagent (USER) cloning method can also be used as a cloning 
tool to check for mutated sequences [303].  
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Figures and Tables 
Figure 5-1. (5-1A) Schematic of CRISPR/Cas9-mediated gene mutation. (5-1B) The illustration of 
sgRNA binding sites in the FUT8 gene. (5-1C) The workflow of px458 plasmid construction.  
 
Figure 5-2. Workflow of the knockout cell line generation and analysis using the CRISPR/Cas9 method 
described in this protocol.  
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Figure 5-3. (5-3A) LCA lectin blot analysis of α-1,6 fucosylation level on antibody secreted from FUT8-
KO stable pools. (5-3B) The mutation detection assay of FUT8 exon 9 knockout efficiency in stable 
pools. In the mutation detection analysis, equal amounts of knockout stable pool DNA and wild-type 
DNA were mixed together to serve as mutant/WT cross hybridization (Lane 2 and 3).  At the same time, 
equal amounts of wild-type DNA was also prepared to serve as the self- hybridization control (Lane 1). 
After annealing, equal amounts of self-hybridization and cross hybridization mixtures were treated with 
Surveyor Nuclease individually and analyzed by gel electrophoresis. The mutant/WT cross hybridization 
results in mismatched heteroduplexes. Surveryor Nuclease can digest the mismatched DNA and produce 
cleavage products as shown as an uncut wild-type fragment and multiple cleavage fragments in the cross 
hybridization mixtures (lanes 2 and 3).  While no mismatch results from the wild-type self-hybridization 














Figure 5-4. (5-4A) Mutation detection analysis of knockout efficiency in FUT8-knockout clones. (5-4B) 














Figure 5-5. LCA lectin blot of CHO cell lysates.  
 





Primers for cloning into Px458 (5' to 3') 
sgRNA 1 GTCAGACGCACTGACAAAGTGGG Forward CACCGTCAGACGCACTGACAAAGT 
Reverse AAACACTTTGTCAGTGCGTCTGAC 
sgRNA 2 GGATAAAAAAAGAGTGTATCTGG Forward CACCGGATAAAAAAAGAGTGTATC 
Reverse AAACGATACACTCTTTTTTTATCC 
 
Table 5-2. px458 digestion reaction. 
 
Component  Volume 
BbsI enzyme  3 µl 
px458 plasmid  3 µg 
1× NEBuffer 2.1  5 µl  
Total Reaction Volume  50 µl 
 Reaction conditions 
Incubation Time  2 h 










10× NEBuffer 4 10 μl 
sgRNA forward primer (100 μM) 10 μl 
sgRNA reverse primer (100 μM) 10 μl 
NFW 70 μl 
Total 100 μl 
 
Table 5-4. Reagents for sgRNA plasmid ligation. 
 
COMPONENT ligation (20 μl reaction) 
T4 DNA Ligase Buffer (10×) 2 μl 
px458 linearized plasmid DNA  100 ng  
Annealed sgRNA insert DNA  1 μl of oligo duplex from Step 3.2.3 
(1:20 dilution) 
T4 DNA ligase  1 μl 
NFW to 20 μl 
Reaction Conditions 
Incubation Time 2 h 
Incubation Temperature Room Temperature 
 
Table 5-5. Reagents for FUT8 sequencing PCR reaction. 
 
Component FUT8-KO (4.5 reactions)  Control (4.5 reactions) 
5× HF buffer  5×4.5=22.5µl 5×4.5=22.5µl 
NFW 15.9×4.5=71.55µl 15.9×4.5=71.55µl 
10 mM dNTPs 0.6×4.5=2.7µl 0.6×4.5=2.7µl 
10 µM Forward Primer 1.25×4.5=5.625µl 1.25×4.5=5.625µl 
10 µM Reverse Primer 1.25×4.5=5.625µl 1.25×4.5=5.625µl 
Genomic DNA (from Step 
5.4.6.3) 
FUT8-KO genomic DNA 
100 ng 
Control genomic DNA 100 ng 
Phusion Polymerase  0.3×4.5=1.35 µl 0.3×4.5=1.35 µl 
Total reaction volume 25×4.5= 112.5µl 25×4.5=112.5µl 
 






Table 5-7. Reagents for DNA hybridization. 
Step Temperature Time 
Initial denaturation 98°C 3 min 
30 cycles Denaturation 98°C 10 sec 
Annealing 62°C 20 sec 
Extension 72°C 22 sec 
Final extension 72°C 7 min 




Knockout PCR 400 ng 
Control wild-type PCR 400 ng 
10× Taq buffer  2 μl 
NFW Up to 20 μl 
Total  20 μl 
 
Table 5-8. PCR program for DNA hybridization. 
 
95°C 10 min 
95°C -85°C -2.0°C /sec 
85°C 1 min 
85-75°C -0.3°C /sec 
75°C 1 min 
75-65°C -0.3°C /sec 
65°C 1 min 
65-55°C -0.3°C /sec 
55°C 1 min 
55-45°C -0.3°C /sec 
45°C 1 min 
45-35°C -0.3°C /sec 
35°C 1 min 
35-25°C -0.3°C /sec 
25°C 1 min 
4°C Hold ∞ 
 
 
Table 5-9. Reagents for surveyor enzyme mutation detection. 
 
Component Control WT PCR product KO-WT hybridized PCR mixture 
hybridized DNA sample 10 µl 10 µl 
MgCl2 solution 1 µl 1 µl 
Enhancer S 1 µl 1 µl 
Nuclease S 1 µl 1 µl 
Total 13 ul 13 µl 
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Chapter 6 Conclusions and future work 
 
6.1 Final Thoughts 
 
 
The goal of this dissertation was to apply multiple glycoengineering strategies to tailor 
the glycan profile on recombinant proteins in CHO cells and to develop an advanced glycoprofile 
analysis method. 
The development of a rapid glycopeptide analysis method can reveal site-specific glycan 
information on recombinant EPO-Fc protein secreted from CHO cells in different media 
compositions. Retaining glycans on the peptides enables users to simultaneously elucidate the 
glycan structure on the specific glycosylation sites and provide insights about how proteins are 
modified at different points along the polypeptide chain under different culture conditions. As a 
complementary approach to the conventional released glycan analysis method, this rapid and 
easy glycoproteomic method-intact glycopeptide analysis can decipher site-specific glycan 
information on therapeutic proteins, which is highly beneficial for biopharmaceutical 
manufacturing. Intact glycopeptide characterization may become increasingly important as an 
analytical tool for producing protein therapeutics with well-defined physical properties. 
With the assistance of genetic, protein and metabolic engineering, glycoengineering on 
glycosylation process can delicately manipulate the glycan profile in mammalian cells. However, 
given the non-template driven nature of glycosylation, the regulation of one glycotransferase 
expression can unexpectedly affect other glycotansferase expression in Golgi. Plus, the 
nucleotide sugar substrate content is also determinant to the final glycan profile. That’s why the 
culture media composition is of significant importance for the biopharmaceutical manufacturing. 
Therefore,a comprehensive and  sophisticated design of glyco-engineering approaches 
173  
containing  genetic, protein and metabolic engineering is highly recommended to achieve well-
defined and precisely-controlled glycan profile in mammalian cells.  
 
6.2 Future Work 
 
A comparison of intact glycopeptide analysis with the conventional released glycan 
analysis to reveal the discrimination between these two methods will be performed on EPO-Fc 
protein cultured in the same media and same cell culture condition.  Further optimization is 
needed for these two methods to improve the detection sensitivity and accuracy for glycan 
characterization for providing better-defined therapeutic proteins.  
B3GNT2 is a critical gene for LacNAc extension in mammalian cells. Previous work and 
my current work both demonstrated that the overexpression and inhibition of B3GN2 gene  
expression both adversely impact the LacNAc unit initiation and extension on recombinant 
proteins in CHO cells. Nevertheless, although causing similar results, these two approaches  are 
attributed to different machines. The knockdown of B3GNT2 resulted in the reduction GlcNAc 
content on N-glycan profile, while the overexpression of B3GNT2 resulted the reduction of Gal 
content on N-glycan profile . Given that LacNAc unit is composed of GlcNAc and Gal. The 
missing or reduction of either component will result in the decline of LacNAc units on N-
glycans.  For generating long LacNAc extensions, the overexpression of B4GALT1 in B3GNT2-
expressing cells is necessary, by optimizing the expression system, such as testing different 
promoters. Another approach is to increase neclueotide sugar transporter expression on the 
membrane of Golgi, which can bring more UDP-galactose and UDP-GlcANc substrates for 
LacNAc extension.  
The overexpression of B3GNT2 somehow resulted in the inhibition of sialylation of 
glycoproteins and glycolipids in CHO cells, indicating its suppressing effect on the sialylation 
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process in Golgi. Nevertheless, the sialyltransferase expressions at transcriptional level has 
unaffected. Next step, the detection of CMP-sialic acid substrate is highly recommended to bring 
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Summary 
• Biotechnological researcher focusing on the glyco-engineering and glyco-analytics of 
therapeutic proteins secreted from mammalian cells.  
• Mammalian cell culture and cell line development expert 
• Mass spectrometry glycan analysis expert 
Education 
Ph. D. of Chemical Engineering (08/2015-Now, expected to graduate in May 2019) 
      Department of Chemical and Biomolecular Engineering, Johns Hopkins University (JHU)             
                                                     Advisor: Dr. Michael Betenbaugh, Department of Chemical Engineering  
                                                                    Dr. Hui Zhang, Department of Pathology  
                                                                    Dr. Kevin J. Yarema, Department of Biomedical Engineering  
Master of Science Engineering (08/2013-05/2015) 
Department of Chemical and Biomolecular Engineering, Johns Hopkins University (JHU)             
       Current GPA: 3.88/4                                                                         Advisor: Dr. Michael Betenbaugh 
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Research Experience 
Glyco-engineering to optimize the glycan profile of recombinant Erythropoietin (EPO) and 
antibody 
1. Overexpressing branching genes (GNT IV+V) together with a2,6 sialyltransferase (ST6) to 
generate glyco-modified CHO EPO expressing cell lines using RT-PCR, immunoblot and lectin 
blot detection. The sialylation of recombinant EPO is detected by HPLC.  
2. Using ManNAc analog supplementation to further increase sialic acid content by increasing the 
sialic acid substrate availability. Explore the effects of this chemical feeding on CHO cell growth 
by metabolite analyzer, on recombinant protein (EPO and IgG) expression by Immunoblot and 
Coomassie blue staining and on sialylation content by intracellular sialic acid assay, lectin blot and 
HPLC.  
Explore the functions of glycotransferases through gene knockouts and knockins  
1. Systematically knockdown three essential genes for a2,3 sialyltransferase in CHO, silenced these 
genes with RNAi and monitored the reduction of sialylation level on total protein using ELISA 
method; applied this gene silencing approach on the expression of recombinant EPO in CHO cells 
Qiong Wang 
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and analyzed the reduction of sialylation by lectin blot and HPLC. 
2. Use CRISPR knockout to disrupt glycotransferases genome, use ELISA and immunoblot to screen 
monoclones, then use Surveyor assay and Sanger sequencing to analyze genome modification 
Develop methods to efficiently express and purify recombinant human 
butyrylcholinesterase (HuBChE) in mammalian cells  
Explore various promoters and codon optimization method to establish CHO BCHE stably 
expressing cell lines with high enzymatic activity. Use proline-rich sequences through in vivo 
coexpression and in vitro assembly to achieve efficient recombinant BCHE tetramerization by 
native electrophoresis. Purify HuBCHE tetramers through Tangential flow filtration (TFF), Ni-
NTA method, ultrafiltration and dialysis.  
Publications  
Research Articles:  
Wang Q, Ganglong Y, Tiexin Wang, Weiming Y, Betenbaugh MJ, Zhang H. Characterization of 
intact glycopeptides reveals the impact of culture media on site-specific glycosylation of EPO-Fc 
fusion protein generated by CHO-GS cells. Biotechnology and Bioengineering. 2019 
Wang Q, Chung C-Y, Yang W, Yang G, Chough S, Chen Y, Yin B, Bhattacharya R, Hu Y, 
Saeui CT, Yarema KJ, Betenbaugh MJ, Zhang H. Combining Butyrated ManNAc with 
Glycoengineered CHO Cells Improves EPO Glycan Quality and Production. Biotechnology 
journal. 2018 
Wang Q, Chung C-Y, Rosenberg JN, Yu G, Betenbaugh MJ. Application of the CRISPR/Cas9 
Gene Editing Method for Modulating Antibody Fucosylation in CHO Cells. In: Hacker DL, 
editor. Recombinant Protein Expression in Mammalian Cells: Methods and Protocols. New 
York, NY: Springer New York; 2018. p. 237-57. 
Wang Q, Chen CH, Chung C-y, Priola J, Chu JH, Tang J, Ulmschneider MB, Betenbaugh MJ. 
Proline-Rich Chaperones Are Compared Computationally and Experimentally for Their Abilities 
to Facilitate Recombinant Butyrylcholinesterase Tetramerization in CHO Cells. Biotechnology 
journal. 2018;13(3):1700479. 
Yin B, Wang Q, Chung C-Y, Ren X, Bhattacharya R, Yarema KJ, Betenbaugh MJ. Butyrated 
ManNAc analog improves protein expression in Chinese hamster ovary cells. Biotechnology and 
Bioengineering. 2018;115(6):1531-41. 
Chung C-Y, Wang Q, Yang S, Ponce SA, Kirsch BJ, Zhang H, Betenbaugh MJ. Combinatorial 
genome and protein engineering yields monoclonal antibodies with hypergalactosylation from 
CHO cells. Biotechnology and Bioengineering. 2017;114(12):2848-56. 
Yin B, Wang Q, Chung CY, Bhattacharya R, Ren X, Tang J, Yarema KJ, Betenbaugh MJ. A 
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Biotechnol Bioeng. 2017;114(8):1899-902. Epub 2017/03/16. 
Chung CY, Wang Q, Yang S, Yin B, Zhang H, Betenbaugh M. Integrated Genome and Protein 
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CHO. Biotechnology journal. 2017;12(2). Epub 2016/12/13. 
Chung CY, Yin B, Wang Q, Chuang KY, Chu JH, Betenbaugh MJ. Assessment of the 
coordinated role of ST3GAL3, ST3GAL4 and ST3GAL6 on the alpha2,3 sialylation linkage of 
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mammalian glycoproteins. Biochem Biophys Res Commun. 2015;463(3):211-5. Epub 
2015/05/23. 
Ganglong Yang, Yingwei Hu, Shisheng Sun, Chuanzi Ouyang, Weiming Yang, Qiong Wang, 
Michael Betenbaugh, and Hui Zhang, Comprehensive Glycoproteomic Analysis of Chinese 
Hamster Ovary Cells, Analytical Chemistry 2018 90 (24), 14294-1430 
Reviews:  
Wang Q, Chung C-Y, Chough S, Betenbaugh MJ. Antibody glycoengineering strategies in 
mammalian cells. Biotechnology and Bioengineering. 2018 
Wang Q, Betenbaugh MJ. Metabolic engineering of CHO cells to prepare glycoproteins. 
Emerging Topics in Life Sciences. 2018;2(3):433-42. 
Wang Q, Yin B, Chung CY, Betenbaugh MJ. Glycoengineering of CHO Cells to Improve 
Product Quality. Methods Mol Biol. 2017;1603:25-44. Epub 2017/05/12. 
Wang Q, Stuczynski M, Gao Y, Betenbaugh MJ. Strategies for Engineering Protein N-
Glycosylation Pathways in Mammalian Cells. Methods Mol Biol. 2015;1321:287-305. 
Heffner KM, Wang Q, Hizal DB, Can O, Betenbaugh MJ. Glycoengineering of Mammalian 
Expression Systems on a Cellular Level. Advances in biochemical engineering/biotechnology. 
2018 
Chung CY, Majewska NI, Wang Q, Paul JT, Betenbaugh MJ. SnapShot: N-Glycosylation 
Processing Pathways across Kingdoms. Cell. 2017;171(1):258-.e1. Epub 2017/09/25. 
Presentations 
Qiong Wang, Sandra Chough, Michael J. Betenbaugh, and Hui Zhang, "Intact glycopeptide 
analysis of recombinant protein from CHO cells" in "Cell Culture Engineering XVI", A. 
Robinson, PhD, Tulane University R. Venkat, PhD, MedImmune E. Schaefer, ScD, J&J Janssen 
Eds, ECI Symposium Series, (2018) 
Qiong Wang. “Glycoengineering in CHO cells for biomanufacturing. Abstract of papers of the 
American Chemical Society (2016) 
Skills 
Molecular Biology:  Plasmid design and construction, site-specific mutation, CRISPR, ZFN, 
immunoblot and lectin blot, native electrophoresis, ELISA, RT-PCR, confocal microscopy, 
FACS and analysis, HPLC, sialic acid analysis, antibody ADCC and CDC assays 
Cell culture: adherent and suspension mammalian cell culture (CHO and HEK), human B and T 
cell culture, cell adaption, cell line development and characterization, Lipofectamine and 
electroporation transfection 
Protein purification: TFF, FPLC, Ni-NTA purification, Protein A purification 
Mass spectrometry (MALTI-TOF and LC-MS/MS): Released glycan analysis, Glycan 
permethylation, Glycan derivative labeling (2AA and 2AB), Intact glycopeptide analysis  
Animal Skills: Vein tail injection  




1. Cell line development Co-op at Eli Lilly, Indianapolis, IN (08/2016-02/2017)  
Teaching Experience 
Mentored high school students, undergraduates, masters and junior Ph.D. students 
 
